Company name Booth Number Meeting status

3SBio, Inc - Business Forum

3SBio, Inc - Exhibitor 5719 Requested
Abbisko Therapeutics Co. Ltd.
Abbott Labs Declined
AbbVie, Inc. 2611 Declined
AbCellera
Abogen Biosciences
ACADIA Pharmaceuticals, Inc
Accord Healthcare Requested
Aché - Exhibitor 4035 Requested
Aché Laboratórios Farmacêuticos S.A. - Business Forum Declined
Acino Requested
Adaptimmune Therapeutics plc.
Advanced Enzyme Technologies Limited 4807
Advanz Pharma
Agenus Inc.
Agios Pharmaceuticals, Inc
Aidoc
Aju Pharm Co., Ltd.
Akebia Therapeutics, Inc
Alantra
Alexion, AstraZeneca Rare Disease Requested
Alfasigma Declined
Alfred E. Tiefenbacher GmbH & Co.KG
Alkermes Inc
ALLIFE MEDICINE INC.
Almatica Pharma
Almirall S.A Declined
Alnylam Pharmaceuticals, Inc
ALVOGEN Declined
Alvotech
American Regent, Inc.
Amgen
Amgen Biosimilars
Amgen Business Development Declined
Amicus Therapeutics, Inc
Amneal Pharmaceuticals, LLC
Antengene
AOP Orphan Pharmaceuticals GmbH
Apellis Pharmaceuticals, Inc
ApicHope Pharmaceutical Co., Ltd
Apobiologix
Apotex Corporation Declined
Apsen Pharmaceuticals Requested
Ardelyx Inc.
argenx Requested
Aristo Pharma GmbH Declined
ARL Biopharma, Inc. 4635
Asahi Kasei Pharma Corporation Requested
Ascentage Pharma Scheduled
Ascletis Pharma Inc.
Asieris Pharmaceuticals
ASKA Pharmaceutical Co, Ltd
AstraZeneca Requested
Atara Biotherapeutics Inc.
Aurigene Oncology Ltd
AustarPharma, LLC
Autolus Ltd
Avantor Sciences 3027 Requested
Avistone Biotechnology
Azurity Pharmaceuticals
Basilea Pharmaceutica International Ltd
Bausch Health Companies, Inc. Declined
Bayer Requested
BeiGene, Ltd. Declined
BenevolentAI
BESINS Healthcare
Best Buy Health - Business Forum
Betta Pharmaceuticals Co.,Ltd
Bial
Bicycle Therapeutics Limited
BIOCODEX Inc. Declined
Biocytogen Pharmaceuticals(Beijing)CoLtd Declined
BIOFABRI SLU
BIOGARAN
Biogen
Biolab Farmacêutica 4035 Requested
Biolab Sanus Farmaceutica Requested
BioMarin Pharmaceutical, Inc
BioNTech Requested
Bioprofarma Bagó S.A. 5219 Requested
BioRay Pharmaceuticals
Bio-Thera Solutions
Biotheus Inc
Blanver 4035
Blau Farmacêutica 4035
bluebird bio
Blueprint Medicines
BlueRock Therapeutics
BMIKorea
Boehringer Ingelheim Animal Health
Boehringer Ingelheim Human Pharma Requested
Boryung Biopharma
BORYUNG CO., LTD. Requested
BrightGene
BrightGene Bio-Medical Technology Co., Ltd 4507
Bristol Myers Squibb Business Development Declined
BuChang Pharmaceutical
Bukwang Pharmaceutical, Co. Ltd
Byondis B.V.
Camurus AB
CanSino Biologics Inc.
Carnot
CARsgen Therapeutics
Cell and Gene Therapy Catapult - Business Forum
Cellectis
Celltrion, Inc. 4925 Requested
Celon Pharma S.A.
Centurion Pharma
Ceva Animal Health Declined
CHA BIOTECH
Chengdu Baiyu Pharmaceutical Co. Ltd.
Chia Tai TianQing Pharmaceutical Group Co., Ltd.
Chiesi Farmaceutici SpA Requested
Chipscreen Bioscience (US) Ltd
Chong Kun Dang Pharmaceutical Corp. Requested
Chugai Pharmaceutical Co., Ltd
Cipla Ltd. Canceled
Clear Street LLC
Clinigen Declined
CMG Pharmaceutical Co., Ltd.
Codexis, Inc
Coherus Biosciences
Collegium Pharmaceutical, Inc.
Createrna USA, Inc.
CRISPR Therapeutics
Cristália Requested
CSL Requested
CSPC Pharmaceutical Group Ltd
CStone/GS
CTS Ltd.
CureVac SE
Cytiva Technology Acquisition, Licensing & Partnering Scheduled
Cytokinetics, Inc
Daewon Pharmaceutical Co, Ltd
Daewoong Pharmaceutical Co. Ltd.
Daiichi Sankyo Co., Ltd. Requested
Debiopharm International S.A. 1911
Deciphera Pharmaceuticals, LLC
Denali Therapeutics
Dendreon Corporation Ltd.
Deutsche Bank
Deva Pharmaceuticals Declined
DKSH Requested
Dompé Farmaceutici SpA
Dong-A ST Co., Ltd. Requested
DONGWHA PHARM. CO., LTD.
Dr. August Wolff
Dr. Falk Pharma GmbH
EA Pharma Co., Ltd.
Eddingpharm Group Co.,Ltd
Editas Medicine
EGIS Pharmaceuticals Requested
Eisai Co., Ltd. Requested
ElevateBio
Eli Lilly and Company Scheduled
EMD Serono, Inc. 2319
Emergent 5835
EMS
Enable Injections
Er-Kim Pharmaceuticals
Esperion Therapeutics
Esteve Requested
EuBiologics., Ltd.
Evercore Partners
Evopoint Biosciences
Exagen, Inc.
Exegenesis Bio
Exeltis USA
Exscientia Ltd Declined
Extrovis AG
Faes Farma S. A. Declined
Ferrer Internacional, S.A. Requested
Ferring Pharmaceuticals Requested
FibroGen, Inc
Flagship Pioneering
FOSUN KITE BIOTECHNOLOGY
Fosun Pharmaceutical Group
Fosun Pharmaceutical USA
Frontier Biotechnologies Inc
Fuji Pharma Co. Ltd. Requested
FUJIFILM Pharmaceutical Division Declined
Fuso Pharmaceutical Industries, Ltd.
G.L. Pharma GmbH Requested
Gador S.A. 5219 Requested
GAIA AG
Galapagos NV Declined
Gan & Lee Pharmaceuticals Requested
GC Biopharma Requested
GC Cell
Gedeon Richter
Genentech and Roche Requested
Generate Biomedicines Inc
Genescience Pharmaceuticals Co., Ltd
Genmab BV Declined
Gensciences Biopharma
GenScript Requested
GenScript USA Inc. Scheduled
Gilead Sciences, Inc Requested
Glenmark Pharmaceuticals
Greenpine Pharma Group Co.,Ltd
Gritstone bio, Inc.
Grünenthal GmbH Declined
GSK 4023 Requested
Guangdong Raynovent Biotech
Gubra
Gyre Therapeutics Inc.
H. Lundbeck A/S
Haihe Biopharma
Haisco Pharmaceutical Group Co. Ltd
Haisco-USA Pharmaceuticals, Inc.
HanAll Biopharma
Handok Inc.
Hansoh Pharma
Harbour BioMed
Helsinn
Henlius Biotech 1719
Hikma Pharmaceuticals Requested
Hisamitsu Pharmaceutical Co., Inc. Requested
HK inno.N Corporation Requested
HLB Pharmaceutical
Huadong Medicine Co., Ltd.
HUTCHMED
Hypera Pharma - Business Forum Requested
Hypera Pharma - Exhibitor 4035 Requested
Hyundai Pharmaceutical Co (South Korea)
IASO Biotherapeutics
Ichnos Sciences
IGM Biosciences
Ildong Pharmaceutical Co., Ltd
Immatics GmbH
Immunocore Ltd
Incyte Corporation
InnoCare Pharma Ltd
Innovent Biologics, Inc. Declined
Inovio Pharmaceuticals, Inc
InSilico Medicine 5657
Insmed, Inc Declined
INSUD 5219
Intas Pharmaceuticals Scheduled
Intellia Therapeutics
Intra-Cellular Therapies, Inc.
Ipsen Declined
Ironwood Pharmaceuticals, Inc
Italfarmaco Group
Jamp Pharma Corporation
Japan Blood Products Organization
Jazz Pharmaceuticals, Inc Declined
JCR USA, Inc.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd Requested
Johnson & Johnson Declined
JT Pharma Requested
Jubilant Therapeutics, Inc.
JumpCan Pharmaceutical
JW Pharmaceutical Requested
Kaken Pharmaceutical Co., Ltd. Declined
Kamada Ltd.
Karyopharm Therapeutics, Inc.
Kashiv Biosciences
Kelun Pharmaceuticals
Keymed Biosciences (Chengdu) Co., Ltd
Kintor Pharmaceutical Limited
KISSEI Pharmaceutical Co., Ltd. Declined
KM Biologics Co., Ltd. Requested
Knight Therapeutics Inc. 4035
Kolon Life Science Inc.
Kolon Pharmaceuticals, Inc.
Kowa Company, Ltd. Requested
Kuhnil Pharm. Co., Ltd
Kwangdong Pharmaceutical Co., Ltd. Requested
Kyorin Pharmaceutical Co, Ltd Declined
Kyoritsu Seiyaku Corporation
Kyowa Kirin
Laboratorios Bagó. S.A. Requested
Laboratorios Biopas
Laboratorios Farmaceuticos Rovi Requested
Laboratorios Liomont S.A. De C.V. 3416
Laboratorios Pisa Requested
Laboratorios Saval
Laboratorios Silanes, S.A. de C.V. Scheduled
Lantheus
Legend Biotech USA, Inc. Declined
Leo Pharma A/S Declined
Lepu Biopharma
LG Chem
LifeArc Requested
LNC Pharm
Lubrizol Corporation
Lupin, Inc. Requested
Mabwell BioScience
MacroGenics, Inc
Madrigal Pharmaceuticals
Mankind Pharma Ltd
MannKind Corporation
Marjan Farma 4035
Maruho Co., Ltd. Requested
Maruishi Pharmaceutical Co., Ltd.
MEDIS
Meiji Seika Pharma Co., Ltd.
MeiraGTx
Menarini Group Declined
Merck Requested
Merck Animal Health Requested
Merz Therapeutics
Metagenomi
Mirum Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation Requested
Mochida Pharmaceutical Co., Ltd. Requested
Neopharm Israel
Neopharmed Gentili Declined
Neuraxpharm Requested
Neurocrine Biosciences, Inc
Neurophth Therapeutics
NewBridge Pharmaceuticals- MENA
NHLBI/NIH Seed Fund Programs (SBIR/STTR)
Nippon Chemiphar Co., Ltd.
Nippon Kayaku Co., Ltd. Requested
Nissan Chemical Corporation
NITTO DENKO CORPORATION Declined
Nobelpharma Co., Ltd.
Nomura Securities International, Inc.
Nordic Pharma Ltd
Noucor
Novartis 1421 Requested
Novartis - Exhibitor 4725 Requested
Novavax, Inc
Noven Pharmaceuticals, Inc Declined
Novo Nordisk A/S Declined
Novocure Limited
Nurix Therapeutics, Inc
Nxera Pharma Japan (formerly Sosei Heptares)
Nxera Pharma UK (formerly Sosei Heptares)
Om Pharma 2111
Organon & Co. Declined
Orion Corporation Requested
Otsuka Pharmaceutical Co., Ltd. Requested
Otsuka Pharmaceutical Factory Declined
PARI Pharma GmbH
Partex
PeptiDream Inc.
Pharmacosmos A/S
Pharmaessentia Corp. - Business Forum
Pharmaessentia Corp. - Exhibitor 1817
PharmaMar
Pharmanovia
PharmaResearch
Pharmathen
Pharming Group N.V.
Pierre Fabre SA Declined
Pint Pharma GmbH
Polpharma Biologics 4049
Poseida Therapeutics
Protalix Biotherapeutics Inc.
PTC Therapeutics, Inc Declined
Purdue Pharma LP
Radius Health, Inc
Rafa Laboratories
Rakuten Medical, Inc.
Recordati
Recursion
Regeneron Pharmaceuticals, Inc. Requested
REGENXBIO Inc.
Relay Therapeutics, Inc
RemeGen
Revvity Declined
Ribocure Pharmaceuticals
Rocket Pharmaceuticals, Inc.
Roivant Sciences
Rosemont Pharmaceuticals
Ryvu Therapeutics 4049
Salus
Salvat 4256
SAMIL PHARM CO, LTD
Samjin Pharm.Co.,Ltd
Samsung Bioepis
Samyang Holdings Corp.
Sana Biotechnology
Sangamo Therapeutics
Sanofi 2223 Requested
Sanofi Australia Requested
Sanofi's Vaccines Business
Santen Pharmaceutical Co., Ltd. Declined
Sanwa Kagaku Kenkyusho Co., Ltd.
Sarepta Therapeutics Requested
Saurav Chemicals Limited 4807
Schrödinger
SciClone Pharmaceuticals, Inc
Seacross Pharmaceuticals
Sebela Pharmaceuticals
Senju Pharmaceuticals Co. Ltd
SERB Pharmaceuticals
Seres Therapeutics
Servier Declined
Shanghai Huaota Biopharm
Shanghai Jemincare Pharmaceuticals Co.,Ltd.
SHcell Cell Therapy Group
Shin Poong Pharm. Co., Ltd.
Shionogi & Co., Ltd. Requested
Sinergium Biotech S.A. 5219
Sino Biopharmaceutical Ltd. Requested
Sinomab Bioscience Limited
SK Biopharmaceuticals
SK Bioscience Requested
SK Chemicals
SK Plasma
Spark Therapeutics
SRI International
SRS Life
STADA Requested
STALLERGENES GREER Requested
Sumitomo Pharma Co.,Ltd Requested
Sun Pharmaceutical Industries Limited
Sunsho Pharmaceutical Co., Ltd.
Sutro Biopharma, Inc.
Swedish Orphan Biovitrum Requested
Tabuk Pharmaceuticals
Taiho Oncology, Inc.
Taiho Pharmaceutical Co., Ltd. Requested
Taisho Pharmaceutical Co., Ltd. Declined
Takeda Pharmaceuticals 2625 Declined
Tamer Group Scheduled
Taro Pharmaceutical Industries Ltd
Tarsus Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd,China
Teijin Pharma Limited Requested
Teikoku Seiyaku Co., Ltd.
Telix Pharmaceuticals Requested
Tenry Pharma
Tessera Therapeutics
Teuto Laboratories Requested
Teva Pharmaceutical Industries Requested
Theramex
Tillotts Pharma - Corporate Development
Toray Industries Requested
Transcenta Therapeutics
Travere Therapeutics, Inc.
TRINOMAB
Tris Pharma Inc
Tsumura USA, Inc.
TTY Biopharm Co., Ltd
UBE Corporation Declined
UCB Declined
Ultragenyx Pharmaceutical, Inc
United Therapeutics Corporation
Valneva SE
Verve Therapeutics, Inc.
Vetoquinol S.A.
Viatris Declined
Viiv Healthcare
VIRBAC SA
Waterswtone Pharmaceuticals
WaVe Life Sciences
Whan In Pharm Co., Ltd
Wiener lab. 5219
Xencor, Inc
Xenon Pharmaceuticals, Inc
Xeris Pharmaceuticals
XtalPi Inc. - Business Forum
XtalPi Inc. - Exhibitor 2505
Xuanzhu Biopharmaceutical Co., Ltd.
Yifan Pharmaceuticals Declined
YOOYOUNG PHARMACEUTICAL CO, LTD
Yuhan Corporation
Zai Lab
Zambon Group SPA Requested
Zealand Pharma A/S
Zelgen Biopharmaceuticals
Zentiva Group, a.s. Requested
Zeria Pharmaceutical Co, Ltd Requested
Zymeworks
 Company status Company type(s)

Biotech or pharma, therapeutic R&D

Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Diagnostics
Digital
Biotechhealth
or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Investment bank
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
 Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device or technology
Digital
Biotechhealth
or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, animal health
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, animal health
COMPANY
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Investment bank
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Diagnostics
Biotech or pharma, therapeutic R&D
SPONSOR Medical device or technology
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Investment bank
Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech - food
Biotech or & agriculture
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Investment bank
Biotech or pharma, therapeutic R&D
Medical device or technology
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
 Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Digital health
Biotech or pharma,
Biotech or therapeutic R&D
pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
 Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
MEMBER Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
 Biotech or pharma, therapeutic R&D
MEMBER Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
Medical device or technology
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Diagnostics
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device or technology
Biotech or pharma,
Biotech or therapeutic R&D
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Investment bank
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Medical device or technology
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device or technology
Digital health
Biotech or pharma,
Biotech or therapeutic R&D
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma,
Biotech or animal health
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
 Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Diagnostics
Biotech or pharma, animal health
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Digital
Biotechhealth
or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
BIO BOARD Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma,
Biotech or therapeutic R&D
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
SPONSOR Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Diagnostics
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech - industrial & environmental
Biotech or pharma,
Biotech or therapeutic R&D
pharma, therapeutic R&D
BIO BOARD Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
 Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, animal health
Biotech or pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Diagnostics
MEMBER Medical device
Biotech or or technology
pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Medical device
Biotech or or technology
pharma, therapeutic R&D
MEMBER Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
Biotech or pharma, therapeutic R&D
PRESENTING Biotech or pharma, therapeutic R&D
COMPANY
 Brief description

3SBio seeks to in-license the China rights to novel therapies

in oncology,
3SBio seeks to nephrology,
in-license auto-immune,
the China rights metabolic,
to novel therapies
opthalmology
in oncology, and dermatology.
nephrology, auto-immune, Seeking for out-license
metabolic,
Abbisko is a clinical stage, publicly-listed biopharma focused
partners as well.
opthalmology and dermatology. Seeking foroncology
out-license
on the discovery
Abbott is a globalofcompany small moleculein branded targeted
pharmaceuticals, and
partners as well.
I/O therapeutics. Leaddevices
assets and target FGFR, CSF-1R, EGFR,
diagnostics, medical
AbbVie is a global, research-based biopharmaceutical nutrition.
KRas, PD-L1, PRMT5, CD73 are FIC/BIC.
company
AbCelleracommitted
is breakingtobarriers delivering innovative
to develop bettermedicines
antibody
which
drugs. have a remarkable impact on people’s lives across
Abogen Biosciences is a clinical-stage biotech company
core therapeutic areas, including immunology, oncology,
dedicated to
ACADIA delivering transformative
Pharmaceuticals medicines through
is a biopharmaceutical company
mRNA innovation.
focused on the The company
development and has established industry-
commercialization of South
With an extensive presence in North America, Europe,
leading proprietary
innovativeAustralia,
medicinesNew mRNA
thatZealand,
address unmet
America,
Aché is a leading Brazilian South medical
pharmaceutical Africa
company
needs
and morein
with a
central nervous
recently in the systemand
MENA (CNS) ASEAN disorders.
regions, Accord
strong
Leading commercial presence in prescription
Brazilian pharmaceutical company medicinesseeking in-and
Healthcare
specialty has very The
products. rapidly
companybecome is one of the in
interested fastest
R&D and
licensing
Acino is aofspecialty
late-stage innovative assetscompany
biopharmaceutical (new small focused on
late-stage
molecules licensing opportunities
and 505(b)(2)/hybrid with
products) small biotechs and
for Brazil/ LatAm,
the commercialization
Adaptimmune is a clinicalof innovative and established
stage biopharmaceutical company
as well as co-development
therapeutics across emerging andmarkets,
out-licensing
including of proprietary
LATAM,
focused
Enzyme on novel
manufacturing cancer immunotherapy
company with huge products
capacity based
in on
CIS,
its MENA
T-cell and Africa
receptor (TCR) platform.
fermentation of Biocatalyst
Seeking partnerships, licensing enzymes for API,deals
/ acquisition Speciality
for
Chemicals
innovative, based out in India. R & D Set up in Germany as
Agenus Inc.value
(NASDAQ: add, promoted,
AGEN) rare disease, biosimilar or
well. Enzyme
high value evolution,
generic assets,Enzyme
for late Development,
stage hospital /Pilot scaling
specialist
**We are not accepting meetings with CROs, CMOs, and
products for Europe, Canada and Australia.
consultants**
Aidoc is a leading provider of clinical decision support AI,
increasing
Founded inspeed 1953,toAju diagnosis,
Pharm istreatment
a prominent and pharma
clinical trial
enrollment.
company Our
in Korea with platform is adopted globally
a strong commercialization by 1200+
Akebia Therapeutics (NASDAQ: AKBA) is a fully
hospitals, providing
capability complemented access to 2M patients
withbiopharmaceutical
regulatory expertiseevery month.
and
integrated, commercial
Alantra Partners, stage
S.A. provides investment banking company
and asset
clinical development
dedicated to deliver experience.
oninitsSpain
commitment Fully integrated
to better theThe from
lives of
management services and
Alexion, AstraZeneca Rare Disease, is the group within internationally.
people impacted
company offers by kidney
financial disease.services to companies or
advisory
AstraZeneca focused meeting
No service providers on rare diseases,
requests created
please! following the
institutions
2021 in corporate
acquisition of Alexionfinance operations; and
Pharmaceuticals, stock market
Inc.
Alfasigma
We develop, is manufacture,
an international andfully integrated
register innovative pharmaceutical
as well as
companydrugs
generic focused for on specialty
our B2B products.
customers and Seeking
distribution late stage
Alkermes is a fully-integrated, global biopharmaceutical
programs mainly in GI and rare diseases.
partners. focused
company
A leading iPSC derived on developing
Cell & Gene innovative
Therapy medicines
company inin
the
field
China.of neuroscience
Almatica Pharma, Inc. is a private, US pharmaceutical
companyisfocused
Almirall a leading on Medical
the development,
Dermatology acquisition
global and
commercialization
pharmaceutical of brand
company named pharmaceutical
dedicated to apply Scienceproducts.
tonovel
Alnylam is a biopharmaceutical company developing
improve the health
therapeutics of patients worldwideor byRNAi.
fighting against
Alvogen is anbased on RNA pharmaceutical
international interference, company,
skin diseases and helping people feel and look their best.
focused
Alvotechonis developing, manufacturing,
vertically integrated Biosimilars marketing and
developer,
distributing
offering its innovative , branded speciality, partners globallyas
OTC products
Portfolio of portfolio
hospital, for commercialization
injectable products; Seeking
well as generics.
commercial and late-stage clinical in-licensing, M&A, and
commercial collaboration opportunities (acute care, ED, ICU,
Amgen Biosimilars is committed to leveraging its extensive
transplant centers, infusion centers)
biotechnology experience to create high-quality biosimilars
and reliably supply them to patients suffering from serious
Amicus Therapeutics (Nasdaq:FOLD) is a global
illnesses worldwide.
biotechnology
Amneal has a portfoliocompanyofatover the forefront
225 marketed of advanced
products and
therapies
also to treat
markets a a rangeofofbranded
portfolio devastating rare and orphan
pharmaceutical products
Antengene is a leading commercial-stage R&D-driven global
diseases.its Specialty segment focused principally on central
through
biopharmaceutical company focused
The AOP Health Group is the European pioneer for on the discovery,
nervous system
development, and endocrineand
manufacturing disorders. For more info
commercialization of visit
integrated
We therapies
are a global for rare diseases
biopharmaceutical and in critical
company that is care.
innovative first-in-class/best-in-class therapeutics for cancer
committed to leveraging courageous
ApicHope pharmaceutical Co., Ltd, founded science,in creativity,
2002, locatedand
compassion
in Guangzhou to city,
deliver life-changing
China, a listed therapies. Leaders in
Apobiologix is a division ofis Apotex (Stock
Inc., code:
Canada's leading
targeted C3 therapies,
300723.SZ) pharmaceutical we aim to develop
company transformative
integrated with
manufacturer of generic & biosimilar
Apotex Inc. is a Canadian-based global health company medicines. Our focus
thatis
innovative
the drug research
commercialization of and development,
biosimilars & manufacturing,
differentiated small
produces high-quality, affordable and complex medicines for
molecules delivering
patients around quality
the world, with anda value
strategicfor focus
patientson andbecoming
a Canadian Health Champion and an Americas Partner of
APSEN is a Brazilian pharmaceutical company, focused on
innovative drugs, interested in-licensing opportunities.
argenx discovers and develops human therapeutic antibodies,
focusing
Aristo ison severe autoimmunity.
a pharmaceutical company The Company
focussed in theis seeking
new collaboration
commercialization and in-licensing
and promotion opportunities to continue
ARL Bio Pharma, DNA Solutions of andpharmaceutical
the Kupiec Group products
to
in develop
the areas its
of product
Gynecology, pipeline Heavy Pain , Urology,
offer aKasei
Asahi comprehensive
Pharma Corporation range of(AKP) analytical, bioanalytical,
is an R&D-based
Dermatology
microbiological, andgenetic
Psychiatry and across Europe.
forensic services We forare the not
pharmaceutical company headquartered
Ascentage Pharma is a globally-focused, clinical-stage in Tokyo, Japan,
pharmaceutical
specializing in company andtherapeutic
the biotechnology areas industries.
of Immunology,
biotechnology
Ascletis is an innovative engaged R&D driven in developing
biotech listed novelon the
Transplant-adjacent,
therapies for cancers Specialty,
and hepatitis andB.Bone&Joint.
Hong
AsierisKong Stock Exchange
Pharmaceuticals is a (1672.HK),
clinical-stage covering
biotechthe entire
company
value chain from
focusingPharmaceuticals discovery
on discovery, development and development to
and commercialization
ASKA is a fully integrated mid-sized
manufacturing
of innovative and commercialization.
diagnostic and therapeutics, with a focus in
specialty pharmaceutical company
AstraZeneca is a global biopharmaceutical company. based in Japan,
genitourinary
specializing in: diseases.
AstraZeneca operates inInc.
Atara Biotherapeutics, overis100 countries
a pioneer and its
in T-cell
innovative
immunotherapy medicines are used by millions of patientsT-cell
Founded in 2002,leveraging we are a clinicalits novelstage allogeneic
biotechEBV company
worldwide
platform to to
develop transformative therapies for patients with
committed
AustarPharma the discovery
is seeking and development
commercial partnersoffornovel the and
severe diseases
effective therapeutics including solid
for the treatmenttumors, hematologic cancers
development and commercialization
Autolus is a clinical-stage biopharmaceuticalof ofourcancer.
CNS,
company
Cardiovascular
developing and immunology
next-generation, pipeline.T cell therapies for
programmed
the treatment of cancer and autoimmune disease.
Avistone Biotechnology is a global Oncology company,
focused Pharmaceuticals
Azurity on targeted therapeutics is a specialtyfor lung cancer. The
pharmaceutical
company has
company, a differentiated
focused on pioneering pipeline, in-house R&D
Basilea Pharmaceutica Ltd. is a fully integrated commercial-
capabilities, and an emerging commercial presence in China,
stage
Bausch Company, headquartered
Health Companies Inc. in is Basel,
a global Switzerland
company that and
listed on
develops, the SIX Swiss Exchange (SIX: BSLN).
Bayer is a manufactures
Life Science company and markets witha arange
moreofthan 150-year
pharmaceutical,
history and medical device and over-the-counter
BeiGene is acore competencies
globally in the areas of health
focused biopharmaceutical care and
company
products,
agriculture. primarily
With ourininnovative
the therapeutic areaswe
products, of are
eye health,
dedicated to becoming a leader
BenevolentAI (AMS: BAI) is a leading developer of in the discovery and
contributing
development to
offinding
innovative, solutions to sometargeted
molecularly of the major and the
advanced artificial
BESINS Healthcare intelligence
(“BESINS”) technologies that unlock
is a well-established,
immuno-oncology
value of multimodal drugs
data, for the treatment
surface novel of cancer.
insights, and
independent
Monitor, manage, and family-owned,
and communicate with study participants
accelerate biomedical discovery.
remotely.
Founded in 2003 at Hangzhou, China, Betta
Pharmaceuticals
< NO SERVICE Co., PROVIDERLtd. is a REQUESTS>
Chinesea pharma company
that has
BIAL successfully developedpharmaceutical
and marketed Conmana with
Bicycleis Therapeutics
an innovation-driven (NASDAQ: BCYC) is a company, clinical-stage
a(icotinib)
strong - the focus
R&D
biopharmaceutical
first targeted
on
company
oncology therapeutics
Neurosciences
developing and
a
developed
neurology-based
novel class of
Biocodex is a family-owned pharmaceutical company that
Rare Diseases,
precision-guided with an established
therapeutics commercial
(Bicycles®) presence in
provides innovative
Biocytogen Pharmaceuticalshealthcare solutions
(Beijing) Co.,toforLtd.
diseases
patients
is a in that
more
global
Europe
are and successful track record of partnering.
thanunderserved
100 countries
biotech
by worldwide,
existing therapeutics.
with a specific focus on three
Biofabricompany that drives the research and development of
areas of expertise: microbiota
new drugs with innovative technologies. care, women’s health and
No service-provider
Leading generics and biosimilars company in France
meeting schedule at BIO,
At Biogen, our mission is clear: we are pioneers in
neuroscience.
Biolab is a major pharma and prescription company in
Brazil,
Biolab, ranking
a leading among
company the top 10, with
in Brazil, a presence
ranks in 7
top 10 nationally,
countries
present inand over 400It's
7 countries. products.
a key playerWe are the leader Market,
ininnovative
LATAM in the
BioMarin develops and commercializes
Cardiology
pursuing field and
licenses for offer
innovativeinnovative drugs healthcare
through products
flexible in
deals,
biopharmaceuticals
BioNTech is a global, forclinical
rare andstage serious diseases and medical
biopharmaceutical
including
conditions. stages development from Phase 2b with exclusive
company thatBagó
Bioprofarma researches, develops, andcompany
is a pharmaceutical manufactures based its
innovative,
HQ in highlyand
Argentina potent
with and well tolerated
presence in almost all LATAM.
BioRay is a PE-backed biopharmaceutical company focusing
immunotherapies.
Ourimmune-mediated
best expression ofdiseases expertise is oncology.
in Oncology, Hematology
on and
Bio-Thera Solutions, Ltd., a leading innovative, global
and also Neurology. The development of niche products is
biopharmaceutical
Biotheus, Inc. is aiming company in Guangzhou,
to develop oncologyChina, and is
dedicated
inflammatory to researching and developing novel therapeutics
BLANVER is disease
a Brazilian products . We have several
pharmaceutical company platform
with 39
for the treatment
technologies of
establishedcancer, autoimmune,
to achieve cardiovascular
first- or best-in-class and
years of experience, looking for in-licensing
Blau Farmaceutica is a private owned company, established and distribution
assets.
opportunities for Brazil and theall restover
of Latin American
in Sao Paulo,
bluebird bio iswith subsidiaries
pursuing curative gene LATAM.
therapies to give
Market for innovative Oncology & Hematology products.
patients
Blueprint Medicines develops transformative precision in
and their families more bluebird days. Founded
2010, bluebird
medicines focusedhas on been setting the defined
genomically standarddiseases
for geneincluding
therapy
for more than a decade—first as a scientific
cancers and rare diseases. We seek licensing and partnerships pioneer and now
that complement our portfolio, research areas, and growth
BlueRock Therapeutics is a leading engineered cell therapy
company
BMI Korea, with a missionin
established to2005,
develop is aregenerative
South Korean medicines
for intractable
biopharmaceutical diseases.
In 2017, Boehringercompany Ingelheim focusing
AnimalonHealth the development
(BIAH) joined
and commercialization
forces of new medicines, including
As a world-leading, global pharmaceutical company animal
with Merial to form the second largest global our
biologics,
health companyand medical with alldevices.
of the capabilities requiredfor to our
outstanding team creates value through
Boryung Biopharma Co., Ltd. has strong marketing and sales innovation
maximize
three the valueareas: of your animal health Animal
asset. Health and
force key
Boryung
business
in pediatrics
has been one and of Human
OB/GYN
the leading
Pharma,
areas based on long
pharmaceutical historyin
firms
Biopharmaceutical
of Korea businessContract
vaccineachieving in South Manufacturing.
Korea. We709 are Milseeking toinin-
S. its revenue around
BrightGene Bio-Medical Technology Co., Ltd (stock code: USD
license
2023. Itlate-stage
has been products
fully and wepharmaceutical
integrated are providing company
688166)
BrightGene is an innovative
Bio-Medical pharmaceutical
Technology Co.,enterprise Ltd (stock code:
covering R&D,
participating Clinical trials,
ininnovative
international Licensing, RA,
competition.
688166) is an pharmaceutical
Bristol Myers Squibb is a global biopharmaceutical company enterprise
participating
whose mission in isinternational
to discover, competition.
develop and deliver innovative
Buchang Pharmaceuticals is one of Chinese leading
medicines that
companies. We help
are patients partners
seeking prevail over to serious diseases.
in-license, co-develop
R&D focused pharmaceutical company based in Seoul
For
and more information
out-license of late aboutstage Bristol
assets. Myers Squibb , visit us at
Byondis is a clinical stage biopharma company. We develop
next generation
Camurus is a Swedish Antibody Drug Conjugates
science-led (ADCs) and
biopharmaceutical
monoclonal
company committed antibodies (mAbs)
to developing for use in
andglobal oncology
commercializing and
CanSinoBIO is dedicated to providing solutions for
immuno-oncology
innovative and and (IO).
differentiated medicines fordiseases
the treatment of
the prevention
Carnot is a privately treatment
owned Latin of infectious
American through
Pharmaceutical
severe
research and chronic
& specializes
development, conditions.manufacturing
Group
CARsgen that is a commercial-stage in Women Health,and
biopharmaceuticalGastroenterology,
company
commercialization
Respiratory, CNS, of innovative,
Pediatric and high-quality
recently and affordable
Immunology
operating in China and the U.S. Driven
The Cell and Gene Therapy Catapult is a centre of excellence by the vision of.
Headquarter
making in
cancerwith Mexico
curable, with
CARsgen presence in all
hasofdeveloped Latinoamerican
in innovation,
Cellectis the core
is a biopharmaceutical purpose company building
focused aaworld-
suite of
on cell &
differentiated
leading technologies, a rich
cell and gene therapy sector in the UK as a key product pipeline, and part
end-
gene therapies.
Celltrion, Inc. (South Korea) is a recognized biologics
of a global industry.
industry
Celon PharmaleaderS.A. withisover 2,000 employees company
a biopharmaceutical who specialize with ain
the R&D,
diverse manufacture
portfolio of marketedand commercialization of innovative
Centurion is a leading Turkishmedicines
pharmaceutical and innovative
company,
biopharmaceuticals
product candidates, and
from antibody
early- to biosimilars.
late-stage development in
activeSanté
Ceva in CIS, MENAis,Balkan
Animale countriesglobal
a fast growing, for orphan
animaldrugs,
neuroscience,
rare diseases, diabetes,
biosimilars oncology,
,plasmathe autoimmune
products diseases
anddevelopment
vaccines. and
healthcare company,
We are clinical-stage focused
biotech on research,
group specializing in
The EU approved
production cell manufacturing
and therapies.
marketingWe of vaccines facility focuses
andpartners on sterile
pharmaceutical
innovative are
Baiyu focuses on developing small molecules for CNS seeking for the co-
products for companion
development of CAR-NKs, animals,
and livestock,
licensing swine and
partners for 4
disorders,
CTTQ is one Oncology,
of the leadingAutoimmune R & D driven diseaseslarge and pharma
Anti-aging
clinical
solutions. stage
We assets in
are looking the areas of
for strategic NK cell
partnerstherapy and stem
companies
Chiesi in China.
Farmaceutici We
is seek
a Global toPharmaceutical
out-license ourfor50+out-
company,
licensing
preclinicalour & innovative
clinical stageassets
NMEs andtoin-licensing/acquisition
the global pharma and
headquartered
Chipscreen is ainpublic Parma, Italy,
biotech dedicated
in to the research,
China dedicated for
biotech companies.
development, and commercialization of(688321.SH)
ethical products.
FIC/BIC innovative drug development
CKD, a fully integrated pharmaceutical company with in 83
the
areas
years of Oncology,
of ahistory, is ofMetabolic
oneRocheof thegroup,and
industry autoimmune disease. For
Chugai, member is aleaders
Japanese in Korean
company
the moment,
pharma market we have two
withinnovative FIC
major influence products launched
in market in China
development.
focused
Cipla is aonglobal
creating pharma Company medicinal
with US$3 products which
bn revenues;
address
with largeunmetUS, medical
India, needs.EU, AZ, Latam businesses
Africa,
Clear Street’s investment banking team provides a broad
suite of financial
Clinigen (Clinigensolutions,
Group) isincludinga global equity and debt capital
pharmaceutical and
markets,
services M&A
company advisory,
with a and
unique corporate
combination access ofcombined
businesses
CMG is a fast-growing pharmaceutical company based in
with the on
focused firm’s best-in-class sales,
providing trading,toand prime the
Korea. CMG is activeaccess to medicines
in development improve
and commercialization
quality
of unique of reformulation
people's lives around productsthe(branded world. Gx).
US-based Oncology Commercial Stage Company
Collegium Pharmaceutical, Inc. is a publicly traded
(NASDAQ:
We develop COLL), specialty pharmaceutical
novel therapeutics targeting signalcompany pathways in
developing
large and orphan and commercializing
diseases, are novel to
looking medicines
out license for ex-
patients
Developing Transformative Gene-based Medicines for
suffering
China rights from chronic pain and other diseases.
Patients
CRISTÁLIA withfor is
several
Serious
a private
Phase I and Phase II stage assets ,
Diseases
owned pharmaceutical company,
and completed 2 out-license deals with large pharmas in the
with a broad footprint
CSL (ASX:CSL; USOTC:CSLLY) across the main is aLATAM markets. A
global biotechnology
leader
company in intensive
withofathe care,
dynamic the company operates in 3 main
CSPC is one leadingportfolio
innovative of lifesaving
pharmaceutical medicines,
segments:
including Oncology,
those that treat Eye Care
haemophilia and CNS.andcapabilities
immune of
companies
CStone is an ininnovative,
China with research-based,
fully integrated oncology focused,
deficiencies,
R&D, manufacturing, vaccines to prevent influenza,
and commercialization. andThetherapies
company in
bio-pharmaceutical
A leading well-established company basedpharmaceutical
private in China. CStone is
was founded
looking for one in 1938 and
in-license, its HQ in strategic
out-license, Shanghai, also listed on
partnership
distributor,
***NO SERVICE of the most
PROVIDERS prominent PLEASE*** companies in Israel
Global
opportunities
engaged in with global
healthcare sinceand1921.domestic partners.
biopharmaceutical
Formerly GE Healthcare company Lifedeveloping
Sciences a new class of
transformative medicines based on messenger RNA.
Cytokinetics is a late-stage, specialty cardiovascular
biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle
Since its foundation in 1945, Daewoong Pharmaceutical has
activators and next-in-class muscle inhibitors as potential
grown
Daiichiinto Sankyo Korea’s is a leading pharmaceuticalcompany.
global pharmaceutical firm through
endless challenges and innovations. Seek for lincensing
Debiopharm develops innovative therapies that target high
opportunity based on overseas corporations and branches (8)
unmet
We aremedical needs in oncology
a commercial-stage and bacterialcompany
biopharmaceutical infections. on a
We are seeking
mission to deliver to transformational
in-license promising preclinical
medicines to oncology
patients.
Denali Therapeutics is a biotechnology company focused on
assets (small molecules,
Headquartered in Waltham, biologics)
MAofwe with solidinnovative
develop tumor
the discovery
A U.S. and
commercial-stage, development vertically therapies
integrated for immune
patients cellwith
science to provide hope
neurodegenerative diseases.to people living with cancer.
therapy
Leadingcompany.
global bank providing a full range of financial
productsfounded
DEVA, and services. in 1958, Healthcare investment company
is a pharmaceutical banking team with a
of 60+generics
broad professionals portfolio. withAmongdeep expertise
others across capabilities
DEVA biopharma,
DKSH Healthcare, a leading market expansion service
services
compriseand HealthTech; active in M&A, andequity and debt of
provider tofully
Dompé farmaceutici Asia, integrated
covering development
14 markets with
is a privately-owned
manufacturing
8,000 specialists
biopharmaceutical
mammalian
and 6 billion cell
CHF culture based Webiosimilars for highly or
company
Dong-A ST, with 130 revenue.
a subsidiaryyears of focus on
of experience
Dong-A Socio anin-licensing
end-to-end
Holdings
acquisition
coverage of pharma products and leverage our footprint
(formerlyof
DONGWHA
the value
Dong-APHARM,
chain, from drug
Pharmaceutical), discovery
is one
the first pharmaceutical
to
of thecompany
leading in
manufacturing,
pharmafounded
companies development
in Korea. and commercialization.
It focuses on the development
Korea in 1897, has been
Dr Wolff develops, manufactures and markets branded contributing to human
of innovative
health and(Rx, drugs and
well-being biosimilars,
through innovativewith particular
drug emphasis
products
The Dr. Falk OTC, is
Group Cosmeceuticals)
a family-ownedand is oneR&D
pharmaceutical of theand largest
commercialization,
medium-sized, driven by the
family-owned state-of-the-art
companies in the German
company
EA Pharma specializing
Co., Ltd. isinthe developing,
new integrated producing,company and of
pharma and cosmetic
commercializing industry and
state-of-the-art among the to
medications toptreat
100
Gastrointestinal
Edding is a leading Division of Eisai and
pharmaceutical Ajinomoto
company based in China
gastrointestinal
Pharmaceuticals and
andhepatic
establishesdisorders 1stwith
onmedicines
April,high unmet
2016. EA
focusing on developing
Editas Medicine is a clinicalinnovative
gene editing company for unmet with
Pharma
medical Co.,
needs Ltd. is
globally orresponsiblelocally for gastrointestinal
in for
China through disease
focus
Egis isonone CRISPR/Cas9
of the leading and Cas12a
value-added in vivo
generic and in-
pharma ex vivo
licensing and. M&A
applications The pipeline includes assets within
companies
Eisai Co, Ltd in Central Eastern Europe. Currently, we are
hematology,
looking for ocular,
new, and oncology
late-stage biosimilar, indications.
peptide, value-added
As a global is
ElevateBio pharmaceutical
a tech-driven company company,built we are a fully
to power
generic license-in
integrated pharmaceutical opportunities businessItsmainly
with in cardiometabolic,
discovery, clinical,
transformative
At Lilly, we unite genetic
caring medicines.
with discovery integrated
to createtechnologies
medicines
manufacturing
model offers and marketing capabilities.
that make lifeturnkey
better for scale and biotech
people around the capabilities
world. We to do
power
this
cellputting
by and gene thetherapy
more than processes,
45 million programs,
people and that companies
depend on to
We have the scientific and regulatory compliance experience,
our medicines at the center of everything we do.
end-to-endPharma
EMS/NC development is the #1 and manufacturing
pharma organization expertise,
in Brazilandand
efficient
top 10 in technology
Latam with transfer
an capabilities
established required
footprint in to bring
Prescription,
Enable Injections is looking to partner with pharma and
life-saving,
Hospital,companies life-extending
Oncology, products
Speacialty Care,to market.
OTC, Dermatology,
biotech
Er-Kim is a specialty that have IV or
pharmaceutical subcutaneous
company exclusively (SC)
Ophthalmology
therapies in Government
development (all and
stages)Generic
and business.
would benefit from
focusing
Esperion on is athe commercializing
pharmaceutical company novel with
treatments
the only in oral
three
aregions
differentiated
consisting and flexible
of 300M+ drug delivery system.
non-statins
ESTEVE isFDA
a leadingapproved private to people.
lower LDL-C and
pharmaceutical reduce group
chemical the
risk of MI and in
headquartered coronary
Spain, revascularization
with a widespread ininternational
primary
EuBiologics is a publicly traded biopharmaceutical company
prevention
presence. We andare secondary prevention. Strong
a partnership-oriented company developing
and we
specializing
Established in in 1995,
human vaccines(NYSE:
Evercore targeting infectious
EVR) diseases.
is a leading
offer substantial expertise and successful experiences in our
global
Evopoint independent
Biosciences investment bankingPharma)
(f.k.a. Sinovent advisoryisfirm. a clinical
stage biotech
Exagen develops with&multiple programsautoimmune
commercializes in human clinical diagnostic
studies, and
products via more programs in preclinical
a CLIA/CAP/NY stage.lab. Our disease
Seeking partners for our Phase State clinical
1/2 Spinal Muscular WeAtrophy
develop
areas of
and Phase focus
support1/2 include
critical oncology
biomarker and
testing anti-infectives.
in Degeneration
pharma Clinical
and
Branded Specialty wet Age Pharma Related Macular
operating in the Women's Health
Trials for programs.
(wAMD) primary, secondary, We also and best
have experimental
in end for
class licensing’s
data points
our
market.
Exscientia is a global pharmatech company using patient- or
Looking for acquisition opportunities,
proprietary
partnerships. Muscle and Ocular capsids.
first Extrovis
The artificial Groupintelligence (AI) to optimize
is headquartered and accelerate
in Switzerland,
drug development
operating worldwide to deliver
with potentiallyand
subsidiaries BIC and FICindrugs.
affiliates India,
Faes Farma S.A 1933, publicly traded Spanish
Our pipeline
the EU, the US and www.exscientia.ai/pipeline
Japan,with focusing focuses
on creating on
and, devoted
pharmaceutical company,
Privately-held multinational international
specialty bio-pharma scope efficiently
commercializing
to develop, pharmaceutical
manufacture and market products
a acrosswhich
portfolio the globe.
managing a comprehensive, end-to-end
Ferring is a research-driven, specialty biopharmaceutical value chain
includes
consisting Rx, OTC products and APIs.
committedaof
FibroGen to in-house
helping people
commercial-stage
capabilities
build healthy families
biotechnology company and live
better lives.
focused on Ferring
the is a leader
development of in reproductive
therapeutics that medicine
address and
We are a biotechnology company that invents platforms and
maternal
pancreas health,
cancer and and in areas within gastroenterology and
builds companies
Fosun Kite is dedicatedthatanemia.
change the world.
to innovative immune cell therapies
and its commercialization
Founded in 1994, Shanghai Fosun Pharmaceuticalto benefit cancer patients(Group)in China.
Fosun Kite is founded as a joint
Co., Ltd is a leading healthcare group in China with 7 bnventure between Shanghai
Fosun Pharmaceutical
USD revenue and 38 thousand (Group) employees.
Co., Ltd, and Kite Pharma.
A global innovation-driven pharmaceutical and healthcare
industry commercializes
Frontier group. Fosun Pharma directly operates
first long-acting HIV fusion businesses
including pharmaceuticals,
inhibitor in China Albuvirtide. medical devices, medical
Tokyo-listed specialty pharma, Itfocuses seeks ex-China
on women’s commercial
health,
diagnosis,
partners and and healthcare
late-stage services.
products for products.
China market. It is also
biosimilars, and acute medical care
We are seeking out-licensing and investment opportunities With
developingin
operations a long-acting
Japan HBV entry weinhibitor and aninto siRNA
for
Fusoour clinical
Pharmaceutical stageand Thailand,
oncology
Industries,pipeline,
areFF-10502
Ltd. Established
expanding
in(small
1937,
ASEAN
molecule countries, reflecting our growth aspirations and
GL startedDNA
and Pharma our
is an
damage repair
business
independent from the andsale
Austrian
replication inhibitor),
ofpharmaceutical
glucose. Today,FF- we
10832 (liposomal
manufacture gemcitabine),
and sellbysmall- and
to large-size FF-10850
infusion (liposomal
and We
company — driven science, research
Gador is a leading Argentine pharmaceutical company with and production.
injection
are a leadingproducts,
European led by our mainstay
specialty dialysis product,
pharmaceutical company
presence throughout
World leaders, pioneers Latam.and advocates in clinically validated,
with a direct presence in more than 15 countries - with more
safe, scalable
Galapagos and effective
(Euronext & NASDAQ: novel (digital)GLPG)therapeutic
is a fully assets.
integrated is
Gan&Lee biotechnology
a China-based company focused company
pharmaceutical on discovering,
developing and
specializing in commercializing
the development, innovative medicines
production, anda pioneer in
GC Biopharma based in South Korea, has been
addressing the
commercialization highest unmet
of recombinant needs in immunology
insulin analogs and andother
the
GC field
Cell isof ahealthcare,
leading cell since 1967.
therapy GCBP specializes
developer including in NK / T
innovative drugs
biological treatments including for diabetes
vaccines, and obesity.
plasma-derivatives,
cells.
Gedeon Richter- a European specialty pharmaceutical in
We have autologous CIK T cell therapy approved
recombinant
HCC adjuvant proteins
and seeking and cell therapy.
regional or local licensing
Company
Roche is a-global
is focused pioneer on in Female Healthcare
pharmaceuticals and diagnostics
and CNS
partners worldwide.
disordersonand Also
has microbial openand to discuss
mammalian CAR-NK cell CMO pipelines
focused advancing science to
Pioneering generative biology to create breakthrough improve people’s lives. As
capacity
an integral in member
Europe. Furthermore,
of the Roche Group Gedeonand Richter
founder is engaged
of the
therapeutics.
- A fully-owned subsidiary of Changchun High-Tech
biotech industry, Genentech brings transformative medicines
Industry
Genmab Group (SZ000661,biotechnology
is an international market cap at 202 company billionfocused
RMB)
contributing 80%+
on innovativeBiopharma revenue.
antibody therapies with the biopharma
core purpose of
Gensciences is a China-based focused
improving
on hemophilia the lives
and of people diseases.
metabolic with cancer We and
have other serious
established
GenScript is a global technology company with antibody
diseases.
proprietarygene long-acting
discovery,
GenScript has anand cellbiologic
established therapy platforms
globalplatforms.
presence
toWe improve
are looking
across Greater
patient's
for quality
strategic partnersof life.in cell therapy and therapeutic antibody
China, North America, the EU, and
Gilead Sciences, Inc. is a research-based biopharmaceutical Asia Pacific.
manufacturing areas.
company that
Glenmark discovers, develops
Pharmaceuticals and commercializes
is a global, integrated, research-
innovative
led medicines in areaspursuing
of unmetthe medical need.and
GreenPine (Tianjin GreenPine Pharma Co.,discovery
pharmaceutical company Ltd.) is a
development
company which of innovative
extensively products
involves ininto
ourhealthy
focusedproductsin
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage
therapeutic
and commits areas
to of dermatology,
provide safe and respiratory,
effective healthyimmuno-
products
biotechnology
The Grünenthalcompany Group isthat aims to develop
an independent, the world’s
family-owned,
for
mostpeople.
potent vaccines.
international
GSK is a fullyresearch-based
focused biopharma pharmaceutical
company. company We prioritise with
focus on innovative
innovation in vaccines treatments
and in chronic
specialty pain conditions.
medicines, maximising
Raynovent is a commercial stage Bioharma dedicated to
the increasing
advancing opportunities to preventand andcommercialization
treat disease.
Gubra is a the research,
pre-clinical development,
peptide drug discovery powerhouse
of innovative
within drugs, with a specialization in the fieldsWe of
Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE) is a are
metabolic (e.g. obesity) and fibrotic diseases.
metabolism,
looking liver,
for partners and respiratory
(pharmacompany diseases.
or biotech) to out-license our
clinical-stage
Lundbeck is abiotechnology
global CNS focused developing
company with anti-
pipeline assets
fibrotic therapeutics and/or forto co-develop
a varietyinofmore novel
chronic peptide drugs
approximately
A clinical-stage5,600 Oncology employeescompany searching thanorgan 50 diseases.
forcountries.
out-
licensing partners for its
Haisco Pharmaceutical is oncology
a publiclyassets listedthatcompanyincludes focusing
inhibitors
on R & D of
of PI3Ka,
therapeutic c-Met, new ERK1/2,
drugs. EZH1/2
Haisco is and
now looking
Haisco is a publicly traded specialized pharmaceutical group
AXL/Flts/NTRK.
for Also interested in in-licensing early stage
thatacombines
HanAll
global partner
BioPharma
for 1)out-licensing
new medicine
Co., Ltd isresearch a globaland
their assests
development
biopharmaceutical
in China
with
2)In-lisencing
manufacturing or
and co-development
sales. Haisco our pipeline
focus on CNS/Pain,out-side of
company with a presence in Korea,
HANDOK is a leading pharmaceutical company in Korea, the U.S., Japan, and
Pulmonary/Respiratory,
Indonesia. HanAll has Oncology
been developing and Metabolic
innovative Disease.
products
established
Founded in in 1995,1954. HANDOK
Hansoh Pharma is located
is a leading in Seoul and
in the areas
recorded $448of engineered
mil sales in protein
2021. and monoclonal
HANDOK currently antibody
has
biopharmaceutical
Harbour BioMed iscompany headquartered in China,
a global biopharmaceutical company with
over 900
additional employees.
R&D developing
locations ininnovative
the US. therapeutics for
discovering
Helsinn is a and
global pharmaceutical company that builds,
cancer with a focus
manufactures, on immuno-oncology and immunological
Shanghai Henlius Biotech, Inc. is a leading products to
launches, and commercializes
diseases.
improve the qualitycompany of life for patientsonwith cancer and
biopharmaceutical
Hikma helps put better healthfocused within reach oncology,
every day for
chronic disease,
autoimmune with aand
diseases, focus on supportive
ophthalmic diseases,care,with oncology
fully
millions
Hisamitsu ofPharmaceutical
people in more Co., than Inc.
50 countries
is Japan based around the
integrated
world. R&D,
For 40 years, marketing
we've and
been commercial
creating manufacturing
high-quality
pharmaceutical
HK inno.N is a fully company with
integrated full capability
pharmaceutical of company
development
medicines
and sale and
of RxR&D making
and OTC them accessible
products in Japan,the
to thepeople
U.S.A., whoBrazil
with a strong and marketing
Advanced drug delivery platform technology and products position in South Korea.
and south
We Long-acting east
have outstanding asian countries.
track-record of new drug
for
Huadong Medicine, injectable
a leading formulation
Chinese pharmaceutical
commercialization and are seeking in-licensing late-stage
company
HUTCHMED based(China)in Hangzhou Limited (near Shanghai), China.
(Nasdaq/AIM:HCM;
Huadong Medicine is ranked
HKEX:13), an innovative, commercial-stage 18th largest pharmaceutical
company in China(among
biopharmaceutical company committed to the both MNCs and locals) by
discovery and
global development of targeted therapies and
Hypera is the largest fully integrated Brazilian
Pharmaceutical
Hypera Pharma Company is a leading with a strong
company infocus
Brazil, inwith
business
innovation.
distinguishedPharm. capability
HYUNDAI was in different
founded areasas
in 1965 of athe
pharmaceutical
pharmaceutical
company in South sector
Korea. - prescription, GX, OTC,
IASO Biotherapeutics is an innovative, clinical stage
hospital/government/oncology - and with a strong focus in
biotechnology
Ichnos Glenmark company
Innovation based(IGI)in Chinacreateand andthe U.S. focusing
develop
on discovering,
cutting-edge developing,
therapies manufacturing
in oncology based and
onofcomplementary
IGM Biosciences is pioneering a new class antibody
commercializing
biologics and smallinnovative
molecules cell therapiesengines
discovery and antibodies
to designfor
medicines
ILDONG Pharma is a leading pharmaceutical in Korea. and
for the treatment of cancer, and autoimmune We
and develop multi-specific
inflammatory diseases. opportunitiesantibodies and small molecules.
are seeking partnership
Immatics combines the discovery of true targets for cancer in various types of
therapeutic
immunotherapies areas. with the development of the right T cell
Immunocore is a commercial stage biotech focused on the
receptors
development withofthe goal of enabling
off-the-shelf a robust and
TCR-bispecific specific T
Incyte is a global biopharmaceutical companytherapeutics
that is focused
cell
called response
ImmTAX against these
for oncology, targets.
on finding
InnoCare issolutions
a public for seriousinfectious
commercial unmet
stage medical
and inflammatory
needs through
biopharmaceutical
diseases.
the discovery, development and commercialization of novel
company committed
Innovent Biologics istoa discovering, developing andcompany
leading biopharmaceutical
medicines.
commercializing potential best-in-class and/or first-in-class
in China developing
INOVIO is a biotechnology both innovative
companyand biosimilar
focused mAbs for
on developing
drugs
China for
and thefor treatment
global of heme-onc,
markets. Innovent advanced
has a solid portfolio
broad tumors
and commercializing
Insilico Medicine is aDNA leading medicines
clinical stage,to helpAI-powered
treat and
of IO targeted
protect people monospecific
from HPV-related and bispecific
diseases,biotech mAbs available
cancer, and
drug discovery
Well-capitalized and development
biotechnology (AIDD)
company focused company.
on rare and
infectious
We are seeking diseases. licensing partnership for our pipeline assets
pulmonary
Insud (Innovation, diseases Sustainability and Development) is a
as well as AIDD platform collaborations.
highly diversified group
Intas is a multinational pharmaceutical of companies with companya global presence
founded in
in the pharmaceutical
1976, dedicated to the and biotechnological
research, development, field.
manufacture
Intellia is a leading genome editing company, focused on the
and marketingofofproprietary,
development generics and biosimilarcurative medicines.
Intra-Cellular Therapies is a potentially biopharmaceutical company therapeutics.
focused
Ipsen is aonglobal the discovery, clinical development
biopharmaceutical group dedicated and to
commercialization
improving of innovative,
lives through innovative small molecule
medicines in Oncology, drugs that
Ironwood Pharmaceuticals is a patient-focused,
address
Neuroscience underservedand Rare medical
Diseases. needs in neuropsychiatric and
-biopharmaceutical
In-licensing of late company
stage assets on a for mission
markets to push
mainly thein EU
https://www.ipsen.com/our-company-2/
boundaries of the gastrointestinal (GI) field by advancing the
in nichePharma
JAMP areas Group is one of the fastest growing Bio
treatment of GI diseases and redefining the standard of care
Pharmaceutical
We are the No.1companies in Canada ,maker
plasma fractionation activeininJapan.
all sectorsWe
with BioJAMP
discovered a biosimilar
novel virus products,
inactivated JAMP
plasma Pharma
powder generic
with
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an
products,
high and Orimed
coagulation activityPharma by using branded/innovative
Micro Powder products.
international
NO REQUESTS biopharmaceutical
FROM SERVICE company
PROVIDERS focusedDry on System
PLEASE-
in collaboration
improving patients’ withlivesULVAC, by Inc. Looking
identifying, for a and
developing,
JCR
JEILPharmaceuticals
has an established Co., Ltd.,
presence founded
in Korea, in 1975, is
based onaits
commercializing
research-driven meaningful
specialty products
pharmaceuticals that address
company unmet
that is
strong
LicenseR&D capacities
out partnership; and
Samllexclusive
Molecule; marketing & sales
Lung Cancer, ALS,
redefining expectations
performance. JEIL is and expanding
seeking to in-license possibilities
innovative for
PD, Ischemic Strok; Solid Tumor;
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) is Triple-Negative Breast
medicines and out-license JEIL's newly developed assets for
committed
Cancer；
As the world’s to bringing
colorectallargest highmost
cancer,
and quality & affordable
cholangiocarcinoma,
broadly-based products
EGFR, to
healthcare
patients
Ret
company, bywe
Inhibitor, R&D are innovation
Proteasome
committed and
Inhibitor,
to collaboration
using TDP-43,
our reach in
Stip
and the
1, areas
HSF
size for1of
JT Pharma is dedicated to the discovery, development, and
oncology,
good.of We metabolic,
arehuman
blending autoimmune, respiratory,
our heart, science, andofingenuityand
renal, CV to
sales
Jubilant novel
Therapeutics therapeutics
is focused onindiscovery the areas and
profoundly change the trajectoryMuscle,
Cardiovascular/Kidney/Skeletal of healthImmunology
for humanity. and
development
Jumpcan Pharmaceutical of novel small is amolecules for the treatment
national high-tech enterprise of
Neuroscience.
cancer and autoimmune disorders.
group,
JW one of top 100
Pharmaceutical of nationalispharmaceutical
Corporation one of the leading industry,
and the Shanghai
pharmaceutical Stock Exchange
companies in Korea. A-share listed company
Kaken is fully-integrated Japanese pharma company founded
(stock code: 600566).
in 1948. We
Kamada is a helps improve the quality
NASDAQ-traded, FDA-approved of life for patients by
Biopharma
serving
company as many
based people
in Israel. The as possible to return
markets its ofpharma
smiles
Karyopharm Therapeutics Inc.company
is a commercial-stage
happiness
proprietary to their
products faces,
through through supplying
strategic partnerships superiorin more
company.
Kashiv is a1)US-based
Interested in partnership
fully discussions with
integrated biopharmaceutical
than 20 countries.
companies thathaving
have Kamada
late is also
stage cancer a leading
treatmentsdistributor
(Ph IIIinand the
company
Kelun Group with is a highly product portfolio
specialized that includes
innovative
beyond) 2) Eltanexor development
biosimilars/biologics, partnership 3)likeSelinexor
pharmaceutical
Keymed Biosciences, group NCEs,afounded
specialty
China based in 1996, products
whose
public capability
Biotech
505(b)2,
and NicheR&D,
covering peptides.manufacturing, sales & marketing, GSP
company,
Kintor is focusedlisted ononthe HK Exchange.
oncology Keymed founded
and AR (Androgen in
Receptor)-
Logistics,
2016 , is an etc. Combined
integrated stock value company
biotechnology now reachthat to CNY
has 100
relatedisdiseases,
Kissei a R&D includingoriented JapaneseProstate pharmaceutical
Cancer, HCC, company.
consistently
Androgenetic developed
Alopecia, innovative
Acne Vulgaris antibody therapies.
and COVID-19.
We
KM have
Biologicsclinical is aand pre-clinical
Japanese vaccine, stage assets
blood-plasma seeking for a
products,
partner outside
recombinant Japan. and
proteins, We veterinary
are also seeking vaccine formanufacturer
clinical stage
Knight Therapeutics Inc. (TSX:GUD) is a publicly-traded,
in-licensing
with over 75 opportunities
years of combinedfor Japan/Asian
experience. countries.
specialty
Kolon Life pharmaceutical company focused
Science is a clinical-stage on in-licensing or
biotechnology
acquiring
company advancing portfolio of novel gene pharmaceuticals
late-stage innovative prescription therapies in
in Canadaof
treatment and Latinand
cancer Americaneuropathic pain - currently seeking
partnership.
Kolon Pharma is currently looking for in-licensing
opportunities
Global of late-stage,
fully-integrated pediatrics, respiratory,
pharmaceutical company
dermatology,
headquartered OA and
in Japan. CNS products.
Seeking in-licensing opportunities
KUHNIL is a leading pharmaceutical company in Korea,
for the USAinand
established Japan.
1969. KUHNILNO SERVICE
is locatedPROVIDER
in Seoul and
MEETINGS.
recorded more than $100 mil sales in 2022.
Kyorin is a research-based pharmaceutical company in Japan
with commercial
No.1 Animal Health franchises
Company in ENT/
in Japan.Respiratory/
Pharmaceutical Urology/
IBD/ Pediatric. Current research activities are mainly
manufacturer.
Kyowa Kirin is Japan based fully integrated pharmaceutical
focusing on Pulmonary Fibrosis, Neuropathic Pain and
company
Bagó is a from
leading drug discovery
Argentine to marketing
pharma company, pharmaceutical
member of
products
Bago in over 42 countries in the world.
Biopas is a leading biopharmaceutical company We
Group, with strong presence in LATAM. deliver
focused on
high-quality
in-licensing, results aligned to country specific regulatory
Risvan® is a marketing,
monthly LAI andfor selling specialtyapproved
schizophrenia innovative by the
requirements,
pharmaceutical commercial
products strategy
indemonstrated
Latin America and operational support in
US FDA and Liomont
Laboratorios EMA. It has
is one of the largest outstanding
Pharmaceutical efficacy
in unstable in
companies patients
Mexico with
withsevere
a large to experience
moderate symptoms in marketing
PiSA® Farmaceutica is a Mexican company with almost 80
providing
and a fast onset,
manufacturing of without
small oral supplementation
molecules biologics and or
years of history dedicated to the manufacturing, marketing
vaccines.
and distribution of health product. Our portfolio consists in
We are an innovation driven private Mexican pharmaceutical
more than 1,500 brands of medicines distributed through 17
company
We are anwith 80 yearsleader
established of experience with the purpose of
in the development,
making life aand
manufacture healthy story.
Legend Biotech iscommercialization
a global biotechnology of pioneering
companydiagnostic
dedicated
and
to therapeutic
treating, and products
one day and
curing, artificial
life- intelligence
threatening (AI)
diseases.
Global specialty pharma company focusing on medical
solutions.
We are developing advanced cell totherapies across a diverse
dermatology.
Lepu Biopharma We ishave a mission
an innovation-driven help people achieve
biopharmaceutical
array of technology
healthy skin. platforms.
company
Our primary focusing
focus onis onfirst- and business
global best-in-house oncology
development
therapeutics with
opportunities strong
through China foundation andfor
investment/in-licensing global vision.
We aim to out-license
companies/external our in
assets anti-PD-1
areas of mAb product,
oncology, ADC and
immunolgoy,
LNC Pharm is fast-growing, biopharmaceutical company,
metabolic diseases (diabetes/NASH/obesity), pediatric
provider of complex cutting-edge services on the medical
market all around EAEU and the CIS
Lupin is the 11th largest generic company in the world and
3rd largestis pharma
Mabwell company in the
an innovation-driven US by prescriptions.
biopharmaceutical company
Lupin
with develops
the whole and commercializes
industrial chain of branded,
R&D, generic andand
manufacturing,
MacroGenics is a clinical-stage biopharmaceutical company
biosimilar products TA
commercialization. and covering
also has aauto-immune
strong biologic and small
diseases,
focused onPharmaceuticals,
Madrigal discovering and Inc. (Nasdaq: MDGL) is a
oncology, metabolic disorders, ophthalmologic diseases and
biopharmaceutical
4th Largest Company company
in Indian pursuing
Pharmanovel therapeutics
Market with major for
nonalcoholic
presence steatohepatitis
in Corporation
Chronic and(NASDAQ:
Acute (NASH),
therapy a segments.
liver disease with as
Ranked
MannKind MNKD) is a US-based
high1 unmet
No by medical need.
prescriptions Madrigal’s
generated with medication,
largest field Rezdiffra
force in the
commercial-stage
Founded in 1961, Marjan biopharmaceutical
Farma has been company focused on
a trusted
country.
the Capable
developmentindustry of registering
and commercialization the products including
of innovative
pharmaceutical
Maruho Co., Ltd. is a leading for the past 62 years,
pharmaceutical developing,
company
therapeutic
producing and products and
marketing devices
innovative for people
products living with
to improve
specializing in dermatology in Japan.
Maruishi is a top domestic company in the Japanese
patient health and well-being.
perioperative
Medis is the leadingmarket.commercializing partner of pharma and
biotech companies
Meiji Seika Pharma,inaCEE. Our major
“Specialty partners include
and Generic
Alimera, Bial,
Pharmaceuticals Biogen,
Company”, Biotest, Mundipharma,
is dedicated Pierre Fabre,
to research,
MeiraGTx is a fully integrated, clinical-stage gene therapy
Paion, Santen,
development UCB, and more.
company
Multinationalwithand commercialization
programs
pharma across multiple
company
of innovative
with the TFAs,
presence
and
including
in multiple
generic drugs,
Parkinson's areas: that improve
(Phaseoncology, quality
3-ready), cardiometabolic, of life
Xerostomia/Sjogren'sfor people with 2),
(phase
therapeutic anti-infectives,
and ALS (preclinical).
respiratory, GI, pain, allergology and consumer health
Merck Animal Health is a global leader in the research,
development,
Merz Therapeutics manufacturing
is a Frankfurt and Germany
sale of veterinary
based privately
medicines.
owned pharmaceutical company focused on neurology
Metagenomi is a California based gene editing companywith
global commercialization
committed capability. curative therapeutics.
to developingispotentially
Mirum Pharmaceuticals a public (NASDAQ: MIRM)
biopharmaceutical company
Mitsubishi Tanabe Pharma Corporation focused on (MTPC) debilitating is rare
diseases with three
expandingPharmaceutical commercial
its global operations products.
and building Mirum is based in
for future
Mochida (Mochida) is a Japanese
Foster City, California
growth with the aimcompany with
of becominginternational commercial
a global research-driven and
biopharmaceutical headquartered in Tokyo.
pharmaceutical
Founded in 1913, company
Mochida that
hascan be trusted
played a key byroleour in the
medical industry through its pharmaceuticals, healthcare
NEURAXPHARM, a European leader in pharmaceutical
products for the CENTRAL NERVOUS SYSTEM
We discover and develop innovative and life-changing
pharmaceuticals,
Neurophth is China'sin diseases
leadingwith in-vivo highgeneunmet medical
therapy needs,
company
through our
for ophthalmic novel R&D
diseases. platform,
Astoa be focused
clinical-stage on neurological
company,
NBP was founded in 2010 the First-in-Class
and endocrine
Neurophth based diseases
is dedicated and disorders.
to discovering and developing gene
commercialization platform for the
BioHealth Innovation is a commercialization intermediary Middle East and North in
therapies
Africa for patients
region, focusing suffering
on from blindness
in-licensing only and other eye
innovative
Maryland. With a unique EIR program
Mid-sized pharmaceutical company in Japan, engaging in we both co-found
therapies
bio- and meddeveloped by Global investing
tech companies, Pharma, with our a missioninto
resources
research
Nippon and development
Kayaku Co., Ltd. isofainnovative small
Japanese pharmaceutical molecule
venture
medicines, formation,
looking advise client companies,
forinout-licensing and support
foroncology-related
our assets for IBD, the
company specializing oncology and
Nissan Chemical is an oligonucleotide therapeutics discovery
chronic
fields. We cough, CKD and
are seeking neuropathic
late-stage pain. and development
new sales
company developing
Nitto’s proprietary multiple
delivery pre-clinical
platform provides programs
lipids and
products tofirst-in-class
including strengthen our pipeline.
antisense oligonucleotide therapeutics
formulations that enable organ and
Nobelpharma is an emerging and rapidly growing Japanese cellular delivery of RNA-
using
and our
nucleic proprietary
acid-based technologies.
genetic medicines and vaccines.
pharmaceutical
Nomura is a globalcompanyfinancial established
services in 2003.
group with an
integrated network spanning
Nordic Pharma is a privately owned, medium-size,over 30 countries. We fully
provide a
variety of advisory
integrated and capital-raising solutions to product
NOUCOR Pharma is a B2B company
pharma with company a history of internal
devoted to the R&D,
companies, private
development and equity, governments
acquisitions. We have and
a public-sector
direct presence
licensing, manufacturing and supplying of new and valuein
Europe, and more recently, expanded
added molecules in the dermatology, respiratory, CNS and outside of Europe into
Novartis contract manufacturing offers a fully integrated set
Women's Health therapeutic fields. BIO conference goal:
of Contract
Novavax is aManufacturing
biotechnologyServices companyinthat Mammalian,
promotes
Microbial health
improved (e.g.protein),
globally Cell & Gene
through the therapy
discovery, , pDNA,
development
Noven Pharmaceuticals is a specialty pharmaceutical
mRNA,
and Viral Vector, Fill
commercialization of and Finish vaccines
innovative to meet the to clinical &
prevent
company engaged in the
We seek opportunities insale of prescription
: Diabetes, Obesity,products.
Chronic
serious
Specific infectious
focus inDisease diseases.
ADHD,(heart digital therapy and transdermal
Cardiovascular
We are a commercial-stage failure,
oncology cardiomyopathy,
company developing a
drug delivery.
atherosclerosis, As well
resistant as specialty, small volume niche
novel, proprietary therapyhypertension)
called Tumor Treating Fields, or
TTFields, for the treatment of solid tumor cancers.
Nxera Pharma (formerly Sosei Heptares) is Japan's best
capitalized
Nxera Pharma mid-sized
(formerly biotechSoseifocused
Heptares) on specialty care. We
is a fully integrated
are the
biopharma partner of choice
company, listed to develop and
on the Tokyo Stock commercialize
Exchange; your
A global Geneva-based biopharmaceutical company, leader
innovative
world drugs in
leaders in discoveringJapan & wider APAC.
in the prevention
Organon is a global recurrentand
of healthcare designing
respiratory
company formed andnovel
urinary medicines
throughtracta
targeting
infections, G protein-coupled
alsoMerck
active&inCo., receptors
the Inc.,
treatment (GPCRs)
of vascular diseases.
spin-off from
Orion Corporation is a European, Rahway,
mid-sized, NJ, USA, (NYSE:
pharmaceutical
MRK)
company known as MSD outside
headquarteredisinaFinland of the United States
with a direct commercial and
Otsuka Pharmaceutical global biopharmaceutical
Canada,
presence to focus on improving
throughout the European the market,
health ofinwomenselected Asia-At
company
We are one with a mission
of the to create companies
main operating better healthof worldwide.
Otsuka
Pacific countries
Otsuka pharmaceutical and a solid track record
Company, ourmanufacture, in developing
core interestsR&D, are NCEs
in the
Holdings
PARI Pharma Co., focuses
Ltd., with onconducting
the development of aerosol
areas of psychiatry,
sale, anddevices
import and export nephrology, neurology,
of clinical nutrition drug and products and
delivery
Partex NV is ​the and firstcomprehensive
digital ​pharma inhalation platform that is set to be
other pharmaceutical
development to advance products,
aerosol medical
therapies devices,
where functional
drug and
the largest AI-powered
PeptiDream Drug Assets Manager.
is a public biopharmaceutical company based in
device can be optimized together.
Kawasaki, Japan, focusing on the discovery and development
of macrocyclic peptide-based therapeutics and
Our flagship product ropeginterferon alfa-2b (P1101) is a
commercialization of radiopharmaceuticals in Japan.
novel long-acting,
Our flagship product mono-pegylated
ropeginterferon proline
alfa-2b interferon
(P1101) is a
developed
novel using
long-acting, our PEGylation
mono-pegylated technology
proline platform.
interferon
PharmaMar, is the world-leading biopharmaceutical
developed
company inusing R&D ourof PEGylation
marine-derived technology
anti-cancer platform.
drugs.
Pharmanovia is a global lifecycle management healthcare
company. Our mission is to revitalise
PharmaResearch Co., Ltd., contributes and adds-value to iconic medicines forthe
the benefit of
biomedical patients, prescribers and payors, and utilise our
Pharmathenindustryis one ofoffering
the largest pharmaceutical
developers ofproducts, complex drug
capabilities
medical to launch
devices and novel therapies.
cosmetics utilizing domestic natural
delivery
Pharming Group N.V. (EURONEXT Amsterdam: and
technologies. With its best-in-class R&D
resources
manufacturing and proprietary
capabilities, core technology.
PHARM/Nasdaq:
Pierre PHAR) iswe
Fabre is an independent
have one
a global of the most
biopharmaceutical
fully-integrated health care
extensive
company and advanced
dedicated tointransformingpipelines of LAIs,
the livessustained
of patients release,
with
group headquartered France with
Latin America's community centric biopharma – sourcing a global footprint. Our
rare, debilitating,
therapeutic area focusand life-threatening
is in oncology, diseases.
dermatology, rare
prime innovation
Polpharma Biologics in the is afields
rapidlyof haematology,
expanding immunology,
diseases,
solid urology,
tumours and rheumatology,
inherited genetic and women’s
diseases health.it
to make
biopharmaceutical
Poseida Therapeutics company with state-of-the-art
is a clinical-stage facilities
biopharmaceutical
available
across to
Europe. patients
We across
offer and the region.
deploy fully integrated solutions
company
We leveraging proprietary
are a commercial next-generation,
stage biopharmaceutical non-viral
company
along the biopharmaceutical
gene engineering technologies value chain to serve
to create life-saving cell the needs of
focused on the development
PTC Therapeutics, Inc. (PTC) andis acommercialization
global biopharmaceutical of next
therapies
generation, andclinically
in vivo gene superior therapies
versions for patients with high
of recombinant
company
Purdue Pharma focused and onitsthe discovery,
subsidiaries development
develop, and
manufacture and
therapeutic proteinsofthrough
commercialization novel our rare
and ProCellEx®
disease plant cell-based
medicines.
market medications to meet the evolving
Radius Health is biopharmaceutical company dedicated to needs of healthcare
professionals,
transforming the patients,
future and caregivers. global patient
for underserved,
populations in bone health and related areas.
Rafa Laboratories was founded 85 years ago, today we are a
fully integrated
Rakuten Medicalpharmaceutical company headquartered
is a private biotechnology firm that is in
Israel with
developing multinational
cancer therapies operations. Rafa is looking
target to in-
No service providers meetingwith the ability
requests pleaseto(CRO, cancer
CMO or
license innovative
cells, service
based onproviders) therapeutics into the
a photoimmunotherapy platform with a lead Israeli and CEE
other
Recursion is a clinical-stage TechBio employing a discovery
program that received approval in Japan in 2020.
platform
Regeneronwhich combines
is a leading automation, experimental
biopharmaceutical company with biology,
a
and AI
wideSERVICEto rapidly
array of platform identify drug
technologies development
in genetics, candidates,
biology and
NO PROVIDER (CMO, CRO, etc) MEETING
conduct
biologicscompound
based intelligence
medicines . We and apply identify new targetacross
these platforms
REQUESTS
Relay Therapeutics PLEASE is a clinical-stage precision medicine
all therapeutic areas, resulting in 7 approved products and a
company
RemeGenthat is a sits
public at the intersection of computational
commercial-stage innovative biotech and
experimental
headquartered technologies
Revvity is a lifeinsciences China with andR&D facilities
diagnostics in U.S. We are
company
commited
committedAB to the
to are discovery,
accelerating development and
Ribocure an siRNAthe translation
company withofprograms
genomic in insights
pre-
commercialization
into advanced of biologics
therapies. Our cell with andfocused
gene therapy areas inportfolio
clinical and clinical stages.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”)
spans multiomic discovery tools, payload and delivery and
is a clinical-stage multi-platform gene therapy company
focused on developing first-in-class gene therapy treatment
At Rosemont our mission is to be a rapid developer, reliable
options for rare, devastating diseases.
manufacturer
Ryvu Therapeutics and global discoverssupplier
and of novel-delivery,
develops small molecule patient-
focused medicines.
therapies that address Rxhigh
oralvalue
liquidemerging
medicinestargets for patients
in with
Salus is the leading commercialization and distribution
dysphagia.
oncology.
partner of choicecompany
Pharmaceutical for Healthcare and Biotech
specializing in developingcompanies products
seeking
in the to
areas expand
of their
Otolaryngology,presence and drive
Ophthalmology business and growth
GI .
With 77 years of experience in the pharmaceutical industry,
in 18 countries across Central and Eastern Europe.
Samil Pharm
Samjin is a fully integrated
Pharmaceuticals Co., Ltd.pharmaceutical
seeks to establish company
strategic
with proprietary
alliances prescription
and parnerships thatand OTC drugs
complement ourcovering
expertise R&D,
in
manufacturing, distribution, marketing,
the development of novel therapeutics with important and sales in Korea.
scientific, clinical and business capabilities.
Sana Biotechnology, Inc. is focused on creating and
delivering
SGMO engineered
is not interested cells as medicine
in additional CRO for orpatients.
other service
providers at this time. We will
SANOFI is an innovative global Healthcare company not be accepting these
requests.on human health
focused
SANOFI is an innovative global Healthcare company
focused
Sanofi's on humanbusiness
vaccines health is the Global Business Unit of
Sanofi responsible
Santen for infectious disease
is a global pharmaceutical company vaccines. We areon
fully focused
the ophthalmic
the largest company fields, in"eye
the world
diseases",devoted entirely to human
including
SKK has grown as an R&D-oriented pharmaceutical
vaccines.
pharmaceuticals, OTC products, surgical products,and and
company
Sarepta isand researches,
a global develops,
biotechnology manufactures,
company on an urgent
medical devices.
markets pharmaceuticals and diagnostics since 1953. Also,
mission: to engineer
Saurav Chemicals precision
Limited is agenetic medicine company
well-established for rare
we are
diseases a subsidiary
that devastate of Suzuken,
lives and a leading company
cut futures short. in
manufacturing
Schrödinger aims andtoproducing
improve human APIs health by developing
highly potent, selective
SciClone is a biopharmaceutical company molecules using their
withadvanced
an integrated
computational
platform for drug discovery
product development methods and that accelerate the
commercialization.
Seacross Pharmaceuticals is a global pharmaceuticals
speed and efficiency with which scientists discover, design
company dedicated on theisdevelopment
Sebela Pharmaceuticals® a U.S. pharma of company
generic drugs, with a
innovative
market-leading small molecule
position inJapanesedrugs, and
Gastroenterology next generation
and a focus of on
Senju is a research-based pharmaceutical company
ADC,
innovationwith focus
in Women's on oncology
Health. and immuno-oncology.
that
SERB develops,
is a Global manufactures andOur BD strategy is
commercializes
specialty pharmaceutical groupafocused
focusedof
variety on
on in-licensing
innovative products post-Proof of
as focusing Concept
on therare programs
fieldand through
of life-
prescription medicines which address
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-
ophthalmology.
threatening diseases.
stage
Servier company
is a €5.3bn developing
independent novelpharmaceutical
microbiome therapeutics company
for serious
headquartered diseases.
in France with 22000 employees worldwide. is
Huaota Biopharma, a subsidiary of Huahai Pharmaceutical,
aJemincare
clinical stagegroupbiopharmaceutical
is a leading pharmaceutical company committed company into
discovery,
China development and commercialization ofoncology,
novel
SHcellcovering
is a clinical wide therapeutics
stage cell therapy areas including
company with
biologics in the
nephrology, CV, cancer
analgesic,and autoimmune
anti-infection, therapeutic
respiratory. areas.
innovative
Shin Poongtechnology
Pharm. Co.,platforms Ltd. started including
writingVHH its ownantibody
histroy
discovery, proprietary transposon-based
in Korean pharmaceutical industry 57 years geneago. writing
In our system,
SHIONOGI is a research-driven Japanese pharmaceutical
and novel Tiniplasmid
mission statement "For thetechnology
Health
company
Sinergiumwith affiliates
Biotech is an in the US, of
Argentinean
PeopleUK,
Europe,
pharmaceutical
withChina
Dignity and
and Prudence,"
Taiwan. Total we deliver
revenueinFY2023 the hope that
was $3.1 shines over
billion. Business the
company specialized
Sino Biopharmaceutical the research,
Limited and development,
its subsidiaries (CTTQ,
portofolio includes
production and pharmaceuticals,
commercialization of vaccines,
high-complexity digital, OTC,
Beijing
SinoMabTide, invoX etc.)
BioScience is theisleading
Limited a Hongand largest
Kong-based
vaccines
pharmaceuticaland biological
group products.
in China
biopharmaceutical company with strong R&D capability.
SK Biopharmaceuticals is a global CNS and Oncology
focused
**SK company providing
bioscience** is **a leading therapeuticvaccine solutions
and bioto those
with
company**high unmet needs.
committed to promoting human health from
SK Chemicals is committed to perform practices from
prevention
research & to cure with itstoglobally-competitive
development marketing activities R&D
in Korea.
SK Plasma is a global plasma-derived medical products
capabilities,
The companycutting-edge
is well known production facilities and 1000+
company.
Spark is a We geneare seeking
therapy forfor
leader
extensive
investment domestic
opportunities
seeking to transform
market
the in
lives
coverage
next-gen with talented
biotechnology sales representatives,
to secure innovative facilitating
pipelinesthe forthe
of patients
SRI with debilitating
is an independent, nonprofitgenetic diseases
research through
center founded out
rare
deliveryand incurable
of life-altering diseases. treatments.
of
WeStanford
are looking Univ. forininnovators
1946. Ourwho pipeline
seek includes
access to novel markets
platforms
with for intracellular delivery of wide variety of cargos,
our strength.
etc. We are seeking commercial partners for out-licensing.
Stallergenes Greer is a fully integrated global
biopharmaceutical
Sumitomo Pharma company Co., Ltd.,specialised
is a R&D based in thepharmaceutical
diagnosis and
treatment and
company of allergies,
aims to throughinnovative
provide the development and and new
effective
With 2022 global revenues of over $ 5 Billion, Sun Pharma
commercialisation
drugs. We also of allergen
seeklargest immunotherapy
to contribute to the well-being(AIT) of
is
Sunshothe world's
Pharma's fourthproprietaryspecialty UniORVgeneric formulation pharmaceutical
people through
company. Sun application
Pharma is of thetolatest
looking add digital
to its technology.
growing
technology
Sutro Biopharma, enhances stability,
located in Southabsorption and reliably
San Francisco, is
specialty
delivers branded
drugs to business,
the colon. focused
The on dermatology,
company was founded in
developing
Sobi® a new generation
is a specialised of multi-functional
international biopharmaceutical antibody
1993, had
drug conjugates, approximately
bifunctional $170 million
antibody-basedin annual revenues
therapeutics,
company transforming
Tabuk Pharmaceuticals the lives
is the of people
largest with
private rare andin
company
and engineered
debilitating cytokines
diseases. for targeted cancer therapies.
Saudi
Princeton, ,develops,
NJ - based manufactures,
global oncology marketscompany
and distributesand
branded
subsidiary pharmaceuticals
of Taiho Pharma and under-licensed
Company; part of products
the Otsuka with
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co.,
aHoldings
strong focus on the Middle East and North Africa region
Ltd., is is
Taisho anafamily
R&D-driven of companies
leading Japanese specialty pharma focusing
pharmaceutical company on theandtwo
fields
has twoofsustaining
oncology and immune-related
pillars, Consumer diseases.
Health Care (CHC)
Takeda is a patient-focused, innovation-driven global
business and Prescription
pharmaceutical company that Pharmaceutical
builds Operation Group.
on a distinguished 238-
A $2.6 Billion pharmaceutical & medical products distributor
year
and history, aspiring to bring better health and a brighter
Taromanufacturing
develops high-quality, based in proprietary
Saudi Arabia. andIt off-patent
is the biggest
future for people
reprehensive and/or worldwide.
partner with blue chip pharma
pharmaceuticals
A biopharmaceutical for markets
company in that
the US, Canada,
applies proven Israel and
science
companies,
othernew countries alsoaround
servingthe GCCworld,andfocused
MEA regions through
on dermatology.
and technology to revolutionize
Tasly Pharmaceutical Group Co., Ltd. was listed on Shanghai treatment for patients,
No Service
starting withProvider
eye care. Request Please.
Stock
Teijin Exchange
Pharma is in August 2002
a subsidiary (Stock of
company Code
Teijin 600535),
Limited andand
has its
aJapanese headquarter
fully integrated in Tianjin,
healthcare China.
company responsible for
specialty pharmaceutical company focusing on
pharmaceuticals
pain, dermatology and and home healthcare
transdermal withtechnology.
patch medical devices
Telix is a global, commercial-stage radiopharma company
in Japan. We are actively seeking collaborations and
focused on the development of
Tenry Pharm is a commercial-staged pharmaceutical therapeutic and diagnostic
(‘theranostic’)
company focussing products using molecularly
onisdermatology, targeteddisease,
autoimmune radiation.
Tessera Therapeutics pioneering Gene Writing™—a new
We help
and people with
cardiovascular cancerWe
disease. andseekrare global/ex-China
diseases live longer,
genome engineering technology that
Laboratorio Teuto Brasileiro is one of the leading companies writes therapeutic
partnership
messages on the
into ourgenome
core products to treatand in-licensing
diseases at theira source.
in thePharmaceutical
Teva Brazilian pharmaceutical
Industries market, Ltd. (NYSE boastingand TASE: rich
heritagehas
TEVA) spanning
been over 77 years.
developing and producing medicines to
A mid-sized spec pharma company which sells prescription
improve people’s
medicines lives for andmore than a century. Wediseases
are a
Specializedtocompany physicians pharmacists
in gastroenterology/digestive who treat and
global
that leader
affect womenin genericacross and specialty
Europe, medicines
Australia, Latam . and via
infectious
Toray Group diseases
is an Advanced Materials Manufacturer
partners across the Globe
developing is
Transcenta itsabusiness
late clinical in 29stagecountries and regions
biopharmaceutical
worldwide.
company that fully integrates antibody-based biotherapeutics
At Travere Therapeutics, we are in rare for life. We are a
discovery, research,company
biopharmaceutical development that and manufacturing.
comes together everyisday
With its post-NDA filling and Ph2b assets, Trinomab a to
Therapeutic
help patients, focus
familiesincldue and oncology,
caregivers kidney
of all and bone as
backgrounds
biotech
Tris Pharmacompany dedicated
is a fully integratedto pioneering
biopharma thecompany
discovery,
they navigate and
development life commercialization
with a rare disease.of fully native human
focused developing
Tsumura USA, Inc. and is a 100%commercializing
subsidiary of innovative
a Japan-based
monoclonal
therapeutics antibodies
for company, with added
CNS disorders. Wevalues
also for patients
leverage our in in
pharmaceutical
TTY Biopharm Co. Limited (TTY) is a publiclyistraded,
Tsumura & Co., and engaged fully
proprietary drug delivery
clinical development a technologies
ofpharmaceutical
pharmaceutical to develop
botanical best-in-
drug, TU-
integrated, innovative
UBE corporation is a drug discovery and chemical company company with focus
100,oncology,
on which has been approved
intensive care, and and marketed
primary care inwith
Japan as aand
sales
focused
At UCB,on wesmall molecule therapeutics
are consistently delivering on andour licensing
commitment them
marketing
out to capabilities in
pharmaceutical and Taiwan, China, and
biotechnology SoutheastWe
companies. Asia
to improve the
Ultragenyx is alives of peoplebiopharmaceutical
clinical-stage living with severe company neurological
are
and looking to identify
immunological strategic partners for our projects.
conditions.
committed to bringing
United Therapeutics to market novel
Corporation products for the
is a biotechnology company
treatmentonofthe
focused rare and ultra-rare diseases, with a focusofon
Valneva is a specialty vaccine company focused on unique
development and commercialization
serious, debilitating
products to against
addressdiseases genetic
the unmet diseases.
medical
prevention
Verve Therapeutics with
is a biotechnology major needs
unmetofneeds.
company
patients with
created with
chronic
Valneva’s and life-threatening
portfolio includesthe conditions.
three commercial
a singular focus: to protect world from heartvaccines disease.and a
unique Phase 3 vaccine candidate in development against
Vetoquinol is a top 10 animal health company focused on
small animal
Viatris and livestock
is a unique products.company
global healthcare Vetoquinol SA ison a
focused
interested
wide variety in licensing opportunities
of therapeutic for management
areas. global specialist HIV of
ViiV Healthcare is an independent,
infectious diseases, osteoarthritis, dermatology, parasites ,
company
Worlwidecommitted
pharmaceuticalto delivering
laboratory innovative
dedicated medicines
to Animal for
the care
Health and treatment of HIV. Our mission is to leave no
A leader in developing innovative drugs for metabolic
person living with HIV behind.
diseases.
Wave is aSeeking out-licensing
biotechnology company opportunities
focused onfor the lead
delivering
polymer drug, WS016,
transformational a Global #3 innovative potassium
Whan In Pharm. (located in Seoul, South Korea) is diseases.
therapies for patients with serious a highly
binder for hyperkalemia treatment.
specialized in CNS, fully integrated pharmaceutical
We develop, manufacture and market integrated solutions company
with strong expertise and proven track record
that enable IVD diagnostics in more than 50 countries around in-licensing
and developing
the world. innovative
We offer a broaddrug line candidates
of productsfor for clinical
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage
laboratories and blood banks that enable accurate and timely
biopharmaceutical
Xeris Biopharma (NASDAQ: company committedXERS) is to developing stage
a commercial
innovative therapeutics
biopharmaceutical to improve
company leveragingthe lives ofnon-aqueous
patients with
XtalPi uses AI, physics-based modeling,novel and robotics to fast-
neurologicalplatforms
formulation disorders.to develop ultra highly concentrated
track
XtalPidrug
is a discovery
technologyand development.
platform company that harnesses the
(>450mg/mL), ready-to-use, subcutaneously injectable
power of AI
Xuanzhu and automation to
Biopharmaceutical Co.,build
Ltd.molecular R&D
is an international
ecosystems
research and for drug and materials
development (R&D) development.
enterprise of innovative
Yifan Pharmaceutical is an innovative R&D and production
drugs. focusing on pharmaceutical and health products
company
YOOYOUNG Pharmaceutical Co., Ltd. is a pharmaceutical
including
company macromolecules, small molecules,
Republic ofsynthetic
- YUHANheadquartered in Seoul,
is a leading Korean pharmaceutical Korea.
company We
biologics,
focus on and special
development, TCM.
manufacturing and distribution
expanding
ZAI Lab isR&D spectrum
a NASDAQ in Oncology,
listed leading biotechMetabolism
company &of
finished
Fibrosis, pharmaceutical
and Immunology products.
& Anti-inflammation. We seek
based
Zambon in China
Biotech, focused on discovering
the Centre of Externaland developing
Innovation of
strategic
innovative partnership
medicines opportunities
for unmetleverages for external
medical the needs cutting-edge
globally.
Zambon group of companies,
Zealand Pharma A/S (Zealand) (NASDAQ OMX commercial
capabilities
Copenhagen: of Zambon is SPA , a fully integrated, mid-size
Zelgen is one ZEAL)of the most a mature
innovative biopharmaceutical
biopharmaceutical company
Pharma
based in company,
Copenhagen, operating
Denmark. WW. We We
are are looking
seeking to in-
global
companies
Zentiva in China.
holds a strongZelgen
position hasina all
robust
marketpipeline from late
archetypes
commercialization
clinical stage to early partners
clinical forstage
our late
and stage
pre-IND assets in the GI
programs.
Zeria Pharmaceutical is a Tokyo-based healthcare company
We are seeking partnership for global or ex-China
focused
Zymeworks on the discovery,
(Nasdaq: ZYME) development
is a global and marketing of
biotechnology
novel pharmaceuticals for Japan and
company committed to the discovery, development, and the international
marketplace.
commercialization of novel, multifunctional biotherapeutics.
 Description

3SBio is a fully-integrated biotechnology company in China

with
3SBiocommercial and R&Dbiotechnology
is a fully-integrated programs in oncology, company auto- in China
immune
with diseases,
commercial nephrology,
and R&D metabolic
programs in diseases
oncology, and
auto-
Abbisko Therapeutics (Stock Code: 02256. HK) is an
dermatology.
immune diseases, 3SBio was founded
nephrology, over 25diseases
metabolic years ago andandin is
oncology
Abbott is afocused
global biopharmaceutical
healthcare leader that company
helps people founded live
dermatology.
Shanghai, 3SBioto
dedicated was founded over
discovering and 25 years ago and is
developing
more
AbbVie fully
is aatglobal,
all stages of life.and
research Our portfolio
development-based of life-changing
innovative medicines
technologies spans company to treat
the spectrum unmet medical
of healthcare, needs in China
with leading
biopharmaceutical
AbCellera discovers and develops committed antibody to discovering
medicines for and
businesses and
developing productsmedicines
innovative in diagnostics,that medical
solve serious devices,
health
indications across therapeutic
Abogen Biosciences areas including
is a clinical-stage biotechcancer,company
issues today
metabolic and and address the
endocrine medical and
conditions, challenges
autoimmune of tomorrow.
dedicated
At Acadia,towe delivering
are dedicated transformative
to developing medicines
innovative through
disorders. AbCellera’s
mRNA innovation. The engine
company integrates
has (CNS) technology,
established data
industry-
medicines for central nervous system
With a robust product portfolio in growth segments, spanning disorders, and
leading proprietary
are committed mRNA
to partnerships production and
and collaborations lipid nanoparticle
to expand
Oncology, Cardiology, Neurology, Nephrology, Urology,
our pipelineDiabetology,
Psychiatry, and commercial Painopportunities.
management Core and tenets of
Privately-owned company founded 57 years ago, Aché is
Gastroenterology, Accord’s marketing and distribution
positioned among the largest pharmaceutical corporations in
Brazil, with sales of over $ 1 bn and 3,000+ sales reps.
Adaptimmune is a leader in TCR T-cell therapy, focused on
designing
Huge portfolioand delivering
and librarynovel cancer enzyme
of purified immunotherapy for Biocatalyst
products. We utilize the body’s own machinery – the T-cell –
ADVANZ PHARMA is a global pharmaceutical company
to target and destroy cancer cells. We believe our therapies
with the ispurpose
Agenus to improve
a clinical-stage patients’ lives bycompany
immuno-oncology providing the
specialty,onhospital,
focused the and rare
discovery and disease
developmentmedicines of they depend
therapies that
**We are not accepting meetings with CROs, CMOs, and
on.
engage the body's immune system to fight cancer and
consultants**
Aidoc is the leader of artificial intelligence healthcare
infections. The Company's vision is to expand the patient
solutions
Aju Pharmthat work
is an idealwith physicians
partner to manage
to maximize the entire
the value of
patient lifecycle—from
projectsistogether and help diagnostic
patients aid, to
get access consultation
to qualityto
Akebia a NASDAQ listed (AKBA), fully integrated US
suggested
treatments.treatment
Family paths to clinical
ownership andonthe trials.
close-knit We use management
biotechnology company focused improving the lives of
team with
patients global experience
suffering from kidney bring agilityWith
disease. and theflexibility
recent US in
As a leader in rare diseases for more than 30 years, Alexion
approval of Vafseo®, Akebia is preparing for its next chapter
is focused on
Alfasigma is anserving
Italianpatients and families
privately-owned, affected by rare
integrated
diseases and devastating
multinational Pharmaceuticals conditions
pharmaceutical company through theamong
discovery,
Tiefenbacher is a 100%ranked family-owned the top
development
5 pharmaceutical and commercialization of life-changing
companies in Italy, worldwide oriented,
leading health
Alkermes is a fully-integrated, global biopharmaceutical
with revenues of 1.3 billion Euro, 6 manufacturing plants (4
company
Founded in that applies
2017, its scientific
by scientists from expertise
China and andthe proprietary
UK,
technologies
Allife Medicine to research,
has been develop
at the and
forefront commercialize,
of advancing both
Almatica Pharma LLC is a US subsidiary of Alvogen. The
with partners
healthcare, and
through on its own,
universal, pharmaceutical products that
parent company
Almirall is a leading Alvogen, a off- the-shelf,
globalisbiopharmaceutical
privately owned and innovative
company
cell medicine and
pharmaceutical gene therapy.
company focusedOperating
on developing,globally in China,
focused
Alnylamon Medical
(Nasdaq:ALNY) Dermatology.
is leading the translation of RNA
manufacturing and selling generic, brand, over-the counter
interference
Alvogen is the (RNAi) into a new pharmaceutical
next generation class of innovative medicines
company.
with the
Alvogen potential to improve the lives of people afflicted
Alvotechcurrently
has all inhas house commercial
capacities,operations
capabilities around
and the
with
globe,rare genetic, cardio-metabolic, hepatic infectious, and
experience to develop the products from scratch, alland
with regional hubs based in North America the way
APAC.
to dossier readiness and commercial supply. We are working
Amgen is committed to partnering with innovators in the
with local champions to bring products to patients in need.
fight
Aboutagainst
Amgenserious illness. Amgen’s business development
Biosimilars
team brings together deep scientific, financial, deal,
Amgen is committed to partnering with innovators in the
partnership, and integration expertise—along with an ability
fight against
Amicus serious illness.
Therapeutics Amgen’s business
(Nasdaq:FOLD) is a global, development
patient-
team brings
dedicated together deepcompany
biotechnology scientific, financial,
focused on deal,
discovering,
Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
partnership,
developing and anddelivering
integrationhigh-quality
expertise—along medicines withfor an people
ability
headquartered
Antengene Corporation in Bridgewater, LimitedNJ, is a fully
(“Antengene”, integrated
SEHK:
living with rare company
pharmaceutical metabolicfocused diseases. on the development,
6996.HK)
AOP Health is Group
a leading commercial-stage
is the European pioneer R&D-driven
for integrated global
manufacturing
biopharmaceutical and distribution
company of
focused generic
on theand specialty drug
discovery,
therapies
At Apellis, forwe rare diseases
combine and in critical
courageous science care. andOver the past
compassion
development,
25 develop
years, the manufacturing
AOP Healthmedicines
Groupand hascommercialization
become an the of
established
to life-changing
ApicHope pharmaceutical Co., Ltd, founded in 2002, is a for some of most
provider
challenging of integratedpatients therapyface. solutions operating from its
listed (Stock:diseases
For Canada, 300723.SZ)
LATAM and biopharmaceutical
the United States, Apobiologix company has
integrated
an interest with innovative drug research and development,
Apotex hasinanpartnering
integratedon biosimilar
portfolio and differentiated
of generic, biosimilar and
manufacturing,
small molecule marketing
products toand sales. After
complement itstwo decade’s
existing portfolio
innovative branded pharmaceutical products for global
in Oncology and Hematology.
markets. Apotex employs almost 7,000 people worldwide in
manufacturing, R&D, and commercial operations. Apotex
APSEN has been in the local market since 1969. In these
five decades
Ardelyx was and foundedmore,with APSEN a missionhas launched
to discover, innvative
develop
products, expanded
and commercialize its manufacturing
innovative,biotechnology plant,
first-in-class medicines increased its
argenx is a commercial-stage company that
staff, won
meet significant several awards,
unmet medical conqueredneeds.with the pharmaceutical
Ardelyx has two
developing
Aristo Pharma antibody-based
is a family owned therapies company,highly with the
commercial products
differentiated qualities. approved
We are in the United
dedicated States, product
to creating
headquarters
ARL Bio Pharma is a contract laboratory thatintegrated
in Berlin, Germany. It’s a fully provides
candidates
pharmaceutical with either first-in-class
company with activities potential against
fromnovel
analytical
AKP and microbiological
is a fully integrated pharmaceutical testing to rangingpharmaceutical
company with
own
product
companies anddevelopment, research manufacturing
scientists. Our of nearly all non-sterile
capabilities
Ascentage Pharma in R&D, manufacturing
(6855.HK) andlaboratory
is a global, commercialization.
clinical-stage
is
headquartered
AKP has successfully in Oklahoma partnered City, Oklahoma,
with large and small and serves over
biotechnology company
Ascletis is an innovative engaged
R&D driven in developing
biotech listed novelon the
organizations
therapies forStockto develop
cancers and and commercialize
hepatitis B. Wecovering a variety
focus onthe of
Hong Kong
The company has been Exchange developing(1672.HK),its proprietary R&D entire
developing
value chain therapeutics
from discovery that inhibit
and important
development kinases
to or
platformPharmaceuticals
ASKA and core technologies, is a fullyexploring
integrated new mechanisms
mid-sized
manufacturing
of action,pharmaceutical and commercialization.
and efficiently screening and Led by a management
evaluating
specialty
AstraZeneca is a global, science-led company based in Japan, drug
biopharmaceutical
candidates.
specializing With a well-established in-house 1.R&D system
company thatinfocuses
Atara Biotherapeutics,
three core
onInc.
therapeutic
the discovery,
(@Atarabio)
areas:
development Women’s
is a pioneer in andT-cell
Health, 2. Internal Medicine
commercialisation of prescription (Gastroenterology
medicines in and
Oncology
immunotherapy leveraging its novel
We focus on developing innovative therapeutics addressing allogeneic EBV T-cell
and BioPharmaceuticals,
platform to develop including Cardiovascular, Renalwith&
several hallmarks
AustarPharma &Bostalof transformative
cancer,located leveraging therapies
in US and ourChina, for patients
deep capabilities
severe
in science diseases
andWe including
building solidadded
value tumors, hematologicwith
collaborations cancers
respectively.
The company’s leadaretherapeutic
focused oncandidate,
therapeutic areas a CD19
obe-cel,
leading
include companies
metabolic, globally.
CNS, oncology, immunology, and
CAR
Avantor®,T cell ainvestigational
Fortune 500 company, therapy designedis a leading to overcome
global the
cardiovascular.
limitations in The Company's
clinical activity andinternally-developed
safety compared
provider
The company's of mission-critical
first commercial productsassetand services toto current
(conditionally
CD19
customers CAR T cell therapies. Obe-cel is designed
educationwith & a fast
approved inin
Pioneering
the biopharma,
China)
PATIENT-CENTRIC is Bozitinib healthcare,
(PLB1001)
Medicinesa small-molecule
government, that and
inhibitorPharmaceuticals,
targetsadvanced technologies
METistyrosine kinase &activity,
applied materials
including
Azurity
Basilea at a glance: a specialty pharmaceutical
aberrant activity observed with MET Exon14 skipping
-company,
Well funded, that focuses on pioneering
commercial-stage biopharmaceutical
company with significantly growing cash flows from
Bayer is a global enterprise with core competencies in the
commercialized products
life science
BeiGene is afields
global, of health care and biotechnology
science-driven nutrition. Its products company
and services
focused on are designed
developing to benefitand
innovative people
affordableby supporting
medicines
BenevolentAI (AMS: BAI) is a leading developer of
efforts
to improveto overcome
treatment the major challenges
outcomes and accesspresented forthatpatientsby a
advanced
• BESINSartificial
has demonstratedintelligence technologies
capabilities to develop unlock
and the
worldwide.
value of With a broad
multimodal data, portfolio
surface of more
novel than 40
insights, andclinical
commercialize
Best Buy Healthproducts partnersinwith various territories. Itorganizations
pharmaceutical has grown
accelerate
steadily overbiomedical
the years discovery.
and has nowThrough
sales the combined
around $550M.
to enable
A. Basic Infosafe,ofhigh-quality,
Betta Pharma: effective remote patient
The group
monitoring2003; encompasses <1600 headcounts
and care delivery at home. Through its Current incl. 730 sales
-Founded:
BIAL is an innovation-driven pharmaceutical company
Health solution, Best Buy Health provides an enterprise care-
aiming
BicycleTx to improve people’s lives
is a clinical-stage worldwide. BIAL
biopharmaceutical is
company
strongly
developing committed to therapeutic innovation, consistently
Biocodex isaanovel class of small,
family-owned chemicallycompany
pharmaceutical synthesised, that
investing
highly over 20%
versatile of its annual
medicines turnoverbased
(Bicycles®) in R&D, on a with a
provides
A innovative
clinical-stage Biotech healthcare
committed solutions to patients
to becoming in more
a global
proprietary
than 100 countriesbicyclicworldwide.
peptide platform.
headstream
Biofabri wasoffounded new antibody in 2008drugs with with proprietary
a vision: to research fullyand
human antibody
develop discovery RenMice&trade; platforms.
Foundedhuman in 1996, vaccines.
BIOGARAN is the French Generic and
Biocytogen has launched Project Integrum, the
Biosimilars subsidiary
Since our founding in 1978 of theasServier
one of Group,
the world’s a family-owned
first global
French Medicine
biotechnology company. Its growth is sustainable for more
Biolab is one ofcompanies
the largestbyBrazilian Charles pharmaceutical
Weissmann, Heinz
than 25 years.
Schaller, Kenneth At the end
Murray and of 2022,
Nobel the TO reached
Prize winners more
Walterthan
companies
Biolab is one amongof theBrazil's
largesttop 10
Brazilian pharmaceutical
pharmaceutical companies
Gilbert
in sales andjust Phillip
25 years Sharp, Biogen has led innovative
of history.
companies,
Since our foundingranking among
in 1997,Brazil's
we havetop 10 pharmaceutical
applied our scientific
companies
expertise in and holding
understanding the 5th
the position
underlying in causes
physician of genetic
BioNTech is a global next generation immunotherapy
prescriptions
conditions to nationwide.
create transformative medicines, using a
company pioneering
Bioprofarma Bagó begins novelits therapies
activities forincancer
the early and2003,
other
number
seriouspart of treatment
diseases.then BioNTechmodalities.
being
BioRay is asince PE-backed Bagóexploits
Group.aWe
of biopharmaceutical wide are array of
a Specialty
company focusing
computational
Treatments discovery
leading laboratory. and therapeutic
Ouroncology. drug
main areas of platforms for
on immune-mediated diseases and
Bio-Thera Solutions, Ltd., a leading innovative, global
development are: Biotechnology, Hematology, Oncology and
biopharmaceutical
Biotheus, Inc. is a biotech company in Guangzhou,
company with multiple China,clinical-
is
dedicated
stage programs.to researching
Armed with and developing
our fully novel
integrated therapeutics
BLANVER is a Brazilian company with 39 yearsantibody-of
for
basedthedevelopment
treatment of engine, cancer, we autoimmune,
are focusing cardiovascular,
on therapies for eye
experience.
Blau is a leading Brazilian pharmaceutical company in the
immuno-oncology and inflammatory diseases with
institutional
bluebird bio segment,
is pursuing founded
curative in gene
1987therapies
and a pioneer to give in
biotechnology.
patients We have a proprietary portfolio of highly
Blueprintand their families
Medicines more bluebird days. Founded in
is a commercial-stage
complex
2010, drugs has
bluebird focused been on relevant
setting segmentsfor
the standard in the
gene industry,
therapy
biopharmaceutical company focused on precision therapies,
for
with the goal of transforming patient care. These includenow
more than a decade—first as a scientific pioneer and a
broad portfolio of marketed, clinical stage and research
BlueRock Therapeutics LP is a clinical stage cell therapy
company
BMI focused
is seeking on creating
business cellular to
partnerships medicines to reverse
license Recombinant
devastating
Hyaluronidase diseases. We are harnessing the power
filler of cell
Our mission is and Botulinum
to benefit the healthToxin/Esthetic
and well-being offor the
therapy
US and EU to create
markets. a pipeline of new medicines for patients
mankind
Boehringer byIngelheim
contributing is atoworld-leading,
an adequate supply of safe,
research-driven
nutritious food
biopharmaceutical and by promoting
company. the emotional and physical
Boryung Biopharma Co., Ltd.Making is a fully new and better
integrated
benefits
medicines arising from the human-animal
for patients is at the heartcompany, bond.
of what we We do.are
pharmaceutical/biopharmaceutical
Boryung's main therapeutic categories are oncology, which is
Independent and family-owned,
developing, manufacturing, we have the afreedom
andinfection,
distributing wide range to
cardiovascular, endocrinology,
Relying on R&D drive, the company continues to create respiratory, renalof
medicines
disease and insoKorean pharmaceutical
on. Specially, Boryungmarket. has been ranked No.1
high-tech
Relying onbarriers,
R&D drive, gradually establishes
the company a business
continues system
to create
player
that in both Oncology
integrates APIs and and Cardiovascular
preparations, combines areas in Korea.
generic
high-tech
Bristol Myers barriers,Squibb gradually
is a leadingestablishes
global abiopharma
business system company
drugs
that with innovative
integrates APIs and drugs, and pays combines
preparations, equal attention generic to the
focused on
Buchang discovering, developing
Pharmaceuticals and delivering
is one of Chinese leadinginnovative
drugs with for
medicines innovative
patientsindrugs,
with and pays equal attention to the
companies.
A. CompanyFounded Introduction 1993serious
and went diseases.
publicly Our(603858.SH)
people are
focused
on Shanghaion helping millions
Stock Exchange of patients
in Ltd.
2016, around the world in
Bukwang Pharmaceuticals
Byondis’ development Co.,
portfolio is Buchang
comprises an R&D-focused Pharma had
targeted and
total revenue
pharma company overbased$2.16inbillionSeoul,inin 2022. Buchang
Korea. Founded Pharma
immune-oncology
Camurus' products (IO) Buvidal®therapies weeklypreclinical
and monthly andin 1960,
early-
for
Bukwang
stage has
clinical well-rounded
phases.dependence experience
The candidates in development
combine in Byondis’ of
treatment
CanSinoBIO of opioid
has been listed on wasMain
the launchedBoard 2019
of Hong and is
new drugs,
expertise coming
in linker-drug from the development
(LD) technology, of a novel
antibody-drug hepatitis
now available
Kong in and
20 countries. In addition, Camurus' late- and
CarnotExchange
is a privately Clearing
owned Latin Limited (HKEx:
American 6185.HK)
Pharmaceutical
stage pipeline
on the Sci-Tech includes
Innovation product candidates
Board Health,
(STAR Market, in the CNS SHSE: and
Group
CARsgen thathas specializes in Women
built an integrated cell therapy Gastroenterology,
platform with
688185) of the
Respiratory, CNS,Shanghai
Dermatolgy Stock ,Exchange,
Pediatric making itamong
products, the first
in-house
Supportedcapabilities
by Innovate that
UK, spanourtarget
mission discovery,
is to drive antibody
the
others. As
development, a leader in Women´s
clinical trials, Health Carnot
and commercial-scale through its
growth ofisthe
Cellectis industry
developing by
thehelping
first of cell and allogeneic
its kind gene therapy
manufacturing.
organisations CARsgen
across the has internally
world translatein developed
early stage novel
research
approach
Since the for EMA CAR-Tapproval immunotherapies
of the **world’s oncology,
first ever mAb
into commercially
pioneering Remsima® viable and
the concept of off-the-shelf investable therapies.
and ready-to-use We are
biosimilar
Celon Pharma S.A. is a(Infliximab pioneering biosimilar)**
European in 2013,
gene-edited
following CAR T-cells
approvals to treat cancer
of **Truxima® patients.
andfocused
Herzuma® As a
biopharmaceutical
As an organization company, dedicated primarily
to improving on the of life
the quality
(Rituximab
discovery and and Trastuzumab
clinical-stage biosimilars,
development respectively)**,
of
for patients,
“Together, ourCenturion
passionate Pharma
people is drive
focusing oninnovative
innovative Specialist
health
therapies.
Therapeutic Withareas a deep commitment
like biotech, to
biosimilars,addressing
orphan unmet
drugs,
solutions for all animals, contributing
CHA BIO GROUP has successfully established a bio to the future of our
niche hospital
diverse planet.”​ products, vaccines and plasma products.
ecosystem through integration
Baiyu Pharmaceutical has beenofdedicatedacademictoinstitutions
the production and
hospitals
of Ginkgolidewith business
Products,with organizations
encompassing across seven
Ginkgolide countries
Injection
(Please note: meetings CROs, CDMOs, and service
in
andthe US, Australia,
dropping pills Japan, Singapore
(currently in phase , Vietnam,
III), aimed Indonesia
at
companies
The Chiesi couldGroupnot be accommodated
currently employs ~7,000 due to time
people
enhancing
constraints.the healthfor
Thanks of your
patients with CNS diseases since its
understanding.)
worldwide and had a 2023 turnover
Chipscreen Biosciences was established in March 2001, and of €3.03 billion.
has become
To bring forth to innovative
be a leadingnew biopharmaceutical
medicine, we have enterprise
strong
developing
R&D with and
central manufacturing
research centerinnovative
and new drugs in
FDA/EMA-approved
Chugai, a member of Roche group, is a Japanese company
China.
API manufacturing facilities based in Korea. Morewhich than
focused
Cipla USonrevenues
creatinghave innovative
crossedmedicinal
$ 900 m and products
is fastest
1000 sales
address unmet representatives
medical needs.covering every corner
Our innovative antibody of Korean
growing
Clear Streetcompany among
is modernizing itsthe
peers.
brokerage ecosystem.
technologies have led to multiple therapeutics helping
Clinigen is a leading global expert, trusted by both
pharmaceutical
CMG is active in and biotech companies,
development in acceleratingof
and commercialization
clinical
unique development and providing access
as OraltoSolublemedicines
We are reformulation
focused on finding products such interested
partners Film
in enzymatic
throughout the lifecycle
formulationofofoligonucleotides of medicine,
Rx drugs with improved clinical trials,
convenience andand
production
Coherus’ immuno-oncology pipeline includes multiple via our Enzyme Catalyzed
patient outcomes.
Oligonucleotide CMG has
Synthesis™ (“ECO portfolio of oral soluble
Synthesis™”) the film
candidates
Collegium with differentiated
Pharmaceutical, Inc.mechanisms
is a publiclytargeting
traded
manufacturing
tumor microenvironmentplatform, which that canis currently
be used toindevelop
development next-
(NASDAQ:
1 IND stage, 4 Phase I and 2 Phase II assets company
COLL), specialty pharmaceutical
generation treatment combinations.
developing and commercializing novel medicines for patientsOur antibody
The mission of CRISPR Therapeutics is to develop
suffering from chronic pain and other diseases. Collegium
transformative
CRISTÁLIA isgene-based a private owned medicines for patientscompany,
pharmaceutical with
serious diseases.
operating Our therapeutic approach Asisaby to cure in diseases
Since our in start theinmain
1916, LATAM
we havemarkets. been driven leader
our promise
at the molecular
intensive care level using
medicines, the breakthrough
CRISTALIA supplies gene editing
to
KEYsave lives using
ASSETS the latest technologies.
AVAILABLE FOR PARTNERING: The parent than
more
95% of
company, Brazilian
CSL(TOPO1) healthcare
(ASX:CSL; services
USOTC:CSLLY), with a broad range of
headquartered
- EGFR-ADC
CStone is a biopharmaceutical - Phase 1
company focused on
in Melbourne, Australia, employs 32,000 people and delivers
researching, developing,legacy
CTS has a century-long and commercializing
as a reliable partner innovative
for
immuno-oncology
international and precision
pharmaceutical medicines
companies, to address the
commercializing
CureVac is a global biopharmaceutical company in the field
unmetproducts
their medicaland needs of cancer patients
representing in China
them in Israel, and
demonstrating:
of messenger
Cytiva is a global RNAprovider
(mRNA) oftechnology,
technologieswith andmoreservices thanthat20
years of expertise in developing,
help advance and accelerate the development and optimizing, and
manufacturing
manufacture ofthis versatile biological
therapeutics. Previouslymolecule GE Healthcare for medical Life
Sciences, Cytiva’s diverse portfolio includes well-recognized
Cytokinetics is a late-stage, specialty cardiovascular
biopharmaceutical
Daewon is pharmaceutical companyCompany focused on discovering,
in Korea.
developing
Daewon is 7th and commercializing
ranked in Korea first-in-class muscle
Daewoong Pharmaceutical withETC over market
70 years (excluded
in the
activators
MNC), have new and next-in-class
chemical muscle
entity medicineinhibitors as
which potential
is 12th
pharmaceutical business discovers,
Daiichi Sankyo is dedicated to the creation and supply of develops, manufactures,
new markets
and drug in Korea, various have new drug
medicines. Our launching
sales experience.
achieved 1.3 of
innovative
Debiopharm, pharmaceutical
a privately owned therapies to improve standards
Swiss-based
billion
care USD with
and address diversified,more than 3,600 employees as of 2021 FY.
biopharmaceutical company, unmet focusing medical needs of people
on developing
globally
innovative bytherapies
leveraging thatourtarget
world-class
high unmet science
medicaland needs in
Denali Therapeutics is a biopharmaceutical company
oncology and bacterial infections. Bridging the gap between
developing
Dendreon's aflagship broad portfolio
product, of product candidates
PROVENGE® (sipuleucel-T),
engineered
is the first to cross
FDA-approved the blood-brain
autologous barrier
cell (BBB) for
therapy for solid
the
With operations in over 70 countries, we encourage our
treatment
tumor. of
Currently neurodegenerative diseases and lysosomal
peoplearea
Main to think forDendreon
of operations themselves is aand
includes
profitable
thereward company
integrity. with
development, Our
PROVENGE®
large but focused having
footprinttreated
gives over us a strongpatients
45,000 position ininthe US.
manufacturing and marketing of
DKSH is a leading healthcare company in Asia with 8,000 pharmaceuticals for global
Europe plus
markets. Furthermore a significant presence
DEVA Holding in the Americas
manufactures and Asia
employees
Dompé farmaceutici across 15 is markets and 6 billion
a privately-owned CHF in sales.
biopharmaceutical
veterinary medicinens under the brand of VETAŞ.
company
Founded in with 1932, 130Dong-A
years ofPharmaceuticals
experience an end-to-end has been leading
coverage of
the pharmaceutical the value chain,
company from
in Korea drugfor discovery
over 46 to
years. Inin
DONGWHA PHARM, the first pharmaceutical company
manufacturing,
2013, the company development
underwent and commercialization.
a corporate restructuring, Dompé
Korea founded in 1897, has been engaged
With a strategy based on intensive research in skin and hair in the
spinning
development, off the prescription
production, drug business
distribution, into a new of
anddermatological
marketing
care,
The Dr. in close
Falk Groupcooperation (~950with university
full-time employees) is an
prescription
divisions, thedrugs,
familyover-the-counter
company standsdrugs,out byAPIs, dietary
its development
independent, family-owned pharmaceutical
EA Pharma Co., Ltd. is the new integrated company of company
skills, galenic
specializing formulation
in the development, expertise and creative marketing
Gastrointestinal
Eddingpharm, Division
founded in of Eisaiisproduction
2001, and Ajinomoto
a leading
and
and fast growing
commercialization
Pharmaceuticals of state-of-the-art
which was 100% subsidiary medications for
of Ajinomoto
specialty pharmaceutical company
Editas Medicine has transformed gene editing technology in China with
Co., Inc. and establishes
comprehensive capabilities on including
1st April, manufacturing,
2016. EA Pharma Co.,
clinical
into
Egis new
is one ocular
of theand hematology
leading generic,experimental
value-addedmedicines.generic and
development,
The company marketing,
has generated sales and distribution.
substantial
biosimilar
Eisai Co., Ltd. pharmaceutical companies inintellectual
Central Eastern property
with
Europe.more Our than 220 issued patents and more than 800
At Eisai
The Inc.,activities
ElevateBio humanecosystem
incorporate
health care is all
combines
areas
goal.ofWe
ourBaseCamp®, thegive our first
its genetic
pharmaceutical
thoughts to patientsvalue chain.
and their families, and manufacturing
helping to
medicine process development and
Lilly is a medicine company turning science into healing to cGMP
increase
business, the
with benefits
multiple health
R&D care provides.platforms
technology As the U.S. to
make
We arelifethebetter
healthcarefor people
businessaround theU.S.A.
in the world. & We've
Canada beenfor
pharmaceutical
provide end-to-end subsidiary
solutions of Tokyo-based
and bridge the Eisai
gap150 Co., Ltd.,
between
pioneering
Merck life-changing discoveries for nearly years,
We areKGaA, the contract Darmstadt, Germany,
development andamanufacturing
vibrant sciencedivision and
and today our
technology medicines
company. help more
Science is at thanheart
the 51 million
of people we
everything
of Emergent
EMS/NC PharmaBioSolutions(NYSE:
is the #1 pharmaEBS). Emergent
organization has the
in Brazil
do. It drives
scientific and the discoveries
regulatory we makeexperience,
compliance and the technologies
according to IMS/IQVIA with >USD1.5Bi
Cincinnati-based Enable Injections is a global healthcare in gross sales
development
generated incompany and manufacturing
2019 and top 10 in Latam resources, and
with anthe efficient
established
innovation
Er-Kim broadens andcommitted acceleratestoglobal improvingpatient access patient to
footprint in
treatment Prescription,
experience Hospital,
through the OTC, Government
development and and
innovative treatments by
NO MEETING REQUESTS FROM DIAGNOSTICS, CROs,offering biopharmaceutical
manufacturing
companies of all ofsizes
enFuse®.flexible,enFuse is an innovative
sustainable, and compellingwearable
CMOs,it HEALTH
Since was founded IT, inOR SERVICE
1929, Esteve PROVIDERS
has been firmly PLEASE
business models to commercialize their products in
committed
EuBiologics, to aexcellence
publicly traded in healthcare, dedicating company,
biopharmaceutical efforts to
innovative R&D
specializes of new medicines for unmet medical needs
Establishedin indeveloping
1995, Evercore human vaccines
(NYSE: EVR)for is infectious
a leading
and focusing
diseases. We on high science
leverage a and evidence
state-of-the-art ‐basedthat
strategy research.
includes
global
Please independent
note, we willinvestment not be ablebanking to meet advisory
with service firm.
the use ofadvises
Evercore a proprietary a diverse adjuvant
set of (a TLR4 agonist
investment banking derived
clients
providers products
Exagen's in this event. diagnose, prognose, and monitor lupus,
on a wide range of transactions and issues and provides
rheumatoid
Exegenesis Bio arthritis, and other
is a fully integratedconnective
genetictissue
medicinesdiseases.
We support
company pharmaceutical
operating in USAbranded companies'
and China. critical biomarkers in
Manufacture and markets prescrition products in
Clinical Trials, phases 1-4. We develop and offer specialized
Women's
Exscientia's Health
AI driven drug design methods focus on highly
efficient,
We approaches
are dedicated to theto development
revolutioniseand small molecule drug
manufacturing of
designand
niche anddifferentiated
candidate discovery finished-dose productivity.
pharmaceutical
2021 Turnover was 399 mio €. 1662 employees. 40% sales
products.
force. Our team of over 200 scientists and researchers
Ferrer Ourhas amain proven therapeutic
track record areas inare Allergy,
bringing ENT, in
innovation
focus on complex
Respiratory, APIs and
Metabolism, GI,finished
Diabetes, dosage form health.
Women's products.
pulmonary
Headquartered hypertension
in St. Prex, with a strong focus
Switzerland, Ferringin EU hasandin recent
LatAm on top ofbeyond
yearsareexpanded significanttraditional
operationsEuropean in all continents.
We seeking a globalits ex-North American base:for
partner with
over 6,000 employees
pamrevlumab. We are worldwide,
also looking ittooperates
outlicense subsidiaries
FG-8205, in
We are a biotechnology company that invents platforms and
over 60 countries
our HIFcompanies and
asset in cardiovascular makes its products
disease. available in more
builds
Fosun Kite has launched that change the firstthe world.
commercial CAR-T in
China in 2021. As a market leader
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) in China, Fosun Kite has
been
Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, with
actively looking for collaboration opportunities
biotechs
02196.HK) andisinstitutions on revolutionary
a leading healthcare group intechnologies
China. We have to
built a strong root in China and developed a global operation
Founded in 1994, Shanghai Fosun Pharmaceutical (Group)
Co., Ltd.*
Frontier ("Fosun
Biotech Pharma";develops,
researches, stock code: 600196. SH,and
manufactures 02196.
HK) is a
commercializes global innovation-driven pharmaceutical and
Fuji Pharma has new beenlong-acting
enriching the HIV medicines,
lives of women as in
well as
Japan
healthcare
for immune industry
disorders, group. Fosun Pharma
neurological diseases, directly
and operates
since the early 1960s by developing
FUJIFILM Holdings Corporation brings cutting-edge innovative treatments for
dermatological
women of all ages.diseases.
The company’s growth has been driven
solutions to a broad range
Fuso Pharmaceutical of global
Industries, Ltd.industries.
Established Itsin proprietary
1937,
by
core itstechnologies
women’s health portfolio,
contribute to complemented
various fields by an
including
and Pharma
GL started our is an business
independent from the sale ofpharmaceutical
Austrian glucose. Today, we
healthcare,
manufacture graphic
and sellsystems, highly functional materials,
company
Gador is a— driven
leading bysmall-
science,
Argentine
to large-size
research and
pharmaceutical
infusion and
production.
company with
injection products, led by our mainstay dialysis product,
presence
GAIA is the throughout
global leader Latam. in For
the the last 84 years,
development its mission
of evidence-
has
based, been to
safe isandinvestigate,
accessible develop, manufacture and
Galapagos attending thedigital
BIO meetingtherapeutics. GAIA's DTx
for in-licensing,
commercialize
solutions offer the best quality
physicians, medicines
therapists, payers forandevery patientthe
patients at
M&A andinother
Founded 1998,partnership
Gan & LeeopportunitiesPharmaceuticals in oncology
(603087.SH), (solid
same
tumors, effect sizes, similar
specifically NSCLC safetyandprofiles
SCLC) and and equal levels of
in specializing
immunology
is
GCa leading
Biopharma, pharmaceutical
formerly GC company
Pharma,inisChina, a fully-integrated
(IBD, SLE, RA). production, and commercialization of
in the development,
biopharmaceutical
GC Cell is at the forefront company ofandthe theglobal4th cell
in revenue
therapy('23) marketin
insulinKorea.
South analogs Sinceand other
1967, innovative
GC Biopharma treatments
has for expertise
built diabetes
as a biotech
Gedeon Richter solution pioneer. specialty
- a European Our autologous CIK cell
pharmaceutical
in research,
product, development, manufacturing,
"Immuncell-LC," has received and sales
approval from of the
Company - is
Genentech, focused of
a member on the (i) Women's
Roche Group, Healthcare,
discovers, (ii) CNS
Korean
disordersMinistry and of Food
further (iii)andand
Gedeon DrugRichter
Safety is(MFDS)engaged asinan
develops, manufactures,
Generate:Biomedicines is thecommercializes
first drug generation medicines companyto
global development
treat patients with serious of biosimilars and
and life-threatening is building
medical the
pioneering
2023 Sales:a10.7 machine Billion learning-powered
RMB generative biology
conditions.
platform with Wethe areability
a leading to biotech
create new company,
drugs on with
demand ~40
-Genmab
Top domestic biopharma company
is an international biotechnology and lead player with
company in a
across a
endocrinology wide range
and of biologic
children’s modalities.
health The Generate
core purpose Biopharma
Gensciences guiding its unstoppable
is a China-based, team late-stage
to strive towards
improving the
biopharma lives on
focused of patients
hemophilia through
and innovativediseases.
metabolic and
We are looking for manufacturing technologies, capacities,
differentiated
We have antibody
fullyinin-house therapeutics.
R&D teams and GMP sites.and By
and
Foundedexpertisein 2002 DNA synthesis,
and listed on thegene, Hongcell Kong therapy
Stock
leveragingmanufacturing
antibody our long-acting biologics
spaces. We technologies,
are looking for wein- have
Exchange
We strive to in transform
2015, GenScript and simplify has an care established
for people globalwith life-
licensing,
presence co-development
across Greater and
China, North any other kind of strategic
America, the EU, and
threatening
Below illnesses
description is around
given inthe two world.
parts:Gilead's portfolio of
Asia
productsPacific.
and in Today,
pipeline over
of investigational drugsfrom
300,000 customers includes over 160
1.
ItsGlenmark
predecessor -Innovation
GreenPine (Tianjin) International Trade Co.,
treatments for HIV/AIDS, hepatitis, cancer, and
Ltd. was established
Gritstone bio, Inc. (Nasdaq: in 1994,GRTS), went through 20
a clinical-stage
years’development,
biotechnology now forming a system which consists
The Grünenthalcompany, Group – an is developing
independent, next-generation
family-owned,
prescription
vaccines drugs,
against cancer and medical device,
infectious medical food,
diseases. We medical
develop
research-based,
We are a global mid-size biopharma pharma
company companywith aheadquartered
purpose to unite in
our vaccines
Aachen, technology by
Germany – and leveraging
is antalent a unique
entrepreneurial set of proprietary
science, to get aheadspecialistof disease
delivering
together. We trueaim benefits to patients.
to positively Sustainably
impact the healthinvesting
of 2.5 in
We will NOT be accepting meetings with CROs, CDMOs or
billion people by the end of 2030. Our bold ambitions for
service providers asisyour
Gyre Therapeutics offeringsbiopharmaceutical
a profitable are outside of our focus
for this conference.
company headquartered in San Diego,company CA, withspecialized
a primary in
Lundbeck is a global pharmaceutical
focus on theinnovative
developing development and commercialization
treatments for brain diseases. of anti-
For
fibrotic therapeutics for a variety
more than 70 years, millions of people have been treated of chronic organ diseases.
Welcome to Haisco Pharmaceutical Group Co., Ltd.Haisco is
with our products and our development and distribution of
aHaisco
company advancing with
Pharmaceutical Group the Co.,timesLtd and is growing rapidly,
a pharmaceutical
and aims to
companyBiopharma constantly
dedicated is pursue
toaR&D, the brand perfection and
HanAll globalmanufacturing,
biopharmaceutical company,
development,
commercialization provide the
of innovativebest products and
andcontributions services
affordable medicines to the in
with
We are a mission
one of the to make
leading meaningful
pharmaceutical companies to patients'
in
the
livesdisease
byand areas of CNS,
introducing innovative,oncology, respiratory
impactful and to
medicines
Korea we operate fully integrated
Hansoh Pharma is a leading biopharmaceutical company in business including
addressmanufacturing
R&D, severe unmet in medical needs. HanAll
GMP-certified plant has been
and sales & and
Asia.
Harbour Founded
BioMed in is1995, we
a global are committed
clinical-stage to discovering
biopharmaceutical
marketing
developing activities
life‐changing for various prescription and OTC
companyiscommitted
Helsinn to themedicines
a global pharmaceutical discovery, todevelopment
company
help patientsand
that builds,
worldwide.
commercialization Our rapidly
of novelgrowing antibody workforce
therapeuticsof 12,000+in
manufactures,
No services, CRO, consulting, or investment products
launches, and commercializes advisory to
oncology
improvewill and
the be immunological
quality of life for patients with cancer andunmet
disease areas to address
request
We're a global accepted.
company with a local presence across the
chronic disease, with a focus on supportive care, oncology
United States (US),
Global HQ is in Saga, Japan, and the Middle East and North
Hisamitsu hasAfrica
a 100%-
(MENA)
owned and
subsidiary, Europe, and
Novengroup we use our
Pharmaceuticals, unique ininsight
Florida, and
As a member of Kolmar in key business areas ofthe
expertise
U.S.A. to transform cutting-edge science into innovative
cosmetics,
HLB Pharmaceuticalpharmaceuticals Co., Ltd. and(founded
health supplements,
in 1998, partHK of the
inno.Niswith
HLB) a 38 years of pharmaceutical
KOSDAQ-listed company business
mainly engagedhistory in
Huadong Medicine, a leading Chinese pharmaceutical
discovers, develops,
manufacturing and manufactures
distributing and markets products.
pharmaceutical prescription
company
HUTCHMED based(China)in Hangzhou Limited (near Shanghai), China.
(“HUTCHMED”, previously
HLB
Huadong Pharmaceutical’s
Medicine 125
is ranked of ETC and 40 of
18th largest pharmaceutical OTC products
also known as “Chi-Med”) (Nasdaq/AIM:HCM; HKEX:13),
company
an innovative, in China(among
commercial-stage both MNCs and locals) bycompany
biopharmaceutical IQVIA.
committed to the discovery and global development of
Hypera Pharma, formerly known as Hypermarcas, was
foundedPharma
Hypera in 2001was and founded
since then in the
2001 company
and through has the years it
consolidated
hasFollowing
consolidated its position
its position as Brazil’s
as are leading
onetargets
of the Hyundai pharmaceutical
leading is actively
1) therapeutic areas
company.
pharmaceutical It is listed
companiesin Brazilianin Brazil, stock exchange’s
currently ranked Novo as #2
seeking and focusing on ;
IASO Bio is a biopharmaceutical company engaged in the
in retail market. Hypera has a unique portfolio, with more
discovery,
Ichnos Glenmark development Innovation and commercialization
(IGI) create and develop of novel cell
and antibody
cutting-edge therapies
therapies for oncology
in oncology and autoimmune
IGM Biosciences engineers “super based antibodies”on complementary
by building
diseases.
biologics Leveraging
and small its proprietary
molecules discovery fully engines
human antibody
to design
upon the greater binding power
We are currently seeking out-licensing opportunities provided by the naturally
with a
and develop
occurring IgM multi-specific
antibody antibodies
structure, and
asdevelopment,small
compared with molecules.
the
partner who has expertise in global
Our therapeutic product candidates are Adoptive Cell regulatory
commonly
affairs, andand used IgG structure,
distribution. We have with the potential
internal programs to generate
ready to
Therapies
We are a commercial Bispecific stage TCR molecules
biotechnology (TCER®),
company directed
out-license
against for Gastroesophageal
targets development
which will transform reflux disease
theclass
current (GERD)
landscape of
pioneering
Since 2002 the Incyte has remained of a committed
novel toofthe
TCR targeted
relentless
cancer
bispecific therapy.
immunotherapies called ImmTAX – Immune
pursuit
InnoCare's of science
committed that can improve
to developing the lives of
best-in-class patients,
and first-
mobilizing
make a difference monoclonal TCRs
in healthcare Against
and needs X disease
build sustainable – forvalue
the
in-class
Inspired by the spirit of "Start with Integrity, Succeed solid
drugs to address the unmet in heme-onc,
for our stakeholders.
tumors and auto-immune disease. Since
through
INOVIOAction," Innovent's
uses proprietary mission
technology istotofounded
discover
design DNA
inand
2015,
InnoCare
develop, has evolved
manufacture into a fully
and commercialize integrated
plasmids
We are an— small circular
end-to-end, artificial moleculeshigh-quality
DNAintelligence-driven that work like
drug
biopharmaceutical
software that products
the body’s cells that are affordable
can download to to ordinary
produce
discovery & development (AIDD)
Insmed Incorporated is a global biopharmaceutical company company with a mission
specific
to accelerateproteins drug todiscovery
target andand fight disease. by leveraging
development
focused
Insud is on the
a highly unmet needs of
diversified grouppatients
withwith global rare diseases.
presence that
our rapidly
The Company's evolving,lead generative
product Pharma.AI
candidate is platform across
ARIKAYCE, FDA,
operates across the entire pharmaceutical/biotech
Intas is a vertically integrated global company, leading in the value
EMA,
chain, and PMDAspecialized
delivering approved for treatment
expertise of refractory
in scientific NTM
research,
development,
Intellia manufacturing
is developing potentially and curative
marketing geneof editing
development,
pharmaceutical manufacturing,
formulations, sales and marketing
including generic andof a wide
treatments
Intra-Cellular to transform
Therapiesthe is alives of patients
commercial biopharmaceutical
biosimilar medicinal products. With headquarters in
company
Ipsen sells over 20 drugs in more than 115 research
founded on Nobel prize-winning countries,that and has
allows
aAbout us to
directIronwood understand
commercial how
presence therapies
in over 30affect the inner-
countries. Ipsen’s
Pharmaceuticals
workings
ambition is oftocells
becomein thea body.leaderThe companyhealthcare
in specialty leverages this
NO SERVICE PROVIDERS PLEASE
solutions for targeted debilitating diseases. Its fields of
NO
The CMO
JAMPPLEASE Pharma Group currently commercializes over 350
molecules
<Out-licensingtheon Canadian market, as well as 2 Biosimilars
opportunities>
(Adalimumab
Blood products andforUstekinumab).
transfusion
(NOTE: Given time constraints are used in damage
& strategic priorities, control
we will
resuscitation,
not be however,
meeting with CMOs, available
CROs, products have
service companies, issues for
etc. at
JCR Pharmaceuticals Co., Ltd. is a specialty pharmaceuticals
usability
the meeting) and coagulation activity.
company that is redefining expectations
Founded in 1959, JEIL has over 60 years of experience and and expanding
possibilitiesinfor
know-how thepeople
Southfour with
Korean rarepharma
and genetic diseases over
Our pipeline includes clinical stageindustry.
products With and several
worldwide.
500 medical Founded
representatives,in 1975,JEIL JCR has is a acompany
nationwide of 900+
market
preclinical projects.
JHP is a public listed global biopharma, headquartered in
coverage across various therapeutic areas including CV, GI,
Shanghai,&China.
Johnson JohnsonFounded (J&J) focuses in 1970, on itaccelerating
is one of theallmost stages
innovative
of innovation & worldwide
inventive global and biopharma
forming companies.
collaborations JHP
between
JT Pharma, the Pharmaceutical Division of Japan Tobacco
has 15 new
entrepreneurs molecular
andPharma, entities
J&J’s globalTorii approved
healthcare in China as well
businesses.Japan) J&Jas
(including
WE ARE NOT Akros SEEKINGUS; CRO SERVICE Pharmaceutical,
provides
is dedicated scientists, entrepreneurs,
to the discovery, and emerging
development, companies
and sales of
Jumpcan Pharmaceutical is a national high-tech enterprise
novel human therapeutics.
group,
JW the National Corporation
Pharmaceutical Torch Program is onepharmaceutical
of the leading industry
backbone enterprise,
pharmaceutical companies one ofintop Korea100 of withnational
core competencies
>About Kaken
pharmaceutical
in IV solutions, industry,
cardiovascular, and theendocrinology,
Shanghai Stockurology, Exchange
Kaken
Kamada(Tokyo Stock
is a NASDAQ-traded, Exchange:FDA-approved4521) is a specialty Biopharma
nephrology and company
pharmaceutical anticancer. in JWJapan is currently
with strong focused on in
experience
company
***Pleasebased note thatin Israel.
we are not accepting meetings with
developing and commercializing novel pharmaceuticals in
CROs/CMOs/other
Kashiv is of
an orthopedics
established service providers/vendors.
biopharma company with HQ in NJ
the fields and dermatology. Kaken
USA. Kashiv Biosciences has a product
Kelun is a highly specialized and innovative pharmaceutical portfolio that
includes
group biosimilars/biologics,
with an annual sales income NCEs, specialty
of more thanproducts
40 billionlike
Keymed Biosciences, is a Chinese based public Biotech
505(b)2,
yuan. The and Niche
parent peptides.
company Kelun Pharmaceutical
company, listed on the Limited
Kintor Pharmaceutical HK Exchange. is a HK-listedKeymed founded in
(HK.9939)
(SZ:002422)
2016 , is an successfully
integrated listed in June
biotechnology 2010, and
company that its
has2
pharmaceutical
Kissei is a R&Dcompany oriented with Japanese its main office in Suzhou,
pharmaceutical company.
consistently
China. The developed
company innovative antibody therapies,
We
>KM have clinical
Biologics and is focused onstage
pre-clinical cancers assetsand other high-
seeking for a
incidence
partner diseases
outside to
Japanmain fulfill
in the unmet
therapeutic medical needs.
... has the following business areas:fields
Human of metabolic
Vaccines,
diseases, neurology,
Antitoxins and Antivenoms, gastrointestinal
Blood Plasma disorders, pruritus,
Products, and
Kolon Life Science (listed on KOSDAQ), a subsidiary of
Veterinary Vaccines.
Kolon Group, is a South Korean biotech company
established in 2000. One of its main business areas includes
novel biopharmaceuticals, specializing in cell and gene
KOLON GROUP
Kowa Company, Ltd. (Kowa) is a privately-held, 130 year-
old Japanese
Kuhnil Pharmcorporation
is a medium-sized,headquartered in Nagoya.and
fully-integrated Kowa has
family
98 subsidiaries
owned around the
pharmaceutical world that
company developing,
has been manufacturing,
developing,
Kwangdong Pharmaceutical, headquartered in Seoul, South
marketing, and and
manufacturing trading productssince within a variety of
Korea, top leadingdistributing
Kyorin aPharmaceutical pharmaceutical 1969.
company
Co., Ltd. headquarters with
in a global
presence that
Tokyo/Japan, Kyorin has always been
employs committed to the human
Manufacturing, developing and2300
selling staffs and health
animal consolidated
healthcare.
sales in the Since its
last fiscal establishment
yearvaccines
exceededfor in 1963,
110 not
billion only have
JPYanimals)
(about we1
products
Kyowa Kirin (drug, foodcompanies
Group and strive to petcontribute
and farm to the
billion
in Japan USD).
health and well-being
Laboratorios Bagó, founded of people around
in 1934, is the world Argentine
a leading by creating
new value
pharmaceutical through the
company pursuit of advances
with relevant in
presence life sciences
in Latin
BIOPAS holds leading positions in CNS, Immunology,
and technologies.
America. Its productsTheare Company
manufacturedis strongly
with R&D
high driven,
Dermatology,
Company Oncology, Gastroenterology and Orphan
Description:
international
Drugs is and qualityinstandards.
operates 14 countries with fully owned
ROVI
Laboratoriosa public
Liomontpan-European
has been in company
the market(ticker:
sinceROVI)1938 and
subsidiaries
withgrown
a market andcapmore
of of than
around 350
3,8Memployees in Latin
EUR and revenues America.
of 830
has to be one the top pharmaceutical
In addition to having unique professional teams for research, companies in
M EUR in
Mexico. We 2023.
exportROVIour is a fully-integrated,
products to most of profitable,
Latin America,
development,
Chilean company and with
production in Latin
subsidiaries America,
in South, Grupo
specialty
the United pharmaceutical
States andfollowing company engaged
Europe. inCentral
the research,
PiSA® also
America and has the
the Caribbean, certifications
Headquarter and awards:
Founded in 1943, Laboratorios Silanes is in Santiago
a leading - Chile.
Two Manufacturing
pharmaceutical company sites in(Chile
Mexico and with
Costathe Rica).
missionLeaders
of in
It begins with a passion for innovation.
CNS,
making Cardio-Metabolic, Ophtalmology,
life a healthy story through the development and GI, Respiratory,
For people.
Legend Biotech is a global leader in cell therapy, driven by a
commercialization of innovative medicines.
passion
LEO PHARMA for patients.is anWe continue toinnovation-based
independent, build our pipeline of cell
therapy platforms,
pharmaceutical which
company includes
founded CAR-T,
in 1908 CAR-NK,
and CAR-
headquartered
We have developed a strong pipeline focusing on innovative
γδ T and non-gene-editing
in Denmark. We are committed CAR technologies.
to makingfor a fundamental to
In addition
immuno-therapies
LG Chem Life Sciences and targeted
Company therapies
is leading oncology,
difference
including ADCs for those and who
mAbs need us most in medical
atheadquartered
commercial, clinical and pre-
biopharmaceutical
LifeArc is a self-financing,company non-profit medicalin Korea
research
clinical stages.
specializing in We are seeking
developing, partners to out-license
manufacturing, as well as the
organisation.
LNC Pharm isWe take science ideas
biopharmaceutical out of the
company, lab andonhelp
focused
commercializing
turn them into pharmaceutical
medical breakthroughs products.
thatdrugs
can be
promotion
The Lubrizol andCorporation,
distribution aofBerkshire
innovative Hathaway in life-
EAEU and
company,
changing
CIS for patients.
. In 2022 we reached We have been
a position We doing
#3 in this
the state for segment
more than
is a market-driven global company.
Lupin is an innovation-led transnational pharmaceutical combine complex
of pharmaceutical
specialty chemicals market
to optimizewith annual revenue
the quality, >640 M and
performance
company
Mabwell is headquartered
a global integrated in Mumbai, India, and
biopharmaceutical with a global
company
value of ourWe
presence. customers'
develop products
and while reducing
commercialize a wide their
range of
headquartered
MacroGenics isShanghai, China. biopharmaceutical
a clinical-stage And got listed on Shanghai company
branded
stock and
exchange generic formulations,
in 2022.and biotechnology products
focused on discovering
Mankind Pharma is the 4th largest Pharma company in the
Indian Pharma we
At MannKind, market (as per IQVIA)
are committed with a sales
to developing andturnover
of little more than USD 1 Bn. Mankind is
commercializing innovative therapeutic products and devices recognized as the
youngest amongst the top 5 companies in
for people living with endocrine and orphan lung diseases. India owing to its
Maruho Co., Ltd. is a leading pharmaceutical company
specializing
Maruishi hasinover dermatology
130 years in ofJapan.
history. We We have more than
continue one
to bring
hundred years
innovative newofproducts
experience as a pharmaceutical
to improve company in
the quality-of-life
With 400 professionals and subsidiaries in every CEE
Japan, focusing
(QOL) of patients.on As
research,
a development,
specialty pharmaceuticalmanufacturing
company,
country,
Meiji Seika complemented by 35 years
Pharma is dedicated of experience,
to research, Medis is
development
we
the are aiming
leading to provide
commercialization full line-up
partner of products
for innovativein the field
pharma
and commercialization
MeiraGTx (Nasdaq: MGTX) of innovative and genericfully-
is a clinical-stage, drugs that
companies
improve quality in theofregion.
life for people with diseases. In particular,
integrated, gene therapy company with
MENARINI is a fully integrated privately owned pharma six programs in
we havedevelopment
clinical well-established franchises in the therapeutic areas
company
A Legacywith a long across
of Innovation
ocular, neurodegenerative
and successful heritage in strategic and
salivary gland
partnering acrossconditions.
the globe. MeiraGTx
We have has
a core in-house
profound know-how
Merck
At Merck, has known
a strongashistory of success
MSD outside in translating
of the United States cutting-
and
stemming
edge frominto
research ourlife-saving
strong R&D capabilities
medical in key Our
breakthroughs.
Canada,
Merz we are unified
is focused around the
on addressing our needs
purpose: We use with
of patients the
scientific advances havescience
power of leading-edge made atodifference in the lives
save and(cervical
improve livesof
Neuromuscular
Metagenomi is adisorders
precision and conditions
genetic medicines dystonia,
company
millions
around of patients
thelower
world.limb worldwide.
For spasticity, From Merck’s
more than blepharospasms) development
a century, we’ve Chronicbeen at the
upper and
committed to developing
Mirum Pharmaceuticals iscurative
a globaltherapeutics
commercialfor patients
severeits
using drooling (sialorrhea)
proprietary, and Motor
comprehensive dysfunction (resulting
biopharmaceutical
Mitsubishi Tanabe company focused metagenomics-derived
Pharma Corporation on (MTPC),
debilitating rare was
which
toolbox.
diseases. Metagenomi is harnessing the power of
founded in
Mochida is 1678,
activelyhasseeking
its headquarters in Doshomachi,
both in-licensing and out-Osaka,
which is the
licensing birthplace of
opportunities of Japan’s pharmaceutical
pharmaceutical developmentindustry.
Neopharm, established in 1941, is Israel’s leading distributor
MTPC
programs is expanding its
and pharmaceuticals.global
commercialized products operations and
in ourin building
key for
of innovative
Neopharmed Gentili, led by theWe specialize
private funds Ardianoncology,
and
therapeutic areas
hematology, orphanof interest,
drugs,the such as obstetrics
endocrinology, and
gastroenterology,
Reinassance
NEURAXPHARM together is with
a PE-backed Del Bono family,
specialty is one of the
pharmaceutical
neurology,
leading and
Italian more.
pharmaceutical companies specialized in the
company focused on CNS disorders. Our portfolio includes
marketing
branded pharmaceuticals, value-added medicines and an
of solutions with high therapeutic value, and
consumer health products. With a direct presence in 22
We are a company focused on discovering, developing, and
commercializing
Founded in 2016 innovative
as a result of and thelife-changing
technology and over 20
pharmaceuticals,
years focuses
of clinical in diseases with high unmet medical needs,
NBP on practice
commercializingand academic products experience by Prof.
in the Oncology,
through our novel
Li Bin's team Immunology, research
at Tongji Hospital and development
of Tongji (R&D)
Medical GI College,
Hematology,
Bio & Med tech venture formation, Neurology, NHLBIPsychiatry,
nondilutive andand
Prof. Disease
Rare Li conducted for thebench-to-bedside
region. gene therapy studies,
commercial ventures
Our R&D strategy is to focus on drug discovery and early-
stage development
Nippon Kayaku Co., and to is
Ltd. seek out-licensing
a Japanese or collaboration
pharmaceuticals and
for further chemical
functional development. materialsWe are companynow activelyhaving looking
annual for
About Us
out-licensing
revenue of 1.7orbillion
collaboration
USD, and forfocusing
our innovativeonincancer smalland
Nissan
Nitto Chemical
BioPharma isCorporation
a clinical stage was biotechnology
founded 1887 as Tokyo
company
cancer-related
Jinzo Hiryo, fields first
Japan's in thechemical
pharmaceutical fertilizer business.
manufacturer. Now
whose missionisisantoemerging
Nobelpharma develop and anddeliver
rapidlyinnovative,
growing Japanese life-
Today
changing we are moving
nucleiccompany ahead
acid-based with a
therapeutics keen focus on
for patients our major
with
pharmaceutical
Nomura is a leading global established
financial in 2003.
services Our company
group with over
growth
unmet engines.
medicalinneeds. These encompass
Nitto has performance materials
is specialized
26,000 orphan/niche anddeveloped
highWeunmet
a proprietary
act as need products
Nordic employees
Pharma is an in independent
30+ countries. pharmaceutical a financial
company
in addition
advisor to to gynecology, epilepsy and oncology andwell
is
focused
NOUCOR onidentify
the
is asales
Spanish
andandfacilitate
marketing
B2B
strategic
of niche
pharmaceutical
merger
hospital
company born
acquisition, sale
therapeutics. Nordic of business orhasalliance
directopportunities forEUour
in December
Novartis asPharma
2021healthcare
provides a spin-off ofa URIACH's
solutions
presence
that improve B2BinPharma17
and
countries,
Business as well
Unit. The as the
company,USA, Canada and Japan with a high
extend people’s
NOVARTIS lives.
contract We use based
manufacturing
in Barcelona,
science-based
is a global innovationwas
contract to
founded with
address some ofplayerthe support
society’s of MCH,
most one
challenging of the most well-
manufacturing
Novavax is a biotech company in the biotech field andhealthcare
that promotes cell & gene
improved
issues.
We discover
therapyhealth
offering and collaborate
worldthe class with innovators
manufacturing to develop
servicesand in the
global
Asset Acquisition through Focused! discovery,
Small volume development,
to mid sized, late
Novartis state of artoffacilities
commercialization innovative across USA, to
vaccines Europe
prevent andserious
stage and commercial
NO MEETING REQUESTS FROM DIAGNOSTICS,assets targeted.
infectious diseases. Our proprietary recombinant technology
CROs,
We are CMOs,
a globalHEALTH oncology IT, companyOR SERVICE PROVIDERS
with a proprietary
PLEASE technology called Tumor Treating Fields
platform
Nurix is focused on the discovery, development and
("TTFields"), whichofare
commercialization oral,electric
small fields
molecule that therapies
exert physical andJapan-
Nxera Pharma (formerly Sosei Heptares) is a next-era
forces to kill
antibody cancer cells
conjugates designedvia atovariety
modulate of mechanisms.
cellular proteinOur
first
Nxera biopharmaceutical
Pharma (formerlycompany, Sosei Heptares) committed to translating
is a technology
levels as
world-class a novel treatment
science into approach
life-changing for cancer,
therapeutics. immuneWe have
powered
We biopharma
are specialised incompany,
the discovery, in pursuit of new specialty
development and
operations in
medicines to improve Tokyo, Seoul, Basel, London
the lives oftherapeutics, and
patients withinunmet Cambridge, needs
manufacturing of bacteria-based
https://www.organon.com/organon-business-development/ particular
globally. Nxera employs over 350
bacterial lysates. We are currently manufacturing and talented people at key
Orion Corporation is a European, innovative, mid-sized
marketing two biotechnological products, Broncho-Vaxom®
pharmaceutical
Otsuka Pharmaceutical company headquartered
believes in maximizing in Finland value with a
through
direct commercial
alliances and partnerships. presence throughout Europe. The
(Out-license: NO-13065) Aripiprazole, originally sold
company
under the has
trade recently
name expanded its wasfoot-print to APAC
We
PARI is a worldtoleader
would like haveABILIFY,
an out-licensing
in the development
first developed
opportunity
of aerosolof a
at
Otsuka and commercialized
novel anti-obesity/lipid through
modulation collaboration.
agent, Since this
delivery
Partex NV devices. PARI
is ​the first Pharma
digital focuses
​pharma onNO-13065,
platform pharma in our
that islicensing
set to be
own pipeline.and offers under one roof a complete device and
partnerships
the largest AI-powered
PeptiDream Inc. (TokyoDrug StockAssets Exchange Manager.Prime Section
service portfolio comprising customizable nebulizers based
4587) is leadingisthe
Pharmacosmos translation
a Danish family of macrocyclic
owned worldpeptides leader ininto
a whole new
high-dose class (Rx)of innovative medicines to address unmet
PharmaEssentia Corp. (Taipei Exchange 6446) isObGyn,
IV-iron for hospitals, HemOncs, a globalCV,
medical needs
GI purposes. Approved and improve the quality
and marketed in US,atEurope,of life of patientsRoW.
biopharmaceutical
PharmaEssentia Corp. company,
(Taipeiheadquartered
Exchange 6446)the is state-of-
a global
Ownartoffices
the facility ininUS, China, Europe
NanKang Science -Park
plus in partner
Taipei, network
Taiwan.
biopharmaceutical
As of today, PharmaMar company, headquartered
has three products of at the state-of-
its own drug
PharmaEssentia
the art facility in aims
NanKangto deliver
Science efficacious,
Park in safe, and
Taipei, cost-
Taiwan.
discovery
With in theand
a diverse marketgrowingprogramteam(Yondelis®,
in over 160 countries Zepzelca®,
PharmaEssentia
Aplidin®) and a aims to deliver
richdeliver
pipeline ofefficacious,
drug candidates safe, developed
and cost-
across
Founded theinglobe,
1993,we PharmaResearch high-quality became solutions,
a bio- ethically
with a robust program
and sustainably, acrossof in
our Oncology
four core with world-wide
therapeutic scope.
pharmaceutical
Pharmathen is an leader regenerative
innovation-led and R&D medicine driven inareas
South –
developer
Oncology,
Korea Endocrinology,
dedicated for a better Neurology
and longer and
life Cardiovascular.
as today. Based
of complex
Note: We are pharmaceutical
unable to accept formulations
meeting requests based infrom Athensservice
on active investments
(Greece). By leveraging in our
technology
scientific and nationwide
know-how and human
providers.
The Pierre Please
Fabre Group do not is send requests.
a leading independent French
capital we are working on one of the most extensive and
healthcare group, with activities
Pint is a community-centric ranging from company
biopharmaceutical
pharmaceuticals
serving needsthrough
the Biologics of patient to dermo-cosmetic
communitiesbiotechnology products.
across Latin Our
Polpharma is an international
sales revenues in 2023 were over 2,83 billion €.
America.
company
Our mission with at integrated operations inis the
Poseida Therapeutics European
to redefine Union,
a new
developing
class of cell and manufacturing biosimilar medicines. Using
Protalix is a and gene therapiesbiopharmaceutical
commercial-stage with the capacity to cure.
company We
patented solutions
are developing and state-of-the-art
novel products using platform
our broad gene of technologies,
focused on the development and
PTC is a science-led global biopharmaceutical company commercialization
engineering
recombinant platform
therapeutic technologies,
proteins piggyBacthrough
expressed DNA its
focused on the
Purdue Pharma discovery, development
and its subsidiaries and manufacture
develop, and
proprietary plant cell-based
commercialization expression system,medicines
oftoclinically-differentiated ProCellEx, that
market medications meet the evolving
Radius is focused on the commercialization of products to needs of healthcare
provide benefits to patients
professionals, with rare disorders. Founded over
address unmet patients,patient needs and caregivers.
in bone health Purdue andand its areas.
related
subsidiaries
Radius currently focusmarketson balancingTYMLOS® innovative science with
(abaloparatide)
injection in the U.S. for the treatment of postmenopausal
Rafa Laboratories is a fully integrated pharmaceutical
company
Since 2013, committed
Rakuten to bringing
Medical hasmedicines
been developing that significantly
new
improve patients’
cancer therapies lives
based in through
on1926, the
its Alluminox commercialization of
Recordati, established is a listed European
innovative therapies.
(Photoimmunotherapy) Additional
platform. business
The sales units
Alluminox within
platformthe
pharmaceutical
Recursion (NASDAQ: company, RXRX) with global
is a clinical equal TechBio
stage to Euro
combines
2,082.3 key advantages
million in 2023, of antibody-mediated
dedicated to the research, targeting of
company leading the space by decoding biology to
development,
industrialize drug manufacturing
discovery. Enabling and commercialisation
its mission is the of
REGENXBIO is a leading clinical-stage biotechnology
Recursion OS, a platform built across diverse technologies
company seeking to improve
Relay Therapeutics's main priority lives through
at the BIO theConference
curative
potential
this year is ofto gene therapy.
RemeGen has find
builtpotential
a robust partners
portfoliofor in some
autoimmue, of our non-
core assets.
oncology
Revvity isADC, committedand ophthalmology
to partnering towith independant
accelerate IP and
the progress
ample manufacturing
of novel therapies from capacity.
discovery to the clinic; to improve
Ribocure AB are an siRNA company with programs in pre-
human health
clinical and by turning
clinical stages. biological
These insightsthose
include into action.
targeting
Rocket’s multi-platform development approach applies the
Factor XI. We also
well-established have avector
lentiviral program (LVV) targeting
and adeno-Hepatitis B/D.
Roivant is a commercial-stage biopharmaceutical company
associated
that aims toviral
improvevector the(AAV)
lives gene
of therapy
patients by platforms.
accelerating the
Rosemont Pharmaceuticals (owned by Inflexion) is the UK’s
Rocket
developmentcurrentand hascommercialization
two LVV-based gene of therapy programs
medicines that in
leading
Ryvu liquid pharmaceuticals
Therapeutics is a clinical business. Our mission is to be
stage biopharmaceutical
matter. Today, Roivant’s
a rapid developer, reliable pipeline includes andVTAMA®, a
company
As a "single developing novelmanufacturer
point of contact" small molecule
for our partners,
global supplier
therapies
we handle the
of novel-delivery,
addressing highmedical patient-focused
value emerging medicines. We aim to
market
Salvat isaccess,
an integrated activities,targets
pharmaceutical
in precision
and commercial
company that steps
develops
oncology.
needed for We are focusing
successful market onentry
therapeutics
and growth that of address
and commercializes products through
Samil Pharm. Co., Ltd. was established in 1947, based on the partnerships and
pharmaceutical
distributors products We
worldwide. andalso medicaloperate devices
GMPin andtheseeking
CEE. We
philosophy
Samjin of maintaining
Pharmaceuticals is human
a leading health
Korean with excellent
pharmaceutical
FDA approval
medicines and for our manufacturing
consistent andsites located in Madrid,
company,
Establisheddedicatedin 2012, to theresearch
Samsung development development.
Bioepis isofa biopharmaceutical
innovative
Headquartered
therapeutics in Seoul,
through to Korea,
relentless the company
effort. Since that ourhas full R&D,
company
Founded in committed
South Korea realizing
in 1924,healthcare
Samyang is a conglomerate is accessible
establishment
to everyone. in 1968,innovations
Through we have grown in significantly
product development and
company that operatesInc.
Sana Biotechnology, across variousonbusiness
is focused creatingsectors,and
and a
includingfirm commitment
Biopharmaceuticals, to quality, Samsung
Food, Chemicals, Bioepis aims to
Packaging
deliveringTherapeutics
Sangamo engineered cells as medicine
is a clinical-stage for patients.
biopharmaceutical We are a
and
teamCosmetics.
of scientists, clinicians and medicines
biotechnology veterans
company
We are anwith a robust
innovative genomic
global healthcare pipeline.
company, Using
driven by
focused on
ground-breaking creating an
science, enduring
including company
our that
proprietary makes zinc
one purpose: we chase the miracles
We are an innovative global healthcare company, driven by of science to improve
finger genome
people’s lives.weengineering technology and manufacturing
one purpose:
Sanofi’s vaccines chase
business the miracles
is seeking ofpartners
science who to improvewill share
people’s
the company's lives. pursuit of innovation and drive for excellence,
Santen is a global pharmaceutical company focused on the
while becoming
ophthalmic fields, a part
"eye ofdiseases",
our market successpharmaceuticals,
including story. Our
SKK has more than 60 years of history as an R&D-oriented
diverse culture and
OTC products, surgicalgeography
products, allow usmedical
to collaborate
pharmaceutical
We’re ushering company in a new era based inand
of drug Nagoya,
development Japan.devices.
By taking
with the
full
goal advantage
of driving of being
efficiencies, a subsidiary
including of Suzuken,
shortening a leading
the time
SCL conforms to the regulatory standards of various
company
from lab to inpatient
Japanese andpharmaceutical
building distribution,
the world’s largestwe genecan
agencies
Schrödinger such as aWHO
has Geneva,
substantial andUSFDA,
growingJapanese global business,
therapy manufacturing capacity. We’re collaborating with
licensing
SciClone its industry-leading
Pharmaceuticals physics-based
(HKEx: 6600) is acomputational
commercial
platform
stage to academia,
biopharma that waspharmaceutical,
founded in biotechnology,
1990. We are a China-
Seacross Pharma is a subsidiary of Huiyu Pharmaceuticals
chemical,
focused and electronics
company with a companiesteam
leadership to accelerate
filled with R&D globalin
Co,
SebelaLtd.Pharmaceuticals
that is a publiclyis listed company in Shanghai
a growth-oriented US stock
experience
exchange. and local
Seacross insights. With
Pharma is a pharmaceutical more than 20+ years’
corporation
pharmaceutical
Research-based company
Japanese focused pharmaceutical in gastroenterology
company that
with a strong
including manufacturesfocus on delivering
colorectal cancer detection efficient and
and prevention.advanced We are
develops,
SERB |BTG is a Global and commercializes
specialty pharmaceutical a varietygroup of
ainnovative
pioneer inproducts
colonoscopy screening
as focusing onwhich with a broad
the field of rare and marketed
focused on prescription
Seres Therapeutics, Inc. medicines
(Nasdaq: MCRB)address is a commercial-
ophthalmology. diseases.
life-threatening
stage company developing
A partner with strong commitment: novel microbiome therapeutics
for a number
Servier Biopharma of disease
is an independent states. Seres’
pharmaceutical lead program,
company VOWST
Huaota was founded in 2013, has state-of-the-art
TM, obtained
committed U.S.
to therapeuticFDA approval
progress in April
to serve 2023 as
patient needs. the first
R&D and production
Jemincare group is a leading facilities located
pharmaceutical in Shanghaicompany andin Its
unique
Hangzhou. governance
At present, allowsthere Servier
aretoover to reinvest
twenty novel all its profits
projects underto
China.
SHcell Jemincare
clinicalisstage
isitsa development, committedcell therapy providing
company. healthcare
Centered
support
development, as well as plan and invest with aon
solutions
our cell with9Rx
therapy
of and
them
pipelines,OTC havedrugs
we
obtained
have covering IND wide
established
approval, therapeutics
innovative
Shin Poong Pharm. Co., Ltd. primarily manufactures, at
areas including
technology oncology,
platforms nephrology, CV,generation
analgesic,AI- anti-
current business
SHIONOGI phase,including
concentrates APIs andthe
on following ETCsfourth such as
therapeutic areas:
empowered
cephalosporin VHH antibodyhemostatics,
antibiotics, discovery platform, sedative aagents,
proprietary
infectious
Sinergium diseases,
Biotech isincluding
an Argentinean vaccines, and diseases
pharmaceutical thatand
anti-diabetics.
require significant social andresearch,
medicaldevelopment,
attention, such as
company
Sino Biopharm specialized
(and its in subsidiaries
the including CTTQ, Beijing
dementia, psychiatry,
production and neurodegeneration,
commercialization of mobility disorders,
high-complexity
Tide,
SinoMabinvoX etc.) is a leading
BioScience LimitedChinese is a Hong pharmaceutical
Kong-based
vaccines
company and biological
focused on products.
Oncology, Through
Hepatology, anRespiratory
innovative and
biopharmaceutical company listed on the Hong Kong Stock
Surgical/Pain
Exchange Limited. therapeutics.
We focus Weoncontinue to exploreof
the development
therapeutic platforms of B-cell therapeutics, alarmin-based
SK Biopharmaceuticals commenced research and
development
**R&D Center of innew drugs Korea**
Pangyo, in 1993 as part of our search for
the next-generation
1) The growth
largest vaccine-dedicated engineR&D of SK Group.
center The
in Korea
As an affiliate of SK Group, the third largest conglomerate in
company has focused on the development of treatments for
Korea having total revenue of 119
SK Plasma is a South Korean company, affiliate of the Billion USD as of year
2021,
secondSK Chemicals
largest business hasconglomerate
been rapidly in growing
Korea,its ‘SKLifeGroup’.
Science business domain and its annual sales reached 1.2
SRI Biosciences is looking to meet with commercial partners
interested in the following areas:
https://www.srslife.com/science/
STADA is a German pharmaceutical company, focusing on
three
We are pillars:
committed generics, specialty precision
to furthering pharma and non-prescription
medicine and
consumer
personalised healthcare
AIT treatments products. In 2022, STADA achieved
Sumitomo Pharma's goal is totocreate
address unmet medical
innovative needs
group sales of
for patients with EUR 3.79 billion
allergies. and adjusted
With precision EBITDA of
medicine,
pharmaceutical
Sun Pharma is the world's fourth largest specialty generic as
products. Psychiatry & Neurology as well
Stallergenes
Oncology represent Greer identifies
our focus the mechanisms ofcontaining
allergic
pharmaceutical
Sunsho Pharma company is introducing with therapeutic
global revenues
UniORV,
areas
a new of over $ 5
formulation
significant
Billion and unmet
India's medical
top needs.
pharmaceutical company. A vertically
technology
These therapeutics that enhances both drug absorption
will significantly extend theof difficult
clinical to
integrated
dissolve business,
substances economies
and enteric of scale
delivery, and an
including extremely
to the
impact is
Sobi® ofacurrent
specialised oncology therapeutic
international approaches, and are
biopharmaceutical
colon.
beyond Research
what can and development
be envisioned with activities
current are currently
(cell-based)
company transforming the lives
Established in 1994 and headquartered in Riyadh, of people with rarewe andare the
expression
debilitating technologies.
diseases. Providing Sutro's biochemical
reliable access synthesis
to innovative
largest privately-owned pharmaceutical
The mission of Taiho Oncology, Inc. is to improve the lives company in Saudi
medicines
Arabia, with in athe areasmarket
of haematology, immunology theand
of patients
Taiho withstrong
Pharmaceutical, cancer, atheir
presenceand
families
subsidiary
throughout
of Otsuka theirHoldings Middle
caregivers. Co.,
East
The and North Africa (MENA) region. Over the
and on thewetwo
years,
Ltd.,company
Taisho is is
anaR&D-drivenspecializesspecialty
leading Japanese
in the development
pharma focusing
pharmaceutical company and
commercialization
fields ofsustaining
oncology and of orally administered
immune-related anti-cancer
diseases. Its agents
corporate
has two
Takeda Pharmaceutical pillars, Consumer
Company Health
Limited is Care (OTC)
a global,
philosophy
business and andtakes the formpharmaceutical
prescription of a pledge: “We strive to improve
business.
research
Tamer Groupdevelopment-driven
aims to improve access pharmaceutical
to innovative company
therapies
committed
to better serveto bringing
the better
region’s health
unique and
patients’a brighter
needs future
in to
Taro develops high-quality, proprietary and off-patent
patients by
collaboration translating
with science into life-changing medicines.
pharmaceuticals
Tarsus Pharmaceuticals, forsupport
markets fromthe
Inc. in
the various
appliesUS, Canada,
proven
governmental,
Israel
science andand new
national and
other countries regional agencies
around the world. and research
The for Company centers, from a
produces
technology to revolutionize treatment
Tasly Pharmaceutical was founded in 1994 and listed in patients across
wide
severalrange of prescription
therapeutic categories,and starting
over-thewith counter care. products
Shanghai
Teijin Pharma StockisExchange in 2002,
a fully integrated which is eye
healthcare pioneerOur
a company and
with
lead product,
leading player XDEMVY®
in China's (lotilaner ophthalmic
pharmaceutical industry solution)
focusing
two core businesses of pharmaceuticals
Teikoku Seiyaku is a privately-owned Japanese and home healthcare
on developing, manufacturing
devices/services. We haveengaged more and thancommercializing
50 years & experiences in
pharmaceutical
Telix is a leading company
commercial-stage in biopharmaceutical
research
research,
development, development,
manufacturing and marketing
and marketing of healthcare
innovative
company
Tenry Pharma focused is aon the development
commercial-staged and commercialisation
pharmaceutical
transdermal
of therapeutic patches
and in worldwide.
diagnostic Our leading product
company founded 2010 and(‘theranostic’)
headquartered in Shanghai,
radiopharmaceuticals.
China. The company mainly focuss on dermatology,
Renowned for pioneering the production of generic
autoimmune disease, and cardiovascular disease with
medications
Teva in Brazil,Industries
Pharmaceutical Teuto hasLtd. solidified
(NYSEitsand position
TASE:as a
trusted name
TEVA) has in the
been Brazilian and
developing pharmaceutical
producing market. Beyond
medicines to
Theramex is a global specialty pharmaceutical company
generics, Teuto
improve people’s is evolving
lives for into
more a comprehensive
than aHeadquartered
century. We are healthcarea
dedicated
Tillotts is atospeciality
women and their
Pharma health.
company with a leadingin
global leader
London, UK, in
the generic
company andmarkets
specialty a medicines
broad range with
of a
position
Toray Group in thefuses fieldnanotechnology
of Gastroenterology into itsandoperations,
Specialty using
innovative
Products. and branded
Since September generic
1st, products
2009, across
Tillotts 50 countries
Pharma AG is
organic synthetic
Transcenta chemistry,
is a clinical stage polymer chemistry
biopharmaceutical and
company
100% owned
biotechnology by the Tokyo-based
as its antibody-based
core technologies. Zeria In addition to theCo.,
Pharmaceutical
that fullyisintegrates
Travere a fully-integrated biotherapeutics
biopharmaceutical company
Foundation Businesses
discovery,toresearch, of fibers & and
development, textiles and performance
manufacturing.
dedicated delivering life-changing
Trinomab Biotech Co., Ltd (Trinomab) is a late stage therapies to people (NDA
Transcenta
living with was diseases.
rare listed on the We Main
are Board of
focused on the Stock our
developing
& clinical) biopharmaceutical company
Tris Pharma, Inc. is engaged in research, development, with a global
pipeline
expansion ofperspective.
product candidates The company including isof Filspariengaged
mainly ® in
manufacturing,
Tsumura USA, Inc. and commercialization
is a 100% subsidiary innovative
of a Japan-based
R&D of novel
therapeutics. Wecompany, fully native human
are among the largest monoclonal antibody
privately-owned
pharmaceutical
TTY Biopharm Company Tsumura Limited (TTY) & Co. isTsumura
a publicly
commercial-stage
manufactures biopharma
and sells more companies
than 120 in the U.S.
pharmaceutical
traded, fully integrated, innovative
UBE corporation is one of the largest chemical companies pharmaceutical company in
botanicalindrugs
founded 1960. that have been
Corporate marketed
offices, R&D, inRegulatory
Japan as high- and
Japan, founded over 100 years
UCB, Brussels, Belgium (www.ucb.com) is a global ago. In the pharmaceutical
Manufacturing
segment, Ube has facilities
been are located
engaged in Taiwan
in research andwith sales and
development
biopharmaceutical
Founded in 2010, the company
company focused on thebuilt
has rapidly discovery
a diverseand
of small molecules.
development Our major
of innovative commercial
medicines and drugs are:
solutions to
portfolio of product candidates
We have five approved products, including four for with the potential to address
transform
diseases for thewhich
lives the of people
unmet living
medical withneedsevere
is high,diseases
the of
pulmonary
Valneva is aarterial hypertension,
fully integrated, one for
commercial pulmonary
stage, specialty
biology for treatment
hypertension associated is clear,
with and for which there areand
no one
vaccine company
Verve Therapeutics, focused on interstitial
Inc. (Nasdaq: prevention
VERV)
lung
against disease
diseases
is a clinical-stage
for
withpediatric
major high-risk
unmet needs. neuroblastoma.
Thepioneering
Company's mostapproach
advancedto the
genetic medicines company a new
development-stage candidate includes
care of cardiovascular disease, potentially transforming a Phase 3 vaccine
treatment from chronic management to single-course gene
The 8th largest veterinary pharmaceutical company in the
world,
We Vetoquinol
champion patientis first
access.and Ourforemost
globalanscaleindependent,
and
family-owned
differentiated business.
portfolio Vetoquinol
include brands, is solely
generics, and to
dedicated
We research and develop new HIV medicines:
animal
complex health, and focused on the licensing, development,
The needsmedicines
Founded inof1968
people across awith
by aliving
wideHIV
French veterinarian,
variety
changeof therapeutic
over time,
Virbac is an and
areas. exploring new ways of treating and preventing HIV
we’re
independent pharmaceutical laboratory
Waterstone Pharmaceuticals was established dedicated
in 2009to animal
and is
through
health. new mechanisms
Currently ranked of worldwide,
6th action and drug the delivery. is
company
committed
We to the development
are leveraging and productionmodalities,
a toolkit of RNA-targeting of drugs for
present
metabolic in more than 100 as
diseases, countries, offering a comprehensive
chemistry
DUE TO LIMITED innovationsuch and deep
TIMESLOTS,
hyperkalemia,
insightsWE in WILL
hyperuricemia
human NOT geneticsandto
other metabolic
deliver scientific disorders
breakthroughs The company
thatFROM is divided
treat both into
rare and two
ACCEPT
Our GOAL: MEETING
To be leaders REQUESTS in LATAM and SERVICE
emerging
prevalent disorders.
PROVIDERS
countries
Xencor is through
expanding a professional,
the therapeutic competitive
boundaries andofsustainable
antibody
organization
and are
cytokine where each
drugs.anPowered member is a protagonist,
We advancing excitingby its XmAb®
portfolio protein
of neurology
contributing
engineering the best ofXencor
platform, themselves.
is developing a broad pipeline
therapies
Xeris is a in our product pipeline.
biopharmaceutical company Building upon
leveraging the
ourpositive
novel
of drug candidates
results and compelling that are
data optimized
from our XEN1101to treat patients
Phase with
2b “X-
non-aqueous formulation technology
1. XtalPi integrates AI, physics-based modeling, robotics, platforms, XeriSol™
TOLE”
and study in to
XeriJect™, adult patients
develop and with focal epilepsy,
commercialize our
ready-to-use
and
XtalPiDEL is aservices for accelerated
global technology platformdrug company
discoverypowered
and by
injectable
development andwith
infusible
accurate drugpredictions.
formulations. Xeris focuses on
artificial intelligence
XuanZhu (AI) and robotics.
Biopharmaceuticals, Ltd., a whollyFounded ownedin 2015,
XtalPi is dedicated
subsidiary of SihuantoPharmaceutical
driving intelligent and digital
Yifan Pharmaceutical is an innovativeHoldings R&D and Group Ltd., is
production
transformation
an innovative in
R&Don life sciences
biotechnology and discovering
company, better
company
YOOYOUNG focusinghas richthe pharmaceutical
experience and focused
of in-licensing health on four
sectors.
business as
key therapeutic
Our vision is to areas
develop in the past years:
innovative drugsoncology,
with metabolic
definite
well as out-licensing
- Headquarter: Seoul, Korea and build many success histories.
clinical values, to help disease-afflicted patients regain
- Sales
Zai LabRevenue:
is a NASDAQ USD1.3B listed(2022)
(ZLAB) innovative
biopharmaceutical company.
Zambon Biotech is part of the Zambon The company’sgroup globally-
of companies,
experienced
it is focused drug
in development
growing the team is
portfolio passionate
and pipeline about
of the
Founded 1998
bringing group
Zambon transformative
by entering medicines
into to China and
partnerships, discovering
acquiring assets
Public
Founded in 2009, Suzhou Zelgen Biopharmaceuticals Co.,
and supporting their clinical development up to
Ltd. (China
Zentiva is a Shanghai:
producer of688266) high-qualityis located in the Kunshan
affordable medicines
Nationalpatients
serving New &acrossHigh-tech District (KSND)With in Jiangsu
Zeria Pharmaceutical is a Tokyo-based healthcareacompany
Europe and beyond. dedicated
Province,
team of more China.than It is a joint
4,700 people venture established
and a network by Chinese
of production
focused
Zymeworks on the discovery,
(Nasdaq: ZYME) development
is a global and marketing
biotechnology of
sites - pharmaceuticals
novel including flagship for sites
Japan in and
Prague,the Bucharest and
international
company committed to the discovery, development, and
marketplace.
commercialization Zeria of develops and markets ethical
novel, multifunctional and OTC
biotherapeutics.
Zymeworks’ mission is to make a meaningful difference in
 News

http://www.abbisko.com/

For all the latest news and more information about partnering
with AbbVie, please visit:
https://www.abcellera.com/news

https://acadia.com/media/news-releases/acadia-
pharmaceuticals-announces-u-s-fda-approval-of-daybue-
FDA Approves HERCESSI for HER2-Overexpressing
trofinetide-for-the-treatment-of-rett-syndrome-in-adult-and-
Gastric, Gastroesophageal Cancers - May'24
pediatric-patients-two-years-of-age-and-older/

https://www.advancedenzymes.com/august-2017-advanced-
enzymes-acquires-100-stake-in-evoxx-technologies/
https://www.advanzpharma.com/news

Akebia Therapeutics receives FDA Approval for Vafseo®

As of April 2024
https://www.lifesciencesreview.com/allife-medicine

Recent Deal making track record in Medical dermatology

includes:
Alvogen acquires Korean Dream Pharma for US$ 187
million

https://www.statnews.com/2020/05/27/beating-covid-19-
will-change-how-new-therapies-are-developed/
Jun 8, 2024: Ardelyx Provides Update on Growing
Commercial Momentum and 2024 Strategic Priorities.

Ascletis Announces China NMPA Approval of Conducting a

Phase IIa Clinical Trial for ASC10 to Treat Respiratory
Syncytial Virus Infection - 20230508
Launched Rifxima (Rifaximin) for Hepatic Encephalopathy
(November 2016).

AURIGENE DISCOVERY TECHNOLOGIES LIMITED

ANNOUNCES DRUG DISCOVERY, DEVELOPMENT
AND COMMERCIALIZATION PARTNERSHIP WITH
https://www.autolus.com/investor-relations/news/
EQRX July 5th, 2022

- Sep 2023: BenevolentAI Signs Strategic Collaboration with

Merck (https://www.benevolent.com/news-and-media/press-
releases-and-in-media/benevolentai-signs-strategic-
https://hcahealthcaretoday.com/2024/02/22/hca-healthcares-
collaboration-merck/)
sarah-cannon-cancer-institute-implements-new-outpatient-
Amgen and Betta Pharma Announce Approval of Joint
model-for-car-t-cell-therapy/
Venture in China
https://investors.bicycletherapeutics.com/investor-relations

In 2024Q2, Biotheus entered Phase III pivotal trials for

treating TNBC with an anti-PD-L1 x VEGF bispecific
www.blanver.com.br
(PM8002). Additional Phase III trials are being planned for
2024.
https://www.bluerocktx.com/bluerocks-phase-i-study-with-
bemdaneprocel-in-patients-with-parkinsons-disease-meets-
primary-endpoint/

https://www.carsgen.com/en/news/

New R&D Centre opened in September 2020

https://youtu.be/-o9MYgvN_Nw
Ongoing projects;
Development of rare disease treatments such as treatment
for Sarcoidosis,

https://endpts.com/novartis-licenses-hdac6-inhibitor-from-
koreas-chong-kun-dang-pharma-for-80m-upfront/

http://www.collegiumpharma.com

https://www.forbes.com/companies/cspc-pharmaceutical-
group/#27b72f426392

http://www.cytiva.com
https://ir.cytokinetics.com/news-releases

- Daewoong Pharmaceutical announces success in

developing a new antidiabetic medication and its aims to
enter the market in over 50 countries by 2030 (URL:
https://www.prnewswire.com/news-releases/daewoong-

Eisai started venture investment in 2019, aiming at

accelerating innovation in drug creation and establishment of
ecosystem platform. For more detail, please refer to
https://www.eisai.com/news/2019/news201930.html

October 2023: Enable Injections Receives First U.S. Food

and Drug Administration (FDA) Approval
(https://www.prnewswire.com/news-releases/enable-
Feb 21, 2020 - Esperion Announces FDA Approval of
injections-receives-first-us-food-and-drug-administration-
NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-
Daily, Non-Statin LDL-Cholesterol Lowering Medicine

Selected News:
Licensing of XNW1011 to Everest Medicines
https://www.prnewswire.com/news-releases/everest-
medicines-sinovent-and-sinomab-announce-licensing-
agreement-for-global-development-manufacturing-and-
Best-in-class MALT1 and LSD1 molecules entering the
clinic and precision medicine platform study at the Charite
Hospital in Berlin
https://www.ferrer.com/en/We-acquire-worldwide-rights-to-
ASN90-an-O-GlcNAcase-inhibitor-to-treat-Progressive-
Supranuclear-Palsy
• FF-10850 (liposomal topotecan) has been granted the FDA
orphan drug designation for Merkel cell carcinoma in March
2024.

For further information and news on GAIA, please visit

https://gaia-group.com/en/news.html

http://ir.genmab.com/releases.cfm

Press releases here:

https://ir.gritstonebio.com/investors/press-releases

https://www.gubra.dk/news/

Over two decades since Haisco’s inception, Haisco has

dedicated itself to progress and to making meaningful
impacts in both the pharmaceutical field and the wider
community.

May 23, 2024

Nona Biosciences Announces Global License and Option
Agreement with AstraZeneca for Monoclonal Antibody to be
https://www.henlius.com/en/News.html
Developed into Novel Tumor Targeted Therapies
London, 25 April 2024
The Group had a strong and encouraging start to the year,
supported by all three business segments.
https://www.koreabiomed.com/news/articleView.html?
idxno=23509
*HUTCHMED Initiates Registration Stage of the ESLIM-02
Phase II/III Trial of Sovleplenib for Warm Antibody
Autoimmune Hemolytic Anemia in China in March 2024;
Recent Activities
1) In-licensing:
1. Series B financing:
https://www.businesswire.com/news/home/20200324005225/
en/IASO-Biotherapeutics-Raises-60-Million-in-Series-B-
Financing-Led-by-GL-Ventures-to-Advance-Cell-Therapies-
(1) SAD study of ID110521156, a GLP1RA asset for T2DM
and obesity, has been completed in 1Q 2024 and the MAD
study is expected to be completed in Q2 2025.

• 4 January 2024- INOVIO and Coherus Announce Clinical

Collaboration to Advance Development of INO-3112 in
Menarini-Group-and-Insilico-Medicine-Enter-Global-
Combination with LOQTORZI™ (toripalimab-tpzi)
Exclusive-License-Agreement-for-Novel-KAT6-Inhibitor-
for-Potential-Breast-Cancer-Treatment-and-Other-Oncology-
Indications -

http://www.ipsen.com/medias/news/
https://ironwoodpharma.com/media/

March 2021 - Approval of IZCARGO in Japan - the first

CNS penetrating Biotherapeutic for the treatment of MPS II
(Hunter Syndrome.

JBI-802 initial Phase I data suggests therapeutic potential in

sensitizing immunotherapy resistant tumors and in
Myeloproliferative Neoplasms with thrombocytosis

Please see
https://www.kamada.com/news-main/
https://www.businesswire.com/news/home/
20231003368872/en/Kashiv-BioSciences-Enters-into-
Exclusive-Licensing-Agreement-with-Alvotech-for-
Development-Commercialization-of-a-Proposed-Biosimilar-
Kintor Pharma’s Proxalutamide Demonstrated Reduction in
Hospitalization/Mortality for Patients with Mild to Moderate
COVID-19 in Phase III MRCT Study
http://www.gud-knight.com/en/investors/in-the-news
http://www.gud-knight.com/en/investors/press-releases
- Signed license out agreement for TG-C with Juniper (2022)
- Spin off CDMO business division to Kolon Biotech (2020)
We have developed and launched its first platform in the
area of digital technology.

- SAVAL was ranked as TOP #3 in the IQVIA MAT Dec

2022 in Chile.

CARVYKTI(TM) (ciltacabtagene autoleucel), BCMA-

directed CAR-T therapy, receives U.S. FDA approval for the
treatment of adult patients with relapsed or refractory
News Center:
multiple myeloma. February 28, 2022.
https://en.lepubiopharma.com/news/gongsixinwen
LG Chem Life Sciences Company has recently been very
active in partnering activities with the aim to expand its
expertise and competence in its key therapeutic areas;
https://lnc-pharm.com/
metabolic diseases, oncology and immunology.

https://ir.madrigalpharma.com/news-releases/news-release-
details/madrigal-pharmaceuticals-announces-fda-approval-
rezdiffratm
MannKind’s Technosphere® Inhalation Platform Utilized in
FDA-Approved Tyvaso DPI™. Tyvaso DPI represents the
second FDA-approved product utilizing MannKind’s
innovative Technosphere® inhalation technology and is the
・Allay Therapeutics Announces Development and
Commercialization Agreement with Maruishi Pharmaceutical
for Ultra-Sustained
Meiji Pain
has experienced Therapeutics
successful in Japanwith Pfizer,
partnership
Sanofi, Novartis, Abbvie, Symphogen, Light Sciences,
Nippon Shinyaku, Takeda, Dainippon Sumitomo, Taiho, Ono
https://www.menarini.com/en-us/
Pharmaceutical, Kyorin, Almirall, Mundipharma, Amalyte,

https://metagenomi.co/

https://www.mt-pharma.co.jp/e/release/index.php
Followings are our recent in-licensing activities:
・Daridorexant: a novel orexin receptor antagonist for the
treatment of insomnia, partnered with Idorsia
https://www.nitto.com/jp/en/
https://www.nittobiopharma.com/

Press releases: http://ir.novavax.com/press-releases

Novocure Announces Presentation of Results of the LUNAR

Phase
Nurix 3Therapeutics
Clinical Trial in Non-Small
Announces Cell Lung
Extension Cancer at
of Strategic
2023 Americanwith
Collaboration Society
Sanofiof to
Clinical Oncology
Develop (ASCO) Protein
Novel Targeted
2024:
Annual Meeting
Degraders of STAT6 (April 2024)
-2024:
Joined the World Orphan Drug Alliance
- Joined the World Orphan Drug Alliance
https://www.ompharma.com/media/news/0b8600bc-b5a3-
4490-b603-58342becaadb

https://www.linkedin.com/posts/partexnv_partex-nv-sanofi-
deal-activity-7173957734537555969-Nbu2?
- Announces Expansion of Peptide Drug Discovery
utm_source=share&utm_medium=member_desktop
Collaboration with Novartis (2024.04.30)
www.pharmacosmos.com
2021/1/7
PHARMAESSENTIA
2021/1/7 INITIATES PIVOTAL TRIAL OF
ROPEGINTERFERON ALFA-2B TO
PHARMAESSENTIA INITIATES PIVOTAL TRIAL OF
ROPEGINTERFERON ALFA-2B TO
Recently announced transactions:
September 18, 2023; Pharmanovia acquires global CNS
portfolio from Sanofi
All Pharming news announcements can be found at
https://www.pharming.com/news
• Acquisition of global rights to pan RAF inhibitor
exarafenib from Kinnate Biopharma, currently in clinical
development for treatment of NRAS mutant melanoma and
https://polpharmabiologics.com/en/knowledge/latest-news/
RAF driven solid tumors
article/polpharma-biologics-investigational-biosimilar-
shows-pk-pd-comparability-to-inflammatory-bowel-disease-
http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-
blockbuster-entyvio-sup-r
newsArticle&ID=2145546
In September 2020, Akalux and BioBlade (ASP-1929)
received marketing approval in Japan for the treatment of
http://www.recordati.com/en/news_and_announcements/
unresectable locally advanced or recurrent head and neck
https://ir.recursion.com/news-events/press-releases
cancer.

https://news.revvity.com/press-announcements/press-
releases/press-release-details/2023/Revvity-Announces-New-
License-Agreement-for-Next-Generation-Base-Editing-
Technology/default.aspx

November 2022
Clobetasol Nanoemulsion for Post cataract surgery
Inflammation and Pain - Expected approval Q2 - 2025

In 2023 Sangamo announced our strategic transformation to

a neurology-focused genomic medicine company developing
epigenetic regulation therapies designed to address serious
neurological diseases and novel AAV capsid delivery

Schrödinger Receives $111.3 Million Distribution from Sale

of Nimbus’s
Please see allTYK2 Inhibitor
SciClone news to Takeda
announcements here:
http://investor.sciclone.com/releases.cfm
https://www.marketwatch.com/investing/stock/688553?
countrycode=cn

SERB Pharmaceuticals acquires US rights for bentracimab

from SFJ in 2023
https://servier.com/en/newsroom/
https://www.huaota.com/en/
1.Partnership with Genentech:
https://www.prnewswire.com/news-releases/jemincare-
announces-exclusive-license-agreement-with-genentech-to-
develop-and-commercialize-novel-oral-androgen-receptor-
https://www.shionogi.com/global/en/news.html
degrader-301608317.html
In 2021 Sinergium Biotech was selected as a partner for the
mRNA technology transfer programme launched by
WHO/MPP. Being the first Argentinean Biotech company
working in the field of mRNA tech, Sinergium Biotech is
establishing new manufacturing capacities in South America.
[01/09/2024] SK Biopharmaceuticals Presents Company
Vision to Make Big Bet on New R&D Platforms
https://www.skbioscience.co.kr/en/news/news_01
(Radiopharmaceutical Therapy, Targeted Protein
Degradation) at J.P. Morgan Healthcare Conference

https://www.sri.com/press/story/sri-works-with-n4-pharma-
to-target-and-treat-cells-in-the-human-body-that-had-been-
https://www.srslife.com/products/
unreachable/

https://www.tabukpharmaceuticals.com/en/media-and-news
TAIHO ONCOLOGY, INC. ANNOUNCES
ESTABLISHMENT OF EUROPEAN HEADQUARTERS
https://www.taiho.co.jp/en/

https://telixpharma.com/news-views/

Transcenta Announces First Patient Dosed in Phase I Clinical

Trial of Claudin18.2 Targeting Monoclonal Antibody
TST001 in the US
News from 2023:
In December,
PAIN: TNM 002 NDA filling was submitted at
https://www.trispharma.com/who-we-are/news-and-
NMPA;
media/tris-pharma-reports-positive-topline-data-from-
clinical-study-of-investigational-pain-therapy-cebranopadol-
showing-significantly-less-potential-for-abuse-versus-

https://valneva.com/media/press-releases/
Vetoquinol won Animal Pharma's award for best
Euroopeanawaras been awarded best Animal Health
company in European company in 2020

https://www.xerispharma.com/investor-relations/news-
events/press-releases

https://www.evivebiotech.com/en/news/index
https://en.yifanyy.com/
https://www.fiercebiotech.com/biotech/boehringer-grabs-
yuhan-s-nash-prospect-870m-biobucks-deal
Partnerships with Tesaro, Paratek, Five Prime, BMS, GSK,
UCB and Sanofi amongst others

https://www.zelgen.com/en

2024/04/08- Zymeworks Presents New Data from Multiple

Preclinical Development Programs at 2024 American
Association for Cancer Research Annual Meeting
https://ir.zymeworks.com/news-releases/news-release-
 Primary therapeutic area(s)

Dermatological disease
Hematological
Dermatologicaldisease
disease
Hematological
Neoplasm disease
Neurological disease
Cardiovascular disease
Endocrine disease
Endocrine disease
Immune
Immune disorder
disorder
Infectious
Genetic disease
disorder
Neurological disease
Endocrine disease
Neoplasm
Andrology
Cardiovascular
Cardiovascular disease
disease
Dermatological disease
Cardiovascular disease
Endocrine disease
Unidentified indication
Endocrine disease
Gastrointestinal
Cancer disease
Genetic disorder
Hematological
Cardiovascular disease
disease
Metabolic disorder
Cardiovascular disease
Gastrointestinaldisease
Genitourinary disease
Renal disease
Hematological disease
Metabolic disorder
Gastrointestinal disease
Neoplasm
Central nervous system disease
Cardiovascular disease
Hematological disease
Neurological disease
Psychiatric disorder
Dermatological disease
Bullous skin disease
Genetic disorder
Cardiovascular disease
Endocrine disease
Unidentified indication
Inflammatory disease
Neoplasm
Cardiovascular disease
Gastrointestinal disease
Cardiovascular disease
Gastrointestinal
Metabolic disease
disorder
Musculoskeletal disease
Hyperparathyroidism
Stomach infection
Hematological disease
Neoplasm
Cardiovascular disease
Endocrine
Genetic disease
disorder
Immune disorder
Metabolic disorder
Neurological disease
Cardiovascular disease
Endocrine disease
Gastrointestinal disease
Renal disease
Immune disorder
Inflammatory
Dermatologicaldisease
disease
Genitourinary disease
Hematological disease
Inflammatory
Cancer disease
Hepatitis B virus infection
Liver disease
RNA virus infection
Genitourinary disease
Gynecology
Endocrine and obstetrics
disease
Genitourinary
Cardiovasculardisease
disease
Infectious disease
Hematological neoplasm
Post transplant lymphoproliferative disease
Cancer
Cardiovascular disease
Metabolic disorder
Multiple myeloma
Hematological neoplasm
Non-small-cell lung cancer
Cardiovascular disease
Degeneration
Infectious disease
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Endocrine disease
Neoplasm
Cancer
Immune disorder
Inflammatory
Andrology disease
Endocrine disease
Ocular disease
Breast tumor disease
Neurological
Neurodegenerative
Neoplasm disease
Cancer
Gastrointestinal disease
Genetic disorderdisease
Hematological
Immune
Infectiousdisorder
disease

Genetic disorder
Aging
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Dermatological
Endocrine diseasedisease
Hematological
Immune disorder disease
Infectious disease
Dermatological disease
Endocrine disease
Autoimmune disease
Cancer
Autoimmune disease
Cancer
Immune disorder
Inflammatory
Prostate disease
disease
Testicular disease
Hematological disease
Adrenoleukodystrophy
Hematological disease
Musculoskeletal disease
Neurological disease
Central
Skin nervous disease
appendage system disease
Cancer
Infectious disease
Musculoskeletal disease
Cardiovascular disease
Degeneration
Gynecology and obstetrics
Otorhinolaryngological
Cardiovascular disease disease
Endocrine disease
Cardiovascular disease
Infectious disease
Cardiovascular disease
Infectious disease
Hematological disease
Neoplasm
Cardiovascular disease
Gynecology
Cardiovascular anddisease
obstetrics
Gastrointestinal disease
Non-Hodgkin lymphoma
Cancer
Endocrine disease
Endocrineinfection
Bacterial tumor
Viral infection
Dermatological disease
Gastrointestinal
Cancer disease
Advanced solid tumor
Genetic disorder
Inflammatory disease
Cancer
Gastrointestinal disease
Metastatic breast cancer
Immune disorder
Infectious disease
Hematological disease
Immune disorder
Cardiovascular disease
Dermatological disease
Female infertility
Solid tumor
Cardiovascular injury
Aging
Genetic disorder
Respiratory disease
Endocrine disease
Immune disorder
Cardiovascular disease
Gastrointestinal
Genetic disorderdisease
Hematological disease

Prostate tumor
Skin tumor
Erectile dysfunction
Central nervous system disease
Cancer
Solid tumor
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Gastrointestinal disease
Dermatological disease
Endocrine disease
Cardiovascular disease
Hematological
Neoplasm disease
Neurological
Neoplasm disease
Cardiovascular disease
Dermatological disease
Infectious disease
Neoplasm
Cardiovascular disease
Inflammatory disease
Cardiovascular disease
Diabetes mellitus
Osteoarthritis
Cardiovascular disease
Endocrine
Cancer disease
Central
Cancer nervous system disease
Solid tumor
Gastrointestinal
Degeneration stromal tumor
Genetic disorder
Immune disorder
Respiratory disease
Psoriasis
Cardiovascular disease
Gynecology and obstetrics
Hypertension
Breast tumor disease
Cardiovascular
Degeneration
Dermatological disease
Gynecology anddisease
Gastrointestinal obstetrics
Inflammatory disease
Gastrointestinal disease
Cardiovascular disease
Infectious disease
Genetic disorder
Hematological
Cardiovascular disease
disease
Metabolic disorder
Neurological disease
Breast tumor
Cardiovascular disease
Endocrine disease

Cardiovascular disease
Dermatological disease
Endocrine disease
Hematological
Cardiovascular disease
disease
Neoplasm
Ocular disease
Bacterial infection
Viral infection
Andrology
Cardiovascular disease
Immune disorder
Autoimmune disease
Neurological disease
Ocular disease
Gynecology and obstetrics

Immune disorder
Musculoskeletal disease
Dermatological disease
Endocrine
Neurologicaldisease
disease
Respiratory disease
Gastrointestinal disease
Infertility
Congestive heart failure
Metastatic pancreas cancer

Cardiovascular disease
Gastrointestinal disease
Neoplasm
Infectious disease
Gastrointestinal disease
Gynecology
Solid tumor and obstetrics
Adrenal gland hyperfunction
Adrenal gland hypofunction
Cardiovascular disease
Gastrointestinal disease
Fatigue
Hypertension
Immune disorder
Inflammatory
Diabetes disease
mellitus
Obesity
Cardiovascular disease
Endocrine disease
Immune disorder
Autoimmune disease
Gynecology and obstetrics
Musculoskeletaldisease
Cardiovascular disease
Hematological disease
Inflammatory disease
Endocrine disease
Growth
Cancer disorder
Leukemia
Growth hormone deficiency
Hemophilia

Inflammatory disease
Rheumatoid arthritis
Dermatological disease
Immune disorder
Cardiovascular disease
Immune
Cancer disorder
Solid tumor
Osteoarthritis
Peripheral
Genetic neuropathy
disorder
Immune disorder
Metabolic disorder
Respiratory disease
Cardiovascular disease
Endocrine disease
Inflammatory disease
Liver disease disease
Neurological
Psychiatric
Hematologicaldisorder
disease
Neoplasm
Immune disorder
Surgical
Metabolicprocedure
disorder
Neurological disease
Autoimmune disease
Lacrimal gland
Endocrine diseasedisease
Genetic disorderdisease
Cardiovascular
Dermatological
Neoplasm disease
Respiratory disease
Dermatological disease
Cancer
Cancer
Cardiovascular disease
Dermatological
Dermatological disease
disease
Gynecology anddisease
Cardiovascular obstetrics
Dermatological
Aging disease
Diabetes mellitus
Dermatological disease
Endocrine disease
Hematological disease
Cancer
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Dermatological
Alzheimers disease
disease
Ovary tumor
Multiple myeloma
Autoimmune
Hematologicaldisease
neoplasm
Autoimmune disease
Cancer
Cardiovascular disease
Endocrine
Neoplasm disease
Atopic dermatitis
Insulin dependent diabetes
Dermatitis
Atopic
Neoplasmdermatitis
Systemic lupus disease
Hematological erythematosus
Allergy
Immune disorder
Respiratory disease
Cancer
Dermatological disease
Genetic disorder
Infectious disease
Bacterial infection
Genetic disorder
Cancer
Psychiatric disorder
Degeneration
Endocrine disease
Gastrointestinal disease
Graft versus host
Cardiovascular disease
disease
Dermatological disease
Injury
Surgical procedure
Lysosome storage disease
Fucosidosis
Cardiovascular disease
Endocrine disease
Neurological disease
Cardiovascular disease
Hematological disease
Gastrointestinal disease
Inflammatory
Neoplasm disease
Prostate tumor disease
Dermatological
Endocrine disease
Cardiovascular disease
Endocrine disease
Dermatological disease
Immune disorder
Cancer
Andrology
Dermatological
Andrology disease
Gynecology
Hematologicalanddisease
obstetrics
Immune disorder
Male genital system disease
Male tumor
Urinary tract disease
Renal disease
Genetic disorder
Gastrointestinal disease
Genetic disorder
Neurological disease
Osteoarthritis
Dermatological disease
Metabolic disorder
Cardiovascular disease
Ocular disease disease
Cardiovascular
Metabolic disorder
Cardiovascular disease
Dermatological disease
Genitourinary disease
Infectious
Genetic disease
disorder
Chromosome
Hematologicalaberration
disease
Renal disease
Gastrointestinal disease
Genetic disorderdisease
Cardiovascular
Degeneration
Cardiovascular disease
Genitourinary disease
Endocrine disease
Genetic disorder
Gynecology and obstetrics
Hematological
Psychiatric disease
disorder
Respiratory disease
Cardiovascular disease
Prostate tumor disease
Hematological
Neoplasm
Dermatological disease
Bullous skin disease
Neoplasm
Cancer
Endocrine disease
Genetic disorder
Infectious disease
Neoplasm
Cardiovascular disease
Genetic disorder
Cardiovascular disease
Dermatological
Immune disorderdisease
Infectious disease
Breast tumor
Metastatic gastrointestinal
Gastrointestinal disease cancer
Non alcoholic fatty liver disease
Cardiovascular disease
Endocrine disease
Diabetes mellitus
Insulin dependent
Gynecology diabetes
and obstetrics
Musculoskeletaldisease
Dermatological disease
Immune disorder
Surgical procedure
Shock
Andrology
Endocrine disease
Hematological disease
Immune disorder
Xerostomia
Alzheimers disease
Cardiovascular disease
Dermatological disease
Neurological disease
Psychiatric
Neoplasm disorder
Skin allergy disease
Neurological

Endocrine disease
Gastrointestinal disease
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Gastrointestinal disease
Cardiovascular disease
Endocrine
Andrology disease
Cardiovascular disease
Neurological disease
Psychiatric disorder
Endocrine disease
Neurological
Ocular diseasedisease
Dermatological disease
Gastrointestinal disease
Cardiovascular disease
Degeneration
Respiratory disease
Inflammatory
Cancer bowel disease
Neurological disease
Diabetes
Idiopathicmellitus
pulmonary fibrosis
Liver fibrosis
Dermatological disease
Endocrine disease
Growth disorder
Gynecology
Gynecology andand obstetrics
obstetrics
Infectious disease
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Dermatological
Viral infection disease
Hot flashes
Hormone
Metabolicdeficiency
disorder
Ovary tumor
Pancreas tumor
Immune disorder
Inflammatory disease
Cardiovascular disease
Immune disorder
Immune disorder
Inflammatory disease
Breast tumor
Endometriosis
Cardiovascular disease
Genetic disorderdisease
Cardiovascular
Metabolic disorder
Hypertension
Lung transplant rejection
Cardiovascular disease
Gastrointestinal disease
Myeloproliferative disorder
Myeloproliferative disorder
Mouth disease
Musculoskeletaldisease
Cardiovascular disease
Endocrine disease
Dermatological disease
Immune disorder
Endocrine disease
Gastrointestinal disease
Dermatological disease
Genitourinary
Degeneration disease
Genetic disorderdisease
Dermatological
Inflammatory disease
Genetic disorder
Neoplasm
Genetic disorder
Metabolic disorder
Genetic disorder
Metabolic disorder
Bladder pain
Bladder pain
Endocrine disease
Musculoskeletal disease
Dermatological disease
Endocrine solid
Advanced disease
tumor
Breast tumor disease
Cardiovascular
Endocrine disease
Cardiovascular disease
Degeneration
Cardiovascular disease
Genetic disorder disease
Musculoskeletal
Neurological disease
Systemic lupus erythematosus
Advanced solid tumor
Cardiovascular disease
Degeneration
Fanconi anemia
Congestive cardiomyopathy
Dermatological disease
Endocrine disease
Cardiovascular disease
Endocrine disease
Neoplasm
Cancer
Endocrine disease
Gastrointestinal
Ocular disease disease
Conjunctiva disease
Gastrointestinal disease
Musculoskeletal disease
Fibrosis
Cancer
Cardiovascular disease
Genetic disorder
B-cell lymphoma
Genetic disorder
Neurological
Dermatologicaldisease
disease
Gastrointestinal disease
Dermatological disease
Gastrointestinal disease
Infectious disease
Respiratory syncytial virus infection
Ocular disease
Endocrine disease
Neurological
Cardiovasculardisease
disease
Endocrine disease
Infectious disease
Inflammatory disease
Cardiovascular disease
Hematological disease
Infectious disease
Cancer
Endocrine disease
Aging
Gastrointestinal disease
Genitourinary
Ocular diseasedisease
Myopia
Toxicity and intoxication
Gastrointestinal disease
Hematological
Cardiovascular disease
disease
Neoplasm
Immune disorder
Cancer
Genitourinary disease
Infectious
Advanced disease
solid tumor
Cardiovascular disease
Infectious disease
Infectious disease
Central nervous system disease
Infectious disease
Immunization
Hematological disease
Neoplasm
Immune disorder
Inflammatory disease
Neoplasm
Neurological
Infectious disease
disease
Immunization
Neurological disease
Unidentified indication
Huntingtons chorea
Blood clotting factor
Cardiovascular deficiency
disease
Endocrine disease
Gynecology and obstetrics
Hematological
Dermatologicaldisease
disease
Endocrine disease
Infectious disease
Neoplasm
Dermatological disease
Neoplasm
Gastrointestinal disease
Neoplasm
Cancer
Genetic disorder
Hematological
Andrology disease
Cardiovascular disease
Hematological disease
Neoplasm
Cancer
Inflammatory disease
Metabolic disorder
Genetic disorder
Inflammatory
Genetic disorder disease
Hematological
Dermatologicaldisease
disease
Allergy
Ocular disease
Corneal
Neoplasm disease
Heart disease
Osteopetrosis
Renal disease disease
Dermatological
Neurological disease
Neoplasm
Genitourinary
Bleeding tract tumor
Wound healing disease
Cardiovascular
Genetic disorderdisease
Gastrointestinal
Immune disorder
Inflammatory disease
Neurological disease
Gynecology and obstetrics
Infertility
Dermatological disease
Endocrine
Cancer disease
Solid tumor
Cancer
Solid tumordisease
Endocrine
Genetic
Infectiousdisorder
disease
Psychiatric disorder
Autism
Gastrointestinal disease
Infectious disease
Neoplasm
Inflammatory disease
Renal
Immune disease
disorder
Neurological
Endocrine disease
disease
Genetic disorder
Respiratory disease
Infectious disease
Cardiovascular disease
Infectious disease
Inflammatory disease
Cardiovascular disease
Dermatological
HIV infection disease
Cardiovascular disease
Dermatological disease
Cardiovascular disease
Diabetes mellitus
Metabolic disorder
Musculoskeletal disease
Gastrointestinal disease
Neurological disease
Respiratory disease
Infection
Cancer by organism type
Solid tumor disease
Neurological
Psychiatric disorder
Endocrine disease
Genetic disorder
Inflammatory disease
Atopic dermatitis
Inflammatory disease
Atopic dermatitis
Neoplasm
Cancer
Dermatological disease
Gynecology
Cardiovascularanddisease
obstetrics
Endocrine
Inflammatorydisease
disease
Metabolicdisorder
Immune disorder
Infectious disease
Neurological disease
Respiratory disease
Endocrine disease
Gastrointestinal disease
Hematological disease
Immune disorder
Cardiovascular disease
Endocrine disease
Gastrointestinal disease
Gynecology
Autoimmuneand obstetrics
disease
Solid tumor
 Secondary therapeutic area(s) Number of employees Founded Ownership

1,000 to 10,000 1993 Public

1,000 to 10,000 1993 Public
Cardiovascular disease 200 to 1,000 2016 Public
Metabolic disorder
Gynecology and obstetrics More than 10,000 1888 Public
Hematological disease More than 10,000 2013 Public
Dermatitis 200 to 1,000 2012 Public
Genetic disorder 200 to 1,000 2019 Private
200 to 1,000 1993 Public
More than 10,000 2005 Private
1,000 to 10,000 1966 Private
1,000 to 10,000 1966 Private
1,000 to 10,000 1836 Private
200 to 1,000 2008 Public
200 to 1,000 1984 Public
200 to 1,000 Private
Autoimmune disease 200 to 1,000 1994 Public
200 to 1,000 2009 Public
200 to 1,000 2016 Private
Cardiovascular disease 200 to 1,000 1953 Private
Fatigue 200 to 1,000 2007 Public
200 to 1,000 1997
Genetic disorder 1,000 to 10,000 1992 Public
Immune disorder 1,000 to 10,000 1948 Private
Neurological disease 200 to 1,000 1963 Private
Psychiatric disorder 1,000 to 10,000 1987 Public
200 to 1,000 2017 Private
200 to 1,000 2009 Private
1,000 to 10,000 1943 Public
Cardiovascular disease 1,000 to 10,000 2002 Public
Metabolic disorder 1,000 to 10,000 1966 Public
Neoplasm 200 to 1,000 2012 Private
Cardiovascular disease 1,000 to 10,000 1967 Public
Infectious disease More than 10,000 1980 Public
More than 10,000 1980 Public
More than 10,000 1980 Public
200 to 1,000 2002 Public
1,000 to 10,000 2002 Public
200 to 1,000 2017 Public
200 to 1,000 1996 Private
Necrosis 200 to 1,000 2009 Public
Autoimmune disease
Cardiovascular disease 1,000 to 10,000 2002 Public
Degeneration 1,000 to 10,000 1974 Private
1,000 to 10,000 1974 Private
Genitourinary disease 1,000 to 10,000 1969 Private
Immune disorder 200 to 1,000 2007 Public
1,000 to 10,000 2008 Public
1,000 to 10,000 2008 Private
200 to 1,000 1998 Private
1,000 to 10,000 2003 Private
200 to 1,000 2009 Public
Stomach tumor 200 to 1,000 2013 Public
Lung tumor
Andrology 200 to 1,000 2010 Public
Infectious disease 200 to 1,000 1920 Public
More than 10,000 1998 Public
Immune disorder 200 to 1,000 2012 Public
Infectious
Psoriasis disease 200 to 1,000 2002 Private
Endocrine disease 200 to 1,000 2004 Private
Inflammatory disease
Immune disorder 200 to 1,000 2014 Public
Autoimmune disease More than 10,000 Public
Gastrointestinal tumor 200 to 1,000 2011 Private
200 to 1,000 2019 Private
200 to 1,000 2000 Public
1,000 to 10,000 Public
More than 10,000 1863 Public
Immune disorder 1,000 to 10,000 2011 Public
200 to 1,000 2014 Public
Male contraception 1,000 to 10,000 1885 Private
Male genital system disease More than 10,000 Public
1,000 to 10,000 2003 Public
200 to 1,000 1924 Private
Hematological disease 200 to 1,000 2009 Public
Infectious disease
Cardiovascular disease 1,000 to 10,000 1953 Private
Dermatological disease 1,000 to 10,000 2009 Public
200 to 1,000 2008 Private
200 to 1,000 1996 Private
1,000 to 10,000 1978 Public
Gastrointestinal disease 1,000 to 10,000 1997 Private
Genitourinary
Gastrointestinaldisease
disease 1,000 to 10,000 1997 Private
Genitourinary disease 1,000 to 10,000 1997 Public
1,000 to 10,000 2008 Public
1,000 to 10,000 1934 Private
Dermatological disease 1,000 to 10,000 2019 Private
Immune disorder
Inflammatory disease 200 to 1,000 2003 Public
200 to 1,000 2018 Private
Dermatological disease 200 to 1,000 1984 Private
Endocrine disease 1,000 to 10,000 1987 Private
200 to 1,000 Public
200 to 1,000 2011 Public
Cardiovascular disease 200 to 1,000 2016 Private
Immune disorder
Metastatic pancreas cancer 200 to 1,000 2005 Private
Metastatic
Mitral valvebreast cancer
disease 1,000 to 10,000 1885 Private
Diabetes mellitus More than 10,000 1885 Private
Cardiovascular disease 200 to 1,000 1991 Private
Endocrine disease 1,000 to 10,000 1957 Public
200 to 1,000 2001 Public
200 to 1,000 2001 Public
More than 10,000 1858 Public
More than 10,000 1993 Private
200 to 1,000 1960 Public
200 to 1,000 2012 Private
200 to 1,000 Public
1,000 to 10,000 2009 Public
1,000 to 10,000 1941 Private
200 to 1,000 2014 Public
200 to 1,000 2012 Public
200 to 1,000 1999 Public
Cardiovascular disease 1,000 to 10,000 2002 Private
Hypertrophic cardiomyopathy
Atopic dermatitis 200 to 1,000 2002 Public
Pulmonary fibrosis
Cardiovascular disease 200 to 1,000 1979 Private
Degeneration 1,000 to 10,000 1999 Private
1,000 to 10,000 2002 Public
200 to 1,000 2005 Private
More than 10,000 1969 Public
1,000 to 10,000 1935 Private
1,000 to 10,000 2001 Public
Immune disorder 1,000 to 10,000 1941 Public
Inflammatory disease 1,000 to 10,000 1925 Public
More than 10,000 1935 Public
200 to 1,000 2018
1,000 to 10,000 2010 Private
Psychiatric disorder 200 to 1,000 2001 Public
Male genital system disease 200 to 1,000 2002 Public
200 to 1,000 2010 Public
200 to 1,000 2003 Public
200 to 1,000 Private
200 to 1,000 Public
1,000 to 10,000 1972 Private
Inflammatory disease More than 10,000 1916 Public
Myocarditis More than 10,000 1938 Public
200 to 1,000 2016 Public
Prostate tumor 200 to 1,000 1921 Private
Skin cancer 1,000 to 10,000 2000 Public
1,000 to 10,000 2020 Public
Neuromuscular disease 200 to 1,000 1997 Public
1,000 to 10,000 1958
1,000 to 10,000 1945 Public
Carcinoma More than 10,000 2005 Public
Non-epithelial tumor
Infectious disease 200 to 1,000 1979 Private
Advanced solid tumor 200 to 1,000 Public
Neurological disease 200 to 1,000 2015 Public
200 to 1,000 1992 Private
More than 10,000 1870 Public
1,000 to 10,000 1958 Public
Cardiovascular disease More than 10,000 1865 Public
Dermatological disease 200 to 1,000 Private
1,000 to 10,000 1932 Public
Endocrine disease 200 to 1,000 1897 Public
Fatigue 200 to 1,000 1905 Private
200 to 1,000 1960 Private
Gastrointestinal disease 200 to 1,000 2016 Private
Endocrine disease 1,000 to 10,000 2001 Private
Gastrointestinal disease 200 to 1,000 2013 Public
Dermatological disease 1,000 to 10,000 1913 Private
Gynecology and obstetrics 1,000 to 10,000 1941 Public
200 to 1,000 2017 Private
More than 10,000 1876 Public
More than 10,000
1,000 to 10,000 1998 Public
1,000 to 10,000 1964 Private
200 to 1,000 2010 Private
200 to 1,000 1981 Private
200 to 1,000 2008 Public
1,000 to 10,000 1929 Private
200 to 1,000 2010 Public
1,000 to 10,000 1995 Public
200 to 1,000 2017 Private
200 to 1,000 2002 Public
200 to 1,000 2019 Private
1,000 to 10,000 2002 Private
200 to 1,000 2012 Public
1,000 to 10,000 2007
Dermatological disease 1,000 to 10,000 1933 Public
Respiratory disease 1,000 to 10,000 1959 Private
Endocrine disease 1,000 to 10,000 1965 Private
200 to 1,000 1993 Public
200 to 1,000 2000 Private
200 to 1,000 2017 Private
More than 10,000 1994 Public
 More than 10,000 1994 Public
Dermatological disease 200 to 1,000 2000 Public
Immune disorder 1,000 to 10,000 1964 Public
More than 10,000 2006 Public
1,000 to 10,000 1937 Private
1,000 to 10,000 1953 Private
1,000 to 10,000 1940 Private
Insomnia 200 to 1,000 1997 Other
Obesity
Prostate tumor 1,000 to 10,000 1999 Public
Gastrointestinal tumor 1,000 to 10,000 1998 Public
Infectious disease 1,000 to 10,000 1967 Public
Neoplasm 200 to 1,000 2011 Public
More than 10,000 1901 Public
More than 10,000 1896 Private
Cancer 200 to 1,000 2018 Private
Dermatological disease 1,000 to 10,000 1997 Public
Gastrointestinal disease
Inflammatory disease 1,000 to 10,000 1999 Public
Hematological
Endocrine neoplasm
disease 200 to 1,000 2019 Private
Diabetes mellitus 1,000 to 10,000 2002 Public
1,000 to 10,000 2002
More than 10,000 1987 Public
More than 10,000 1977 Public
200 to 1,000 1994 Private
Immune disorder 200 to 1,000 2015 Public
Infectious disease 1,000 to 10,000 1946 Private
More than 10,000 1715 Public
Inflammatory disease 200 to 1,000 2018 Private
200 to 1,000 2008 Public
Chronic obstructive pulmonary disease 200 to 1,000 Public
Lung failure 1,000 to 10,000 1915 Public
200 to 1,000 Private
Diabetic eye disease 1,000 to 10,000 2000 Public
Chronic obstructive airway disease 1,000 to 10,000 2000 Public
200 to 1,000 1973 Public
Endocrine disease 200 to 1,000 1954 Public
Immune disorder
Endocrine disease More than 10,000 1995 Public
Genetic disorder
Endocrine disease 200 to 1,000 2016 Public
Immune disorder 200 to 1,000 1976 Private
Immune disorder 1,000 to 10,000 2010 Public
1,000 to 10,000 1978 Public
1,000 to 10,000 1944 Public
Degeneration 1,000 to 10,000 1984 Private
Genitourinary disease 200 to 1,000 1998 Public
1,000 to 10,000 1993 Public
Inflammatory disease 1,000 to 10,000 2000 Public
Autoimmune disease
 1,000 to 10,000 2001 Public
1,000 to 10,000 2001 Public
Endocrine disease 200 to 1,000 1965 Public
Hypercholesterolemia
Immune disorder 200 to 1,000 2017 Private
Autoimmune
Autoimmune disease
disease 200 to 1,000 2019 Private
200 to 1,000 2010 Public
Degeneration 1,000 to 10,000 1941 Public
Ocular disease 200 to 1,000 2000 Public
200 to 1,000 2008 Public
1,000 to 10,000 1991 Public
1,000 to 10,000 2015 Public
Autoimmune disease 1,000 to 10,000 2011 Public
Solid tumordisease
Infectious 200 to 1,000 2000 Public
Viral infectionbowel disease
Inflammatory 200 to 1,000 2014 Private
Renal
Geneticdisease
disorder 1,000 to 10,000 1988 Public
Hematological disease 200 to 1,000 Private
More than 10,000 Private
Hematological disease 200 to 1,000 2014 Public
Inflammatory disease
Neurological disease 200 to 1,000 2002 Public
1,000 to 10,000 1929 Public
Interstitial cystitis 200 to 1,000 1998 Public
1,000 to 10,000 1938 Private
200 to 1,000 1988 Private
1,000 to 10,000 2012 Private
1,000 to 10,000 2003 Public
200 to 1,000 1975 Public
1,000 to 10,000 1959 Public
Cancer 1,000 to 10,000 1975 Public
Dermatological disease More than 10,000 1970 Public
Genitourinary disease More than 10,000 Public
1,000 to 10,000 1985 Public
200 to 1,000 Private
1,000 to 10,000 1967 Public
Gastrointestinal disease 1,000 to 10,000 1945 Public
Gynecology and obstetrics 1,000 to 10,000 1948 Public
200 to 1,000 1990 Public
200 to 1,000 2008 Public
200 to 1,000 2011 Private
Cardiovascular disease More than 10,000 1996 Public
Degeneration 200 to 1,000 2016 Public
Dermatological disease 200 to 1,000 2009 Public
Gastrointestinal disease 1,000 to 10,000 1946 Public
Gynecology and obstetrics 1,000 to 10,000 2018 Private
200 to 1,000 2014 Public
Skin cancer 200 to 1,000 2000 Public
Melanoma
 200 to 1,000 1958 Private
Gastrointestinal disease 1,000 to 10,000 1894 Private
Infectious disease
Gastrointestinal disease 200 to 1,000 1969 Private
Psychiatric disorder 1,000 to 10,000 1963 Public
1,000 to 10,000 1923 Public
200 to 1,000 1955 Private
1,000 to 10,000 1949 Public
Vasculitis 1,000 to 10,000 1934 Private
Duchenne dystrophy
Ustilaginomycete infection 200 to 1,000 2002 Private
1,000 to 10,000 1946 Public
1,000 to 10,000 1938 Private
More than 10,000 1945 Private
Cardiovascular disease 1,000 to 10,000 1938 Private
Gastrointestinal disease 1,000 to 10,000 1943 Private
Prostate tumor 200 to 1,000 1956 Public
Breast tumor 1,000 to 10,000 2014 Public
Inflammatory disease 1,000 to 10,000 1908 Private
200 to 1,000 2018 Public
Cardiovascular disease More than 10,000 1947 Public
Musculoskeletal disease 200 to 1,000 2000 Private
Genetic disorder 200 to 1,000 2009 Private
Immune disorder 1,000 to 10,000 1928 Private
More than 10,000 1968 Public
Hematological disease 1,000 to 10,000 2017 Public
Inflammatory disease 200 to 1,000 Public
200 to 1,000 2016 Public
Dermatological disease More than 10,000 1995 Private
Genitourinary disease 200 to 1,000 2000 Public
200 to 1,000 1961 Private
1,000 to 10,000 1915 Private
200 to 1,000 1888 Private
Dermatological disease 200 to 1,000 1989 Private
Gastrointestinal disease 1,000 to 10,000 1916 Public
200 to 1,000 2015 Public
More than 10,000 1886 Private
More than 10,000 1891 Public
1,000 to 10,000 Public
200 to 1,000 1908 Private
200 to 1,000 2018 Public
200 to 1,000 2018 Public
Dermatological disease 1,000 to 10,000 2007 Public
Infectious disease
Dermatological disease 1,000 to 10,000 1913 Public
Genetic disorder 200 to 1,000 1941 Private
200 to 1,000 2011 Private
1,000 to 10,000 Private
Genetic disorder 200 to 1,000 1992 Public
Growth disorder 200 to 1,000 2016 Private
200 to 1,000 2008 Private
Genetic disorder 1,000 to 10,000 Other
Gynecology and obstetrics
Hyperuricemia 200 to 1,000 1950 Public
Gout
Male tumor 1,000 to 10,000 1916 Public
Metastasis 1,000 to 10,000 1887 Public
1,000 to 10,000 1918 Public
200 to 1,000 2003 Private
More than 10,000 1925 Public
200 to 1,000 1995 Private
200 to 1,000 2021 Private
More than 10,000 1996 Public
More than 10,000 1996 Public
Vaccination 1,000 to 10,000 1987 Public
1,000 to 10,000 1987 Private
Cardiovascular disease More than 10,000 1923 Public
Cardiac hypertrophy 1,000 to 10,000 2000 Public
Cardiovascular disease 200 to 1,000 2012 Other
Metabolic disorder 200 to 1,000 1990 Public
200 to 1,000 1990 Public
200 to 1,000 1937 Private
1,000 to 10,000 Public
1,000 to 10,000 1917 Public
Cardiovascular disease More than 10,000 1964 Public
Gastrointestinal
Metabolic disease
syndrome X 1,000 to 10,000 1921 Public
Hyperlipidemia 200 to 1,000 1906 Private
200 to 1,000 Private
200 to 1,000 2006 Public
200 to 1,000 1965 Private
Liver infection 200 to 1,000 2003 Public
Liver infection 200 to 1,000 2003 Public
200 to 1,000 1986 Public
200 to 1,000 2014 Private
Fatigue 200 to 1,000 1993 Public
Growth disorder 1,000 to 10,000 Private
200 to 1,000 1988 Public
1,000 to 10,000 1961 Private
200 to 1,000 Private
1,000 to 10,000 2013 Private
200 to 1,000 2015 Public
200 to 1,000 1993 Public
Growth disorder 1,000 to 10,000 1998 Public
Musculoskeletal disease 200 to 1,000 1892 Private
Musculoskeletal development disorder 200 to 1,000 2003 Private
Autoimmune disease
 200 to 1,000 1937 Private
200 to 1,000 2010 Private
1,000 to 10,000 1926 Public
200 to 1,000 2013 Public
More than 10,000 1988 Public
200 to 1,000 2008 Public
200 to 1,000 2016 Public
1,000 to 10,000 2008 Public
More than 10,000 2023 Public
200 to 1,000 Private
200 to 1,000 2015 Public
200 to 1,000 2014 Public
200 to 1,000 1967 Private
200 to 1,000 2007 Public
200 to 1,000 1969 Public
Gastrointestinal disease 200 to 1,000 1955 Private
Genitourinary disease 200 to 1,000 1947 Public
Ocular disease 200 to 1,000 1968 Public
Autoimmune disease 200 to 1,000 2012 Private
200 to 1,000 1924 Public
Autoimmune disease 200 to 1,000 2018 Public
Alzheimers disease 200 to 1,000 1995 Public
Myotonic dystrophy
Hematological disease More than 10,000 Public
Neurological disease
Hematological disease More than 10,000 Public
Neurological disease More than 10,000 1994 Public
1,000 to 10,000 1890 Public
Kidney dialysis 200 to 1,000 1953 Private
1,000 to 10,000 Public
Genetic disorder 200 to 1,000 1993 Public
Growth disorder 200 to 1,000 1990 Public
200 to 1,000 1990 Public
1,000 to 10,000 2010 Public
200 to 1,000 2013 Private
1,000 to 10,000 1947 Private
Cardiovascular disease 200 to 1,000 1983 Private
Endocrine disease 200 to 1,000 2012 Public
More than 10,000 1954 Private
Dermatological disease 200 to 1,000 2013 Private
Inflammatory
Cardiovasculardisease
disease More than 10,000 1999 Private
Pain
Immune disorder 200 to 1,000 2013 Private
Osteoporosis 200 to 1,000 1962 Public
Osteoarthritis
Respiratory disease 1,000 to 10,000 1878 Public
Atrophy
Infectious disease 200 to 1,000 2011 Private
Respiratory disease More than 10,000 2000 Public
Dermatological disease 200 to 1,000 2001 Public
Neurological disease
Stomach function disorder 200 to 1,000 1993 Public
Gastric motility disorder 1,000 to 10,000 2018 Public
1,000 to 10,000 1969 Public
200 to 1,000 2015 Private
200 to 1,000 2013 Other
1,000 to 10,000 1946 Private
Gastrointestinal disease 200 to 1,000 2002 Private
Inflammatory disease More than 10,000 1895 Private
1,000 to 10,000 Private
Degeneration 1,000 to 10,000 2005 Public
Genetic disorder More than 10,000 1983 Public
Dermatological disease 200 to 1,000 1993 Private
Endocrine disease 200 to 1,000 2003 Public
1,000 to 10,000 2001 Public
1,000 to 10,000 1994 Private
200 to 1,000 2002 Other
Dermatological disease 1,000 to 10,000 1963 Other
Genitourinary
Dermatologicaldisease
disease 1,000 to 10,000 1912 Private
More than 10,000 1781 Public
Cardiovascular disease 1,000 to 10,000 1922 Private
Endocrine disease
Ocular disease 200 to 1,000 1950 Public
Dermatological disease 200 to 1,000 2017 Public
Infectious disease
Immune disorder More than 10,000 1994 Public
Neurological disease 1,000 to 10,000 2002 Public
200 to 1,000 1848 Private
200 to 1,000 2015 Public
Cardiovascular disease 200 to 1,000 2010 Private
Inflammatory disease 200 to 1,000 2018 Private
1,000 to 10,000 1947 Private
More than 10,000 1901 Public
200 to 1,000 1954 Private
200 to 1,000 Private
More than 10,000 1926 Public
Immune disorder 200 to 1,000 2012 Public
Ocular disease 200 to 1,000 2012 Public
Immune disorder 200 to 1,000 2016 Private
Growth disorder 200 to 1,000 2000 Private
Neurological disease 1,000 to 10,000 1893 Public
Hematological disease 200 to 1,000 1960 Public
Dementia 1,000 to 10,000 Public
Osteoporosis 1,000 to 10,000 1928 Public
Endocrine disease 200 to 1,000 2010 Public
Genetic disorderdisease
Cardiovascular 200 to 1,000 1996 Public
Vaccination 200 to 1,000 2013 Public
200 to 1,000 2018 Public
Urinary tract disease 1,000 to 10,000 1933 Other
Urogenital tract infection More than 10,000 Public
200 to 1,000 2009 Public
Degeneration 1,000 to 10,000 1968 Private
Metabolic disorder
Cardiovascular disease 200 to 1,000 2009 Private
Metabolic disorder 200 to 1,000 2009 Public
Gastrointestinal disease 200 to 1,000 1978 Public
Immune disorder
Cardiovascular disease 200 to 1,000 1960 Private
200 to 1,000 1997 Public
200 to 1,000 1996 Public
200 to 1,000 2005 Public
200 to 1,000 2015 Private
200 to 1,000 2015 Private
200 to 1,000 2012 Private
Cardiovascular disease 1,000 to 10,000 2003 Public
Degeneration 200 to 1,000 1981 Private
1,000 to 10,000 1926 Public
1,000 to 10,000 2013 Public
Gynecology and obstetrics 1,000 to 10,000 1906 Private
Infectious disease
Immune disorder 200 to 1,000 1998 Public
Inflammatory
Dermatologicaldisease
disease 200 to 1,000 2009 Public
1,000 to 10,000 1488 Private
1,000 to 10,000 1955 Public
Inflammatory disease 200 to 1,000 2003 Public
 Licensing objectives Company objectives

Seeking in-licensing opportunities 3SBio seeks to partner with international companies of all
Seeking
Seeking out-licensing opportunities
in-licensing opportunities sizes,
3SBiofrom seeksearly stage discovery
to partner platformscompanies
with international to multinationals
of all
Seeking seeking to leverage 3SBio's strong commercial, R&D and
Seeking out-licensing
out-licensing opportunities
opportunities sizes, from early stage discovery platforms to multinationals
manufacturing
seeking to leverageplatform in China.
3SBio's strong commercial, R&D and
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities NO MEETING REQUEST FROM CROS, CMOS, OR
manufacturing platform in China.
OTHER
We welcome SERVICE PROVIDERS
the opportunity PLEASE.
to meet with potential partners
to get to know you and for you
Partnership opportunities with Pharma,to get toBiotech
know AbbVie.
and VCOur
team is ready
Out-licensing to share our
opportunities capabilities and discuss innovative
Seeking out-licensing opportunities Leading the development of mRNA and its delivery
new partnership opportunities that align with our
Seeking
Seeking investment
in-licensing opportunities technologies,
We Delivering
are not currently transformative
considering mRNAtomedicines
opportunities
Seeking in-licensing opportunities commercialize Nuplazid in geographies outside the US so
please refrain from sending invitations to discuss. Our focus
Seeking out-licensing opportunities
at BIO is on in-licensing, acquisitions, and co-development /
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities In-licensing of late-stage innovative assets, including NCEs
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities and value-added products, for Brazil and LatAm.

Expansion of the Enzyme Portfolio in the Biocatalyst

Seeking in-licensing opportunities segment

Seeking in-licensing opportunities Agios seeks to in-license programs for rare diseases to
complement
Finding new our portfolio.
partners to develop algorithms for clinical trials
Seeking in-licensing opportunities and underdiagnosed diseases (NASH,
Seeking opportunities to in-license PAH, ATTR,
innovative IPF,for
products
AFib, Alzheimer's,
Korean market. Stroke, etc)
Seeking in-licensing opportunities
Seeking out-licensing opportunities
Seeking in-licensing opportunities
Seeking in-licensing opportunities To build the pipeline in our key therapeutic areas,
Seeking in-licensing opportunities Gastrointestinal
At BIO, Tiefenbacher Pharmaceuticals is looking for:
Seeking in-licensing opportunities
Seeking in-licensing opportunities Affordable treatment based on cellular therapy, tumor
Seeking
Seeking investment
in-licensing opportunities immunology and gene
Acquire marketed therapy
products or in-license late stage assets
Seeking in-licensing opportunities principally
Almirall in Parkinson's,
External InnovationSchizophrenia,
& Licensing Depression,
team is actively
Anxiety,collaborations
seeking Addiction Medicines/Therapy
and breakthroughand Non-opioid Pain
in-licensing
Management.
opportunities in Medical dermatology at any stage of
Seeking in-licensing opportunities Seeking in-licensing opportunities for the late stage products
development, including:
Seeking in-licensing opportunities in especially
Better access,Oncology,
better life CNS, Nephrology, Orphan/Rare
Seeking diseases, Anti-obesity & Women's Healthcare,
Seeking out-licensing opportunities
in-licensing opportunities
Ophthalmology etc.

The focus at this conference will be to look for in licensing

Seeking out-licensing opportunities opportunities. Key
Opportunities for focus areas
platform are CNSdeals
and product (mainly in thethe
including area
Seeking of Parkinson's disease, migraine, and movement disorders)
Seeking investment
in-licensing opportunities following:
Our partnering activities are focused on:
endocrinology, oncology, and women's health indications.
Seeking
Seeking out-licensing opportunities
in-licensing opportunities
Seeking in-licensing opportunities We are interested in licensing-in First-in-class and Best-in-
Seeking in-licensing opportunities class small moleculeofinnovative
Commercialization biosimilarsassets described assmall
& differentiated follows:
Seeking in-licensing opportunities molecules delivering
In-Licensing, quality and
collaborations, value for and
partnerships, patients and
acquisitions
healthcare systems.
of late stage, submission ready, or marketed products across
our core TAs including Oncology, Ophthalmology, Specialty
CNS, and Women's Health in Canada, the US, and LATAM.
Seeking in-licensing opportunities In - Licensing innovative products for Brazilian market
Seeking in-licensing opportunities
Seeking
Seeking out-licensing opportunities
in-licensing opportunities To identify new antibody collaboration opportunities under
Seeking in-licensing opportunities our Immunology
Aristo Innovation
is seeking small Program,
molecule Valueenabling us to develop
Added Medicines
pipeline
(hybrids, assets in
505(b)2) our areas of
for potential therapeutic focus.
in-licensing
To meet with biotechnology industry experts.to strengthen its
portfolio in Gynecology, Heavy Pain , Urology, Dermatology
Seeking in-licensing opportunities
and Psychiatry.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities To seek global or regional partners for
Seeking in-licensing opportunities
Seeking out-licensing opportunities co-development/commercialization
Seeking innovative products for further and/or licensing. and
development
Seeking out-licensing opportunities marketing
1.Partnershipcollaboration
on APL-2302, in infectious
a potentialdisease
best inand oncology
class USP1
Seeking in-licensing
investment opportunities field
inhibitor preparing for IND Submission
Seeking 1. Seeking in-licensing opportunities forin
theQ4 2024 market
Japanese
Seeking
Seeking out-licensing opportunities
in-licensing opportunities in
Ourthree key areas
Company: Weasarefollows:
a global, science-led, patient-focused
Seeking out-licensing opportunities pharmaceutical company. We are tireless in seeking to
realize the potential of what science can do.
Seeking out-licensing opportunities Seeking licensing and collaboration partners for our pipeline
Seeking out-licensing opportunities programs
To identifyincommercial
oncology and inflammation
partners for out-licensing or co-
Seeking
Seeking investment
in-licensing opportunities developing the Company’s product pipelines:
Seeking out-licensing opportunities
Seeking out-licensing opportunities
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities Azurity Objectives for BIO
Seeking in-licensing opportunities •Seeking
Partnerships with companies
anti-infective in-licensing(bothand Ex-US and US) who
out-licensing
Seeking have 505(b)(2) products in development with no commercial
Seeking out-licensing opportunities
in-licensing opportunities opportunities
We are primarily interested in in-licensing opportunities for
presence in the U.S.
Seeking
Seeking out-licensing opportunities
in-licensing opportunities the US, Canada, and LATAM in Gastroenterology, CNS,
Seeking Dermatology, and rare diseases.
Seeking out-licensing opportunities
in-licensing opportunities Discover the next generation of cancer treatments
Seeking out-licensing opportunities We are building our drug development portfolio through a
Seeking in-licensing opportunities dual approach of collaborations and licensing. BenevolentAI
has many successful ongoing collaborations and we are
Showcase how Best Buy Health’s digital health platform and
actively looking to engage in further strategic partnerships.
Seeking in-licensing opportunities -comprehensive
Out-license theservices
ex-China to support
rights ofthe safe and effective
in-house
Seeking delivery of care at home for clinical trial participants.
Seeking out-licensing opportunities
in-licensing opportunities oncology/ophthalmology
BIAL’s objectives for BIO are: programs.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities Advance oncology pipeline and partner assets at optimal
Seeking in-licensing opportunities time, build to requests
We welcome fully integrated biopharma.
for meetings to discuss in-licensing,
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities acquisition,
Seeking co-development,
for out-licensing co-promotion
of clinical and distribution
stage assets, clinical and
opportunities
strategic earlyinstage
the rare diseases area.
collaboration
Seeking partners wanting to benefit from BIOFABRI Biotech
Seeking in-licensing opportunities expertise
BIOGARAN in the
is development
looking for new andin-licensing
manufacturing vaccines and
opportunities
other biotech products.
for biosimilar products, vaccines or complex generic
products.
Seeking in-licensing opportunities Biolab is committed to seeking out and investing in cutting-
Seeking in-licensing opportunities edge
Biolabpatented drugs and
is committed technologies
to seeking out andthat can improve
investing the
in cutting-
quality
edge of life for
patented patients. We believethat partnering with
In-license drugdrugs and technologies
candidates for treatment ofcan rareimprove
diseasesthe
innovative
quality companies
of life like We
for patients. yours is keypartnering
believe to achieving this goal.
with
Seeking in-licensing opportunities Identify clinical assets and technologies for in-licensing that
innovative companies like yours is key to achieving this goal.
Seeking in-licensing opportunities support BioNTech's
Seeking In-licencingvision
Phase (mRNA, cell and
3, registered and gene,
marketed
antibodies, small molecules)
products
Seeking in-licensing opportunities At BIO International Convention, we are seeking partnership
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities opportunities in the following
Bio-Thera Solutions is lookingareas:
to out-license / partner our
Seeking out-licensing opportunities biosimilar assets and our innovative
-Improve patient treatment options and therapeutics outside of
develop programs
China. We are flexible
towards commercialization. in deal structure. We would consider
Seeking in-licensing opportunities In-Licensing and distribution of innovative products in the
development, co-development and/or commercial
South and Central
In Licensing American Market
, Co-development and M&A opportunities
Seeking in-licensing opportunities Seeking additional late stage or marketed products in
Seeking
Seeking out-licensing opportunities
in-licensing opportunities hematology or that sell into transplant centers
Seeking out-licensing opportunities BMI seeks business partnerships for licensing Recombinant
Hyaluronidase
We are seekingand Botulinum
small moleculeToxin/Esthetic filler for the
and biotherapeutic
US and EU to
approaches markets.
therapeutic areas of interest including arthritis,
We embrace the power of partnership and diversity of minds
pain,
acrossallergy,
the cardiology,
life-science renal
community failure,
and oncology
have aroundand50% of
Seeking in-licensing opportunities • Seeking in-licensing and acquirement of commercial right
endocrinology.
our pipeline We areinalso
anchored seeking
external to in-licenseand
collaborations, anti-more
Seeking in-licensing opportunities in Out-licensing
1. South Korea BR101801 (r/r PTCL treatment, First in
than 150 active partnerships to advance innovation in:
Seeking out-licensing opportunities Class, ODD,
Innovative oncology)
drugs reach out to global patients
Innovative drugs reach out to global patients
Seeking in-licensing opportunities To discover, develop and deliver innovative medicines that
Seeking in-licensing
Seeking out-licensingopportunities
opportunities helpare
We patients
seeking prevail overtoserious
partners diseases
co-develop/out-license multiple
Seeking
Seeking out-licensing opportunities
out-licensing opportunities phase 3/pre-BLA assets of Efbuepoetin-alfa
NOT SEEKING CRO, CMO, CONSULTANT and any , BC001 andother
Seeking in-licensing opportunities BC002.
type We also would
of SERVICE like to in-license
PROVIDERS during late-stage projects
BIO.
Seeking out-licensing opportunities Byondis is interested in partnering its investigational Ph1
to enrich our portfolio.
candidates
In-licensing: for continued clinical development and
commercialization:
Acquire or in-license commercial stage/late-stage
Seeking out-licensing opportunities
development assets in CNS (addiction) and rare disease
Seeking in-licensing opportunities
(endocrinology, oncology)
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities Licensing, co-development, financing
Seeking out-licensing opportunities Drive the growth of ATMP industry by working with cell and
gene therapy organisations across the world, translating early
stage research into commercially viable and investable
Seeking in-licensing opportunities -**ADC** platforms
therapies.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities -**Licensing BsAb, development,
partneting, bussines TsAb, MsAb** for therapeutic strategic
co-development, areas of
interest
partnership for globalnature
development, out-licensing, R&D
Adopting humanity, and respect as its core values.
collaboration
Centurion Pharmaceuticals will opportunities,
continue to focus on higher
We are looking for in-licensing co-dev
goals in the coming
partnerships years,type
or any other withofthe
dealresponsibility
structure thatofcould
being a
Seeking out-licensing opportunities
flexible, creative, competitive and business-focused
bring a new asset on the animal health market (companion company
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities BAIYU is dedicated to transforming into an international
animals, poultry, ruminant and swine).
Seeking in-licensing opportunities
Seeking out-licensing opportunities enterprise
We seek toand is consistently
out-license our 50+ making significant
preclinical strides,
& clinical with
stage
business
NMEs to thepartners spanning across 16 countries.
Seeking in-licensing opportunities In-license andglobal
acquirepharma and for
therapies biotech
the UScompanies. These
and European
NMEs are in oncology, liver, respiratory and autoimmune
markets.
Seeking out-licensing opportunities
disease areas.
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities We are actively searching for new in-licensing products and
Seeking in-licensing opportunities
Seeking out-licensing opportunities global/regional
[Out-License] opportunities for co-development and co-
Seeking in-licensing opportunities commercialization of ourTechnology:
assets as well.
-- Partnering
Antibody Engineering
with innovators and Specialty companies in the
therapeutic segments of Anti-Infectives/AMR,
Respiratory ,Immunology, Cardiology , Diabetes and
Seeking in-licensing opportunities Explore Partnering opportunities, In-licensing, and
Oncology.
Seeking in-licensing opportunities Unlicensed
Out-Licensing Sales, in addition to supporting the clinical
Seeking supply
- AripiprazolePackaging,
chain. Labelling,bipolar
Storagedisorder)
and Distribution.
Seeking out-licensing
out-licensing opportunities
opportunities OSF (schizophrenia, under
Seeking late-stage
US 505(b)(2) track innovative assets for commercialisation in
Seeking in-licensing opportunities Coherus is focused on developing and commercializing a
Seeking
Seeking out-licensing opportunities
in-licensing opportunities diversified portfolio
Actively seeking USof next-generation
in-licensing immuno-oncology
and co-promotion
therapies
opportunities that leverage our retail andsurvival
that potentially extend patient long-termacross
caretumor
Seeking out-licensing opportunities
types. The
channels. foundation of our immuno-oncology franchise is

Seeking in-licensing opportunities Cristalia is searching for strategic partnerships, focused on

hard-to-make, innovative and differentiated products.
Cristalia is open to evaluate technology transfer, co-
Seeking out-licensing opportunities - Partnering for the global development/commercialization of
development, licensing and other possible types of
Seeking out-licensing opportunities CSPC's innovative
Identify Oncology
potential partners for and CNS assets
out-licensing our pipeline
Seeking in-licensing opportunities assets. Not interested in service providers or general
consulting service.
CureVac strives to create transformative medicines to protect
Seeking in-licensing opportunities and improve
To find people’s for
opportunities lives.
partnership that will help Cytiva
Seeking out-licensing opportunities turn innovative technologies into great products.
Seeking in-licensing opportunities
Seeking out-licensing opportunities OUT-LICENSING OPPORTUNITIES

Seeking in-licensing opportunities

Seeking out-licensing opportunities
Dendreon’ scientific research, CMC and clinical
development expertise provides the infrastructure to translate
early-stage science into promising clinical stage assets. We
Seeking in-licensing opportunities To explore possible business models: In-licensing, Out-
also have a well-established sales infrastructure in the US
Seeking out-licensing opportunities Licensing,
In-licensingCo-Development,
of pharmaceuticalDistributorship
products
Seeking out-licensing opportunities Products and brand acquisitions
Following Oxervate commercial success, Dompé
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities farmaceutici is looking to expand its footprint in the US
Seeking through partnerships for mid/late stage innovative assets in
Seeking out-licensing opportunities
in-licensing opportunities - Partnering for R&D pipeline under development.
the rare disease area.
Seeking out-licensing opportunities -Out-licensing
In-license novel drugs in late-stage
the following for drug products:
assets or marketed
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities -commercialization.
OurAxhidrox®, Glycopyrronium
vision is founded on generatingbromide-containing cream for
and sharing knowledge
Seeking out-licensing opportunities the
that treatment of hyperhidrosis
drives innovation, (P3 finished, European MA
Seeking in-licensing opportunities EA Pharma Co., Ltd. iswith the goal
seeking of improving
for in-licensing patients’
opportunities
granted)
lives through the development of novel therapeutics for
Seeking in-licensing
Seeking out-licensingopportunities
opportunities in Gastrointestinal
Seeking partnering disease, Immune
opportunities for disorder,
marketedand or clinical-
gastrointestinal
inflammatory and hepatic
diseasedevelopment diseases.
areas for Asian market.
Seeking out-licensing opportunities stage novel products globally or locally in
China.
Seeking in-licensing opportunities Biosimilar, peptide, innovative late-stage licence-in primarily
for CEEthe
To find region;
collaboration partners, especially in oncology and
Seeking out-licensing opportunities neurology areas, to find out licensing/alliance partner of our
Seeking own assets, to find investment opportunity in startups
Seeking in-licensing
in-licensing opportunities
opportunities PARTNERING
At Lilly, we take smart risks on bold science to discover
treatments and cures, all for one reason – patients. As a
Emergent’s mission is simple – to protect and enhance life by
community of scientists, we recognize our responsibility as
delivering peace
Introduction of newof mind in aninuncertain
therapies world.
the medicines
Brazilian Emergent is
market
partners to help advance innovative within with
our
a globalorlife
radical sciences company
incremental innovation focused
in on providing
several areas, such as
Introduce the enFuse platform to biotech and pharma
specialty
Oncology,products
CNS, for civilian
CVS, Gastro, and military
Dermato, populations that
Respiratory,
Seeking in-licensing opportunities companies
We are looking developing
to expand large
ourand small molecule
portfolio with newtherapeutics
Men's/Women's
for infusion for Health andranging
Ophtalmo.
partnerships andindications
products to deliveracross chronic andto our
novel treatments
serious diseases.
patients across the region.
Seeking in-licensing opportunities Licensing IN:
Seeking out-licensing opportunities •1)We are interested
Seeking to in-licenseopportunity
for an out-licensing late stage specialty
for our products,
Seeking in-licensing opportunities including CNS,
proprietary Ophtha,
platform Onco andand
technologies other areas of
vaccine interest,
program in the
with emphasis
clincal stage. in fast time to market assets
Seeking out-licensing opportunities Due to limited availability, we will not be able to meet with
Seeking out-licensing opportunities service providers.
Support pharmaceutical organizations with biomarker
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities translation
1. Partner ourandPhase
Clinical
1/2Trials
SMA testing
program forGlobally.
critical biomarkers.
Seeking investment Support
2. primary & secondary endpoints
programand experimental
NOPartner
SERVICE our Phase 1/2 wAMD
PROVIDER REQUESTS Globally.
PLEASE
testing for subsegment analysis.
Looking
We wouldtolike acquire or to
to talk license mid-late
companies stage development
interested in inlicensing /
assets or approved
co-developing products
Seeking out-licensing opportunities We are stronglyBIC or FIC to
dedicated clinical
creatingstage andby
value preclinical
developing
oncology
and and neurology
delivering quality assets. that
products Pleasemakecontact
human uslives
also if you
better,
•Faes is seeking for a) in-licensing opportunities of late-stage
are interested
simpler, in
andpendingthe benefits
more convenient that precison
- through oncology & AI
Seeking in-licensing opportunities (approved,
IN-LICENSING approval
of clinical and
stage Phase the
programs
improvement
III)indeveloped
the therapeutic
of
healthcareand
products andalso
medicine.
OTCs and b) looking to acquire products
Seeking out-licensing opportunities areas:
that are already on the market but no longer of strategic
Seeking out-licensing opportunities
Company creation; Strategic partnerships
Seeking in-licensing opportunities Actively looking for in-licensing opportunities and co-
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities development
searching for projects
regional & global partnership for in-house
Seeking investment innovations
Seeking investment Grow innovation-driven pipelines and drive late-stage asset
Seeking in-licensing
Seeking in-licensing opportunities
opportunities launch seeks commercial partners outside of China for
Frontier
Seeking in-licensing
Seeking out-licensingopportunities
opportunities world’s
Fuji first long-acting
is actively HIV fusion inhibitor
pursuing in-licensing Albuvirtide
and co-development
(ABT).
opportunities across all major areas of women’s health,
Seeking out-licensing opportunities • Seeking out-licensing and investment opportunities forasour
Seeking well as in-licensing opportunities for late-stage and
Seeking investment
in-licensing opportunities clinical stage oncology pipeline
commercial-stage acute medical care products.
Seeking in-licensing opportunities Licensing & Distribution Partnerships; Biosimilars Co-
Seeking in-licensing opportunities Development Partner;
In-licencing Phase Portfolio
2, Phase Expansion;
3, registered andCo-
marketed
Seeking Developments; Product/Portfolio Acquisitions; Out-as well as
Seeking out-licensing
out-licensing opportunities
opportunities products including original and biosimilar products
Our mission is to increase the quality of people’s wellbeing
Licensing
oligonicleotides.
Seeking in-licensing opportunities by helping
Looking forthem
BiC to restore and
licensing maintain their
opportunities mental and
for oncology and
physical
immunology health.
Seeking out-licensing opportunities
Seeking
Seeking investment
out-licensing opportunities
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities
Seeking in-licensing opportunities We are seeking :
- licensing-in and distribution opportunities for Europe,
LatAm , China and Australia with a primary focus to
women’s healthcare making best use of Richter’s market
Seeking out-licensing opportunities Top Player in
knowledge, thetrained
well Pediatric Medicines,
field-force, andWomen's
extensiveHealth,
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities Endocrinology in Greater China/Asian Pacific Area. Top
Seeking out-licensing
out-licensing opportunities
opportunities Specificity Pharm in USA.
Seeking Seeking global or regional partners to develop and
Seeking investment
Seeking in-licensing opportunities commercialize our innovative
Life science technology assets for treating hemophilia,
provider
Seeking growth hormone deficiency, cancer cachexia, and diabetes.
Seeking out-licensing opportunities
in-licensing opportunities Seeking for in-licensing cell and gene therapy research and
Seeking out-licensing opportunities manufacturing tech, gene editing, biologics production tech,
AI in biologics drug discovery or protein based products etc.
Seeking in-licensing opportunities Glenmark is pursuing a partnering strategy for key
Seeking
Seeking out-licensing opportunities
in-licensing opportunities innovative assets to de-risk clinical development through a
shared commitment, shared risk approach.
Seeking in-licensing opportunities
Seeking in-licensing opportunities
To look for license out /co-development opportunities for
Seeking out-licensing opportunities Ray1225, Ray 0221,
- Out-licensing ZSP1601
of Gubra´s and ZSP0678.
existing To look for
pipeline assets
regional license out/ commercial collaborations for ZSP1273,
Seeking investment
ZSP1216.
Seeking
Seeking out-licensing opportunities
in-licensing opportunities
Seeking out-licensing opportunities In and out licensing. Not interested in billable services.
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities Haisco is dedicated to seeking out and acquiring innovative
Seeking out-licensing opportunities external
1. Becomeopportunities to grow
the most trusted our own portfolio.
international We can
pharmaceutical
bring our local
enterprise. expertise to conduct China clinical trial,
regulatory approval, marketing, and sales. Haisco is focusing
Seeking in-licensing opportunities ★★No service providers(CRO, CMO, any consulting
Seeking in-licensing opportunities company) please. ★★
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities
Seeking in-licensing opportunities Main objectives for in-licensing are late development stage
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities (late Phase
1) Seek 3 or in registration)
commercial and commercial
and development opportunities
partners for the
Seeking in-licensing opportunities for our USproducts:
following affiliate and/or WW rights in the following
Seeking in-licensing opportunities We are searching for late-stage in-licensing opportunities and
therapeutic areas:
Seeking in-licensing opportunities acquisition of marketed products
Hisamitsu Pharmaceutical in the
is seeking forfollowing areas:
the in-licensing
Biologics/Biosimilars, Vaccines, Oncology, Respiratory,
opportunities and collaboration on Hisamitsu's products and
Seeking in-licensing opportunities
Anti-infectives,
with Hisamitsu'sCardiovascular
TDDS technology.and Diabetes, CNS,
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Seeking out-licensing and R&D collaboration opportunities
Seeking
Seeking out-licensing opportunities
in-licensing opportunities
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities Co-development or out-license ex-China rights of
Seeking in-licensing opportunities clinical/pre-clinical assets; In-license China rights for
oncology products with near-term launch opportunities.
Seeking in-licensing opportunities Licensing and Acquisition
Seeking in-licensing opportunities Licensing and Acquisition
Seeking in-licensing opportunities License-in, License-out, Co-marketing & co-promotion, Co-
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities development.
1. Seeking CT103A global ex-China out licensing in MM
Seeking investment
Seeking out-licensing opportunities and autoimmune area；
Seeking out-licensing opportunities
Seeking in-licensing opportunities Seeking global partnership
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Immatics seeks to establish strong collaborative partnerships
Seeking
Seeking out-licensing opportunities
in-licensing opportunities to furtherthe
Remain strengthen and expand
world leader our bispecific
in soluble, technologyTCRs
platforms in
for the
Seeking out-licensing opportunities target and TCR identification and characterisation.
treatment of cancer, infectious & inflammatory diseases.
Seeking out-licensing opportunities We are seeking ex-China partnership for all of clinical stage
Seeking in-licensing opportunities programs.
1) On the in-bound side, Innovent is looking to in-license or
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities otherwise
INOVIO isacquire rights
interested in to commercial
speaking or late-stage
with specialty pharma
oncology,
companies immunology, ophthalmology or CVRM assets forin
Seeking out-licensing opportunities Our generalthat have commercial
partnering strategy isexperience
to work hand andinsynergies
hand with
Chinese and
rare diseases,Asian markets
infectious .
diseasesInnovent is also
and respiratory interested
diseases.in
Seeking in-licensing opportunities global
Company pharma andtobiotech
aspires companies
grow through BD to harness
deals the power
and partnering,
Seeking of AI in developing innovative medicines for patients in
Seeking out-licensing opportunities
in-licensing opportunities we
Weare
arehighly acquisitive
interested and looking
in start-ups for either
and companies in-licensing
developing
need.
or Our business
acquiring assets model
that are allows
in us to be late-stage,
early-stage, flexible in or
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities novel biotechnology
Offer our Biosimilar platforms
portfolio and or alternative proteins. In
pipeline, co-development
commercially
addition, we approved
are seeking that could treatforpatients
technologies with rare
development of
agreements.
biofertilizers from ash and forest waste.
Speaking with research-driven R&D companies., i.e., please
no
WeCROs, CMOs,
are looking consultants, service-based companies.
for:
Seeking in-licensing opportunities • New indications for existing products in our portfolio
Seeking
Seeking out-licensing opportunities
in-licensing opportunities - In-licensing late stage assets to market in EU in Women's
Seeking in-licensing opportunities Health, CNS, Dermatology, Cardiovascular, Rare and orphan
deseases, and Primary Care. Also interested in other
Seeking out-licensing opportunities Out-licensing or co-development
therapeutic areas in selected geographies.

Seeking out-licensing opportunities JCR is seeking partnerships to accelerate its portfolio of

blood-brain-barrier permeating enzyme replacement
therapies through clinical development and
Seeking out-licensing opportunities
commercialization.
Seeking out-licensing opportunities Collaborate with partners with complementary capabilities to
Seeking in-licensing opportunities help accelerate our global development strategy
Seeking
Seeking investment
out-licensing opportunities
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities Out-license or partner our small molecule assets in oncology,
Seeking investment
Seeking in-licensing opportunities auto-immune disorders
Seeking the potential licensing opportunity in China
Seeking in-licensing opportunities Seeking business partners and/or investors for the further
Seeking
Seeking out-licensing opportunities
in-licensing opportunities development of lead
scouting potential programs Epaminurad
in/out-licensing partners (gout), JW2286
Seeking out-licensing opportunities (oncology) and JW0061 (hair regeneration).
Seeking in-licensing opportunities
Seeking out-licensing opportunities
Seeking in-licensing
Seeking in-licensing opportunities
opportunities We are seeking strategic partnerships for:
Seeking out-licensing opportunities
Seeking in-licensing opportunities 1Lincense
- Out-licensing of our
In, License Outbiosimilars, 505(b)2 , Complex
Seeking Generics & NCEs
Seeking out-licensing
out-licensing opportunities
opportunities
Seeking out-licensing opportunities Seeking for Global Partners for
Seeking in-licensing opportunities * Proxalutamide for COVID-19 (Phase III completed)
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Our company is actively searching new business
Seeking
Seeking out-licensing opportunities
in-licensing opportunities opportunities
In-licensing orboth in domestic
acquisition and international
of late-stage markets.
or marketed assets
Seeking out-licensing opportunities for Canada and/or Latin America
Seeking partnership for out-licensing, in-licensing,
collaborative research or co-development of drug assets.
Seeking in-licensing opportunities Looking for in-licensing opportunities (OA, Respiratory,
Seeking in-licensing opportunities Dermatology,
Acquire, CNS and
in-license, Pediatrics)
or partner to launch new products in the
Seeking in-licensing opportunities USA and Japan.
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Partnering with corporate and strategic partners
Seeking in-licensing opportunities Kyorin is attending the BIO International partnering
conference with two objectives:
We are seeking for in-licensing and/or collaboration
Seeking in-licensing opportunities opportunities at early stage from discovery to clinical stage
in bone & mineral, intractable hematological
Seeking in-licensing opportunities LATAM Licensing Interests
diseases/hematooncology, and rare diseases.
Seeking in-licensing opportunities Partnering Risperidone ISM®
Seeking out-licensing opportunities We are interested in finding commercial partners that will
Seeking out-licensing opportunities help
We areus agrow
groupourofpipeline. Our
reputable, focus is in morally
trustworthy, innovative RX
minded
products,
businesses as well as
thatofare biosimilars.
committed towith
providing excellent
Seeking in-licensing opportunities We take care people's health, quality, access and
customer service,
efficiency, always. employee welfare, and health promotion.
Seeking in-licensing opportunities In-licensing of late-stage or on-the-market innovative RX
Seeking in-licensing opportunities pharmaceutical products forfor
Identify new opportunities Mexico within
licensing andCNS, Diabetes
acquisition.
Seeking and Respiratory therapy.
Seeking out-licensing opportunities
in-licensing opportunities Collaboration, partnership, in-licensing, out-licensing
Seeking
Seeking out-licensing opportunities
in-licensing opportunities LEO Pharma is looking for new differentiated and protected
Seeking out-licensing opportunities product opportunities in medical dermatology indications
including orphan dermatology indications. LEO is looking
Seeking in-licensing opportunities Seeking investment/in-licensing opportunities for
for both global and territorial opportunities, especially for
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities companies/external
Our objectives at BIO assets
2024inare
areas
to: of oncology, immunology,
Seeking in-licensing opportunities metabolic
-WeSource diseases
partnering (diabetes,/NASH/obesity), pediatric
Seeking in-licensing opportunities actively seekingopportunities alignedfor
product candidates to in-licensing
LifeArc’s to
endocrine,
translationalrare pediatric
challenges disease,
in Motor Women's Health.
Neurone Disease/ALS,
add to the
Merger, company's
acquisition orproduct portfolio.
strategic partnership
Chronic Respiratory Infection, Global Health (with a focus
Seeking in-licensing opportunities on antimicrobial resistance, emerging viral threats and
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities
Seeking in-licensing opportunities
Seeking in-licensing opportunities
Seeking in-licensing opportunities Looking to In-License novel / unique / proprietary products
Seeking out-licensing opportunities in commercial or Phase III clinical stage.
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities In-house expertise across all functional areas, including sales
Seeking in-licensing opportunities & marketing,opportunity
In-licensing market access and medical & regulatory
affairs, commitment
Prescription to commercial
drug, aesthetic success of
agents, medical products
device and
and in
Seeking in-licensing opportunities
strong alliance management. Marjan is focused on in-
vitro diagnostics candidates for dermatological diseases
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Commercialization/Partnering opportunities for the CEE
Seeking in-licensing opportunities region.
We seek new attractive in-licensing opportunities within
Seeking out-licensing opportunities therapeutic areas not only those in which we have shown our
presence but also those to which we are expanding, such as
Seeking in-licensing opportunities
psychiatric, neurological, hematologic/oncologic,

Seeking in-licensing opportunities Looking for partnerships and in-licensing opportunities in

specialty neurology (movement disorders, rare neurological
conditions). Focused on Ph2-3 opportunities.
Seeking in-licensing opportunities We are looking for clinical and commercial stage in-
Seeking in-licensing opportunities licensing , acquisition, and collaboration opportunities in rare
・Seeking new products in the United States and Japan
diseases. We are not seeking to meet CROs at this time.
Seeking out-licensing opportunities Partnering, Licensing.
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities Please note:isnothe
Neopharm vendor or of
partner supplier
choicemeetings will be accepted.
and one-stop-solution for
Seeking in-licensing opportunities multinational corporations seeking to enter or expand their
Seeking business in the Israeli healthcare and medical markets.
Seeking out-licensing opportunities
in-licensing opportunities Looking for inorganic growth opportunities via both
acquisition and licensing
 Speaking with research-driven R&D companies., i.e., please
Seeking in-licensing opportunities no CROs, CMOs, consultants, service-based companies.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities Seek In-licensing/Commercialization Opportunities for the
Middle East and North Africa region
Seeking out-licensing opportunities Looking for out-licensing or collaboration for our small
Seeking in-licensing opportunities molecule assets, NC-2600
Cancer Therapeutics for IBD, chronic
and Diagnostics, cough
Research and
collaboration
neuropathic pain, alkalization agent for CKD and NC-2500
Seeking out-licensing opportunities -Set up partnerships for SN-001 program to develop it
and NC-2700 both for gout.
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities outside Japan. industry leading Lipid Nanoparticle Delivery
Nitto develops
systems
Looking for
for nucleic acids,ofincluding
opportunity licensingmRNA,
in siRNA and
DNA. We partner with companies to develop RNA-based
We are interested in connecting with biotech and pharma
therapeutic drug products utilizing Nitto's LNP technology.
Seeking out-licensing opportunities companies across
We are looking forallnew
therapeutic areas that
and innovative areto
assets seeking
in-license or
Seeking M&A, licensing / with
partnering or equity capital markets
Seeking in-licensing
out-licensingopportunities
opportunities distribute, that fit our current portfolio of secondary
Out-licensing our propietary assests in preclin, clinical and care
transactions.
products, in our core therapeutic areas of interest for Europe
Seeking in-licensing opportunities commercial
At Novartis, stage (see description).
we believe that biomedical innovation will have
+ Canada/USA/Japan. We are also keen to grow our
an unparalleled
At Novartis, we impact
believeon allbiomedical
that humankind.innovation
We are excited at
will have
being
an leaders in impact
unparalleled this, andonweall are constantlyWe
humankind. looking for at
are excited
partners who want
being leaders to and
in this, sharewethearejourney withlooking
constantly us. for
Seeking in-licensing opportunities Noven is seeking products for potential in-licensing,
partners who want to share the journey with us.
Seeking investment partnering, or co-promotion opportunities to strengthen their
current pipeline in ADHD, Schizophrenia, and Digital
Commercial Collaboration
Therapeutics.
Seeking out-licensing opportunities
Seeking in-licensing opportunities Our strategic growth plan targets BD in-licensing and
Seeking out-licensing opportunities acquisitions,
Co-developmentand partnerships
we have overon$300m
novel of cash available to
targets
deploy to support
Out-licensing these initiatives.
of internally-generated candidates orout-
Seeking out-licensing opportunities 1. OM-85, Phase 2: partnership, co-development,
programmes
licensing
Seeking in-licensing opportunities Organon has a portfolio of more than 60 medicines and
Seeking in-licensing opportunities products across afor
Orion is looking range of therapeutic
in-licensing, assetsareas. Led byand
to acquire the
women’s health
collaboration portfolio
opportunities coupled with an expanding
Seeking in-licensing opportunities We are looking to in-licenseincompounds
oncology, pain,
in lateneurological
preclinical or
biosimilars
disorders, businesshealth,
women's and stable franchise
asthma & of established
COPD, and allergy.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities clinical development for the following therapeutic areas:
With some limited exceptions, our team is not in a position

Seeking in-licensing opportunities

Seeking
Seeking investment
out-licensing opportunities
Pharmacosmos focus is Human Medicines, Veterinary
Medicines and Carbohydrates.
PharmaEssentia will continue to build the organization for
further clinical developments,
PharmaEssentia will continue to enrich
buildthe
theproduct pipeline
organization forvia
in-house
further R&D capability,
clinical developments,external strategic collaboration and
Seeking out-licensing opportunities PARTNERING STRATEGY enrich the product pipeline via
partnering
in-house activities, and to manufacture and commercialize
R&D capability, external strategic collaboration and
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities OUT-LICENSING:
Pharmanovia's objective for this conference is to meet with
partnering activities, and to manufacture and commercialize
Seeking in-licensing opportunities partners who have licensing
Any pharmaceutical opportunities
and biotech companies forwith
advanced
(or that(PIII
are
Seeking onwards)in)novel products
related in
to:our disease areas of focus
Seeking out-licensing
out-licensing opportunities
opportunities interests assets
(oncology support, endocrinology, neurology and
Pharming Group N.V. is committed to expanding its pipeline
Seeking in-licensing opportunities with innovative
Pierre drug programs
Fabre’s mission is to takeand
carecommercialize them and
of life by designing
globally. We
developing are interested
innovative in WW
solutions right by
inspired or we would be
consumers andan
Seeking in-licensing opportunities
exceptional partner throughout Europe, the Middle East
patients and contributing to the well-being of everyone from and
Seeking out-licensing opportunities
health to beauty. Our Group has been built on a combination
Establish partnerships that leverage our proprietary platform
Seeking in-licensing opportunities technologies towards gene and cell therapy products
Seeking
Seeking investment
in-licensing opportunities In-license in-clinic and/or commercial assets in the neuro-
Seeking
Seeking out-licensing opportunities
in-licensing opportunities metabolic space,global
We are seeking and orphan disease
or ex-US spaceforinsunobinop,
partners general. and
Seeking in-licensing opportunities US partners
Primary goalfor tinostamustine.
is to identify potential in licensing and
partnership opportunities in Endocrinology, Rheumatology
or related areas where our strong commercial leadership and
execution can be utilized to support product growth.
Seeking in-licensing opportunities - In-licensing of late-stage development innovative assets for
Seeking out-licensing opportunities the IsraeliMedical
Rakuten and CEE markets. interested in regional and/or
is primarily
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities co-development
Our partnerships
business development for ourfocuses
strategy ASP-1929 program,oras
on licensing
well as for a Phase 1 program, RM-1995 (targeting CD25).
acquiring:
1) Network with decision-makers at companies who wish to
explore partnerships using Recursion's platform technology
to model and rapidly identify potential therapeutics for
To connect with companies (i) interested in partnerships,
complex disease
collaborations or out-licensing of REGENXBIO programs
and/or (ii) developing AAV-complementary/enabling
RemeGen is primarily seeking strategic-fit partners to
technologies
Seeking out-licensing opportunities expedite
Partneringdevelopment and commerialziation
and out-licensing of our
discussions focused onpipeline
cell and
Seeking in-licensing opportunities ex-China.
gene therapy
Partnering onPin-point base editing,
siRNA platforms. AAV viral
Partnering vector
of individual
delivery and LentiBOOST transduction enhancer
assets.
Asset acquisition or license, divestitures, partnerships
Seeking out-licensing opportunities
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities
Seeking in-licensing opportunities Looking for highly innovative drugs to be introduced and
Seeking out-licensing opportunities launched
We striveintothe
findCEE.
partnerships for our existing and pipeline
Seeking in-licensing opportunities products globally. Our goal
Looking for new product is to work with
opportunities in oursynergistic
main
pharmaceutical companies within our areas of expertise and
therapeutic areas: Gastro-Intestinal, Liver, Musculoskeletal,
Seeking out-licensing opportunities [Out-licensing]
through
CNS, our services. We are also experts in Sterile, Liquid
Seeking in-licensing opportunities We areand Ophthalmology.
seeking out-licensing opportunities for our main
oncology assets, like SJN307A and SJN301.
Seeking out-licensing opportunities We are seeking partnership to apply our mRNA delivery
technology called SENS.
Seeking out-licensing opportunities We seek collaborations that can extend or complement our
Seeking out-licensing opportunities leading genomic medicine capabilities, including:
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities
Seeking in-licensing opportunities
Seeking in-licensing opportunities Seeking investment, in-licensing and collaboration
Seeking in-licensing opportunities opportunity
We are actively looking for Japanese rights to develop and
Seeking in-licensing opportunities commercialize the assets that improve clinical efficacy or
QOL in intractable disease areas below.
Our aim is to be a reliable supplier and CDMO services
Seeking out-licensing opportunities provider for Pharmaceutical
Schrödinger's objective is to intermediates
address unmetand APIs,needs
medical Vaccine
by
Ingredients
licensing or partnering preclinical assets and clinical
Licensing, Co-development, M&A, JV, etc.
candidates discovered
Collaboration internally using our proprietary
Seeking in-licensing opportunities 1. Seeking for format flexible
out-licensing/partnering opportunities for our
computational drug discovery platform.
Seeking out-licensing opportunities innovative fIrst in class ADC, tri-spefic
In-licensing of post POC programs or marketed T-cell engager,
productsa for
small molecule, dual inhibitor
the US market in Gastroenterology targeting KRAS G12C/PI3K,
which is currently in clinical phase I study. We also open to
Seeking in-licensing opportunities Focusing on prescription medicines which address rare and
life-threatening diseases
Research and clinical (Emergency
partnerships Care as
as well and Rare
in-licensing of
Diseases)
microbiome IP/programs and adjacent technologies
Seeking in-licensing opportunities PLEASE REFER TO THE INFORMATION LEAFLET
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities ENCLOSED
To accelerate IN THE development
product CONTENT SECTION OF THISthrough
in global markets
PAGE FOR DETAILS ON OUR AREAS OF INTEREST
co-development.
Seeking in-licensing opportunities License out ex-China right of in-house innovative assets.
BEFORE REQUESTING A MEETING.
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities License in China
Partnership right of late
opportunities withstage assets
SHcell’s in oncology
VHHMAb and
nanobody
Seeking in-licensing opportunities nephrology
platform, area;
Seeking in-licensing opportunities LicensingJL transposon
in/outs, co-R&D,system, and Tiniplasmid
co-marketing, technology.
and co-promotion
Seeking out-licensing
Seeking out-licensing opportunities
opportunities Seeking partnering oppotunities for pre-clinical and clinical
Seeking in-licensing opportunities stage assets
To build for global center
a production and Japanese markets,
of excellence we focus
in human on:
vaccines
Seeking out-licensing opportunities and biological products with highly specialized human
Seeking resources, capable of fulfilling the domestic requirements
Seeking in-licensing
out-licensingopportunities
opportunities Seeking partnership to facilitate and accelerate development
with the local government for the public market and
Seeking investment of our clinical stage pipelines ex. China.
Seeking in-licensing opportunities We are currently looking for:
Seeking
Seeking out-licensing opportunities
in-licensing opportunities Seeking in-licensing & partnering opportunities for both
Seeking in-licensing opportunities earlyare
We stage R&Dfor
seeking programs and
late-stage manufacturing
products platform
or marketed products
technologies
that in:
Seeking in-licensing opportunities Strategic Investment, In-Licensing, Co-development The
can be developed and launched in South Korea.
Seeking investment company continues to aggressively search for potential
candidates to establish successful strategic partnerships with,
Seeking out-licensing opportunities SRI's focus is to partner with commercial companies to co-
Seeking
Seeking investment
in-licensing opportunities develop new Sciences,
At SRS Life therapeuticswe utilizing our novel,
exist to change firstpossible
what’s in class for
Seeking platforms and programs. We workliving
to solve the toughest
Seeking out-licensing opportunities
in-licensing opportunities the healthpartners
Seeking of the 6tobillion people
co-develop in emerging
or commercialize nations.
difficult to
technological problems and create differentiated solutions
Seeking in-licensing opportunities make generics, specialty brands and consumer health assets
Seeking in-licensing
out-licensingopportunities
opportunities in Europe.
Seeking
Seeking out-licensing opportunities
Seeking in-licensing opportunities Over the last few years, Sun Pharma has been focusing on
Seeking out-licensing opportunities branded specialty
The primary products
objective is towhich
secureinclude New Chemical
drug development
Entities, New Molecular Entities, Biologics
partners for UniORV outside of Japan. We wish and Novel
to initiate
technologies. Sun Pharma is actively looking
business relations through product co-development, into business
Seeking in-licensing opportunities
technology licensing, or a CDMO commitment. As
In-Licensing Biosimilars , NCE , Biologics , Patented
Seeking in-licensing opportunities products and hardisto
Taiho Oncology develop
seeking to injectables , reformulated
in-license and acquire
products
additional , focusing
oncology mainly on
marketed Oncology
products and
and autoimmune
late-stage
Seeking in-licensing opportunities <Business Development Strategy and Priorities>
diseases
development therapeutic candidates for treating solid tumors
Seeking in-licensing
Seeking out-licensingopportunities
opportunities In-licensing
As for ConsumerScopeHealth Care (CHC) business, we are
and hematological malignancies addressing the needs of
Seeking out-licensing opportunities looking for the partners for below opportunities. We are open
to joint research. As for territory, we are mainly focusing on
Seeking in-licensing opportunities
Japanese market.
Seeking in-licensing opportunities In-licensing innovative products in the dermatology space.
Seeking in-licensing opportunities No Service
We Provider
are looking Requests
to grow Please.pipeline through
our eyecare
Seeking
Seeking out-licensing
out-licensing opportunities
opportunities partnerships across both front
Tasly is actively looking for: and back of the eye. We are
Seeking in-licensing opportunities also interested
Innovative in global
assets in earlypartnerships
such for all ourcell
eyecare,
Seeking in-licensing opportunities Alliance Opportunities in stage,
pharmaceutical as mAb,
business.therapy,
derm, and
BsAb, ADC, infectious
gene disease
therapy andassets.
other emerging treatment
Seeking
Seeking out-licensing opportunities
in-licensing opportunities We have been expanding our product line ups in the focused
modalities
fields by our internal drug discovery as well as by global
Seeking in-licensing opportunities
alliances/ partnerships.
Seeking
Seeking out-licensing opportunities
in-licensing opportunities in-licensing&out-licensing
Seeking out-licensing opportunities
Seeking in-licensing opportunities In-licensing of novel therapies and biosimilars
Seeking in-licensing opportunities
Seeking in-licensing opportunities We seek companies or late stage assets to complement our
existing
Product, portfolio in the following
product-portfolio M&A inareas: fertility, diseases
GI, infectious
contraception,
and in specialty uterine
business. Toray is lookingand
health, menopause osteoporosis.
Seeking out-licensing opportunities At this Bio International, for the potential
We operate across multiple geographies, and are interested in
Seeking in-licensing opportunities partners for our Pharmaceutical Assets in the field of
Seeking out-licensing opportunities neurology (Pain) and oncology including a cancer
In-Licensing, Collaborations, Partnerships, Acquisition
supportive/ palliative care.
Seeking out-licensing opportunities candidates. Owing to tight &
Identifing co-development scheduling weparteners
distribution will not be
for TNM
accepting
002 vendor
(Tetanus) andinvitations.
TNM 001 (RSV) for territories outside of
Seeking in-licensing opportunities 1. In-license/partner for clinical or commercial-stage
Seeking out-licensing
out-licensing opportunities
opportunities Great China.
opportunities focused on ADHD, Autism, Anxiety, Pain,our
and
Seeking Tsumura is seeking partnering opportunities to facilitate
Seeking investment other Psychiatric
late-phase clinicaland/or Neurological
development programdisorders.
indicating
TTY is seeking to enhance its current marketed and
postoperative stage
development ileus,product
and thenportfolios
the futureinNDA.
anti-infectives,
Seeking out-licensing opportunities Seeking out-licensing opportunities and collaborative
oncology,
research supportive care, critical care acute pain and
UCB is looking for new opportunities that are
immunology by in-licensing products which are in late Phase
Seeking in-licensing opportunities transformational
Please no vendor for patients
meeting and have a clear scientific
requests.
rationale
In and/or
licensing clinical
programs forevidence of therapeutic
rare genetic diseases efficacy.
Seeking in-licensing opportunities Vaccine partnering
Seeking
Seeking investment
out-licensing opportunities
Seeking in-licensing opportunities
Seeking in-licensing opportunities In-licensing or acquisition of technologies applicable to
Seeking in-licensing opportunities veterinary medicine, in the areas of our strategic interest.

Seeking in-licensing opportunities In-license innovations applicable to animal health (see

Seeking out-licensing opportunities below our areas
Out-license, of interest).
global partnership

Seeking in-licensing opportunities We are seeking various types of collaborative opportunities,

Seeking in-licensing opportunities including
Add valuein-licensing, co-development,
to health through brand acquisition,
innovative, reliable and
and R&D investments to expand
accessible diagnostic systems. our portfolio.
Seeking in-licensing opportunities Our team delivers innovative medicines to provide a brighter
Seeking out-licensing opportunities future
Xeris isforinterested
patients suffering from
in licensing its neurological
non-aqueous disorders.
formulation
Seeking
Seeking in-licensing
out-licensingopportunities
opportunities technologies XeriJect and
Drug Discovery Collaboration XeriSol to enable or improve the
Seeking in-licensing opportunities delivery
License-out of biologics and
of pipelines peptides.
Seeking out-licensing opportunities Drug Discovery Collaboration
Seeking out-licensing
Seeking in-licensing opportunities
opportunities License-out of pipelines
Seeking in-licensing opportunities
Seeking in-licensing opportunities Inward opportunities: small molecules or biologicals (CHO-
Seeking
Seeking out-licensing opportunities
in-licensing opportunities based preferred)
Our main in late
purposes clinical development
of attending the conferencestages
are towith
seek in-
Seeking focus on hematology, dermatology, hepatology, endocrine
Seeking out-licensing
out-licensing opportunities
opportunities licensing candidate and to introduce our promising pipeline
- Seeking out-licensing opportunities for YH35324 (IgE trap,
tumor,
to otherinflammatory
companies. diseases, metabolic disorders etc.
Seeking
Seeking in-licensing
in-licensing opportunities
opportunities Allergy),
In-license YH32367
compounds (HER2/4-1BB bsAb,
for development solid cancer)
globally andin
or locally
YH32364 (EGFR/4-1BB, solid cancer)
China
Seeking in-licensing opportunities
Seeking out-licensing opportunities Zealand Pharma is seeking global commercialization
Seeking out-licensing opportunities partners for its rare disease
Seeking partnership assets
for global to treat Congenital
or ex-China development of
Hyperinsulinism
Zelgen'sisprograms.and Short Bowel Syndrome. Both programs
Seeking in-licensing opportunities Zentiva interested in acquiring / in-licensing of late stage
have positive Phase 3 data and are filed in the United States.
Seeking in-licensing opportunities assets (Phase 3 on-going or complete) in the field Oncology
Seeking out-licensing opportunities & IO, Autoimmune Diseases, CVS, Respiratory, Diabetes,
GI.
 Ticker Market cap ($M) Last funding round(s)

1530.HK 3500
1530.HK 3500
2256.HK
NYSE: ABT 215912
ABBV
ABCL (Nasdaq)
C Round
NASDAQ: ACAD

1200

ADAP

Other
AGEN
AGIO 1680
D Round

AKBA
BME:ALNT
ALXN

ALKS 4500
1000 C Round

ALM
ALNY
2250

DSNKY
AMGN
AMGN
AMGN
FOLD
AMRX
6996.HK Other

APLS
1400
ARDX 1870
ARGX 20000

6855.HK 1500
1672.HK
SHSE:688176

AZN
ATRA 700

AUTL
NYSE
A Round
400 B Round
BSLN
BHC
BAYN
BGNE 15630 Other
AMS: BAI

BBY 1595
Shenzhen Stock Exchange SZ300558 6400

NASDAQ:BCYC

HK2315 1500

BIIB
480
480
BMRN 20000
BNTX 22000 Other

2180 Other
SHA: 688177
B Round

BLAU3 5000
BLUE 500
BPMC 5600 Other
CN STAR MARKET 688166 2000
CN STAR MARKET 688166 2000
BMY
603858.SH 3923
003000

NASDAQ STO: CAMX 2700

HKEX 02171

CLLS
16800
CLN 176 A Round

KOSDAQ:A085660 815

1177.hk (parent company)

185750 (KSE) 1113

4519 59000
CIPLA 6000

KOSDAQ: 058820 233

CDXS 0.5
CHRS
COLL 1200 Other

CRSP

CSL.ASX 100000
HKEx.: 01093 14000

CVAC
CYTK
250
KRX: 069620 1600
4568:TSE

DCPH 1257

NYSE:DB

170900

76

EDIT

4523 20888
D Round
LLY

EBS

C Round

ESPR

KOSDAQ 600
EVR

XGN 50

EXAI 1000 D Round

FAES

FGEN
600196， 02196 10000
688221 SH 650
TSE4554 400
FUJIY 22000
70

GLPG.AM (Euronext); GLPG.US (Nasdaq) 2500

SHA: 603087 4000
A005250 4116
500
BPSE: RICHTER

C Round

GEN 20
C Round
HKG:1548 4600
8000
GILD
GLENMARK 1500
200
NASDAQ: GRTS 215

GSK 116840

GUBRA
GYRE 1500
HLUN-A and HLUN-B 4000
A Round
002653 5000 B Round
002653 5000
009420 1700
KRX:002390
3692.HK 18000
A Round
B Round
2696. HK 1018
HIK.L 6220
TYO: 4530 3200

845
000963 7000
HCM 2700
HYPE3 6
HYPE3 3.8
004310 (KRX) 200

Nasdaq: IGMS
000230
NASDAQ: IMTX 1100
IMCR 3000
INCY 16000
HK 9969 2300
1801.HK 10000
INO
D Round
INSM 4000

NTLA
ITCI (NASDAQ)
IPN
IRWD

JAZZ 7500
4552 Tokyo 3000

600276 40000
JNJ
2914 71000

2800
KRX: 001060 586
4521 (TSE)
KMDA 304
KPTI

SZ:002422 6000
2162.HK 923

4547 1000

TSX:GUD 400
102940:KOSDAQ
KRX: 009290
4560 1200
NA
TYO: 4151

ROVI

Prescription Drugs

LNTH 4900
LEGN 8000

HKEX 2157
37000

LUPIN 9000
9467
MGNX
Nasdaq: MDGL 4500
5000
MNKD 1200

MGTX 700 Other

MRK
MRK

MGX B Round
MIRM 900
4508
4534 776
NBIX 10000
C Round

4539: Tokyo Stock Exchange

4272 1700
4021.T
10525
0.11
8604-JP 12096
n.a.

NVS
NVS
NVAX Other

NVO
NVCR 6800
NRIX
4565-JP 1000 Other
4565-JP 1000

OGN

4578 22326

TSE: 4587

6446 841
6446 841
PHM:SM

214450 (KRX) 800

PHARM 820

PSTX
PLX 145
PTCT 3000
REC.MI 11500
RXRX
REGN 82000
RGNX 1000 Mezzanine Round
Other
HKG 9995，SSE STAR Market 688331 5700
RVTY 12780

RCKT 2500
ROIV

RVU
SALR 200

KRX: 000520 165

005500.KS (KOSPI, South Korea)

SANA 2000
SGMO 110
SAN
SAN
SAN
4536 (Tokyo Stock Exchange) 3500

SRPT

2776
SCLN 1500
688553 China: Shanghai 160

MCRB

019170
TYO: 4507 15000

1177 10000
KOSPI 326030 6000
302440 10000
KOSPI

STAGR

29000

STRO 1000
SOBI:ST

4502 36630

TARO 4500
TARS 1500
SH:600535 3300

ASX: TLX 2600

TEVA

4559:JP
3402 15000
06628
TVTX 600 Other
650

4540 Tokyo
4105.TWO 806
4208
UCB (Euronext Brussels)
RARE 7000
UTHR 10000
Nasdaq: VALN; Euronext Paris: VLA 600
VERV
VETO:EN
VTRS

VIRP 2.3

WVE
016580 400

XNCR 1600
XENE 3000
XERS
D Round
D Round

107
000100(KSE)
ZLAB 15310

ZEAL 6000
Shanghai STAR: 688266 2200

4559
ZYME 624
Total funding ($M) Website

http://www.3sbio.com/
http://www.3sbio.com/
http://www.abbisko.com
www.abbott.com
www.abbvie.com
https://www.abcellera.com
1100 https://www.abogenbio.com/
http://www.acadia-pharm.com/
http://accord-healthcare.com
www.ache.com.br
www.ache.com.br
https://acino.swiss/
www.adaptimmune.com
https://www.advancedenzymes.com/
https://www.advanzpharma.com/
http://agenusbio.com/
www.agios.com
267 https://www.aidoc.com/
http://ajupharm.co.kr/en/
http://akebia.com/

http://www.alexion.com
http://www.alfasigma.com/
https://tiefenbachergroup.com
www.alkermes.com
40 http://www.allifetech.com
http://almatica.com
www.almirall.com
http://www.alnylam.com/
www.alvogen.com
www.alvotech.com
https://www.linkedin.com/in/gerripotash/
www.amgen.com
www.amgen.com
www.amgen.com
http://www.amicusrx.com/
amneal.com
www.antengene.com
www.aop-health.com
http://www.apellis.com/
http://www.gdyph.com
www1.apotex.com/global
https://www.apotex.com/global
 www.apsen.com.br
www.ardelyx.com
www.argenx.com
https://www.aristo-pharma.de/en
www.arlok.com and www.dnasolutionsusa.com
http://www.asahikasei-pharma.co.jp/en/index.html
http://www.ascentagepharma.com/
http://www.ascletis.com/
www.asieris.com
https://www.aska-pharma-hd.co.jp/english/
https://www.astrazeneca.com/partnering/our-partnering-teams.html#biopharmaceuticals-0
http://www.atarabio.com/
aurigene.com
www.austarpharma.com
https://www.autolus.com/
avantorsciences.com

www.azurity.com
www.basilea.com
www.bauschhealth.com
www.bayer.com
http://www.beigene.com/
www.benevolent.com
http://www.besins-healthcare.com
www.bestbuyhealth.com
http://www.bettapharma.com/en.php
www.bial.com
http://www.bicycletherapeutics.com/
https://www.biocodex.com/en/
400 https://en.biocytogen.com.cn/
www.biofabri.es
www.biogaran.com
www.biogen.com
www.biolabfarma.com.br
www.biolabfarma.com.br
http://www.bmrn.com/
www.biontech.de
www.bioprofarma-bago.com.ar
218 https://www.bioraypharm.com/en/
www.bio-thera.com/EN/
237 www.biotheus.com
www.blanver.com.br
www.blau.com
http://www.bluebirdbio.com/
http://www.blueprintmedicines.com/
225 https://bluerocktx.com/
http://www.bmikr.co.kr/
https://www.boehringer-ingelheim.com/partnering/working-together-animal-health/connect-with-u
https://www.boehringer-ingelheim.com/
https://www.boryungbio.co.kr/english/index.asp
http://www.boryung.co.kr/eng/index.do
https://bright-gene.com/
https://bright-gene.com/
https://www.bms.com/researchers-and-partners/in-the-pipeline.html

http://www.bukwangpharm.com/
https://www.byondis.com
www.camurus.com
https://www.cansinotech.com/
www.carnot.com
http://www.carsgen.com/
https://ct.catapult.org.uk/
http://www.cellectis.com/
http://www.celltrion.com/en/
67 https://celonpharma.com/en/category/general-en/
www.centurion.com.tr
www.ceva.com
http://eng.chabio.co.kr/
https://www.baiyu.cn/english.php?m=index&a=index
http://www.cttq.com/en-us/
https://www.chiesi.com/en/

http://www.ckdpharm.com/eng/ckd/index.ckd
www.chugai-pharm.co.jp/english
https://www.cipla.com
https://clearstreet.io/
https://www.clinigengroup.com/
www.cmgpharma.com
www.codexis.com
www.coherus.com
www.collegiumpharma.com
https://www.createrna.com/en
http://www.crisprtx.com
http://www.cristalia.com.br/
http://www.csl.com ; http://www.cslbehring.com
https://www.cspc.com.hk/en/global/home.php

https://ctspharma.com/
www.curevac.com
www.cytiva.com
 cytokinetics.com
https://www.daewonpharm.com/eng/main/index.jsp
http://www.daewoong.co.kr
http://dsi.com/business-development
https://www.debiopharm.com
www.deciphera.com
www.denalitherapeutics.com
dendreon.com/partner-with-us
www.db.com
http://www.deva.com.tr/en/

www.dompe.com
http://rnd.donga-st.com/en/
http://dong-wha.co.kr/english/dw_main.asp
https://www.drwolffgroup.com/en/
https://drfalkpharma.com/en/
http://www.eapharma.co.jp/en
www.eddingpharm.com
http://www.editasmedicine.com/
https://int.egis.health/
https://www.eisai.com/index.html
1260 www.elevate.bio
https://www.lilly.com/partners/connect
https://www.emdgroup.com/en/partnering/collaboration-in-healthcare.html
https://www.emergentbio.com
www.ems.com.br
www.enableinjections.com
www.er-kim.com
http://www.esperion.com/
www.esteve.es
http://www.eubiologics.com/en/main/
http://www.evercore.com
400 www.evopointbio.com
http://www.exagen.com
250 https://www.exegenesisbio.com/
www.exeltisusa.com
600 www.exscientia.co.uk
https://extrovis.com/
http://faesfarma.com/en/
www.ferrer.com/en
www.ferring.com
www.fibrogen.com
http://flagshippioneering.com/
https://www.fosunkitebio.com
https://www.fosunpharma.com/en/
 https://fosunpharmausa.com/
http://en.frontierbiotech.com/
www.fujipharma.jp

https://www.fuso-pharm.co.jp/cnt/en/
www.gl-pharma.com
www.gador.com
https://gaia-group.com/en/
www.glpg.com
http://www.ganlee.com
http://www.gcbiopharma.com/eng/index.do
https://www.gccell.com/en/main.do
https://www.richter.hu/en-US/Pages/default.aspx
https://www.gene.com/
750 www.generatebiomedicines.com
http://www.genscigroup.com
www.genmab.com
230 https://www.gensciences.com/
https://www.genscript.com/
https://www.genscript.com/
https://www.gilead.com/
www.glenmarkpharma.com

http://www.gritstonebio.com/
www.grunenthal.com
http://www.gsk.com/
https://www.raynovent.com/
https://www.gubra.dk/
https://www.gyretx.com/
www.lundbeck.com
320 http://en.haihepharma.com/
www.haisco.com

www.hanallbiopharma.com
http://www.handok.co.kr/english/
www.hspharm.com
http://www.harbourbiomed.com
www.helsinn.com
http://www.henlius.com/en/index.html
http://www.hikma.com
www.hisamitsu.co.jp/
http://www.inno-n.com/eng/
https://www.hlbpharma.co.kr/eng/main/main.php
http://www.eastchinapharm.com/
https://www.hutch-med.com/
 http://hyperapharma.com.br/
http://hyperapharma.com.br/
http://www.hyundaipharm.co.kr/
http://www.iasobio.com
https://www.ichnossciences.com/
https://igmbio.com/
http://www.ildong.com
www.immatics.com
www.immunocore.com
http://www.incyte.com/
https://www.innocarepharma.com/
1000 innoventbio.com
www.inovio.com
400 http://insilico.com/
http://www.insmed.com/
https://www.insud.com.ar/

www.intelliatx.com
www.intracellulartherapies.comm
http://www.ipsen.com
www.ironwoodpharma.com
www.italfarmaco.com
https://www.jamppharma.ca/en/
http://jbpo.or.jp/english/
https://www.jazzpharma.com/
https://www.jcrpharm.co.jp/en/site/en/index.html
https://www.jeilpharm.co.kr/english/

https://www.hengrui.com/en/index.html
https://jnjinnovation.com/
https://www.jt.com/about/division/pharma/index.html
http://www.jubilanttx.com/
https://www.jumpcan.com/en/index.aspx
www.jw-pharma.co.kr
https://www.kaken.co.jp/english/
http://www.kamada.com/
www.karyopharm.com
www.kashivbiosciences.com
https://www.kelun.com
https://en.keymedbio.com/
https://en.kintor.com.cn/
http://www.kissei.co.jp/e_contents/index.html
www.kmbiologics.com/en
http://www.gud-knight.com/en/
http://www.kolonls.com/
http://www.kolonpharm.co.kr/
https://www.kowa.co.jp/eng/business/health/index.html
http://kuhnil.com/en/index.php
http://eng.ekdp.com/main/main.asp
https://www.kyorin-pharm.co.jp/en/
https://www.kyoritsuseiyaku.co.jp/en/
https://www.kyowakirin.com/index.html
www.bago.com.ar/en/
http://www.biopasgroup.com/
www.rovi.es
http://www.liomont.com
https://www.pisa.com.mx/
https://www.savalcorp.com/en/
www.silanes.com.mx
lantheus.com
http://www.legendbiotech.com/
www.leo-pharma.com
https://en.lepubiopharma.com/
www.lgchem.com
www.lifearc.org
https://lnc-pharm.com/
http//www.lubrizol.com
www.lupin.com
www.mabwell.com
www.macrogenics.com
https://www.madrigalpharma.com/
www.mankindpharma.com
www.mannkindcorp.com
http://www.marjan.com.br/
http://www.maruho.co.jp/english/
http://www.maruishi-pharm.co.jp/
https://www.medis.com/
http://www.meiji.com/global/
http://meiragtx.com/
http://www.menarini.com
www.merck.com/licensing
www.merck-animal-health-usa.com
www.merztherapeutics.com
https://metagenomi.co/
https://mirumpharma.com/
http://www.mt-pharma.co.jp/
http://www.mochida.co.jp/english/
www.neopharmisrael.com
https://www.neogen.it/it/
https://www.neuraxpharm.com/
 www.neurocrine.com
240 https://www.neurophth.com/en/Index.html
http://www.nbpharma.com/
http://www.nhlbi.nih.gov/about/org/dera/otac
http://www.chemiphar.co.jp/english/
http://www.nipponkayaku.co.jp/english/
http://www.nissanchem.co.jp/eng/
https://www.nitto.com/jp/en/
https://www.nobelpharma.co.jp/en/
http://www.nomura.com/
https://www.nordicpharma.com/
www.noucor.com
https://www.novartis.com/partnering
https://www.novartis.com/about/manufacturing/contract-manufacturing
http://www.novavax.com
http://www.noven.com/index.php
www.novonordisk.com
https://www.novocure.com/
https://www.nurixtx.com/about/
https://www.nxera.life/
www.nxera.life
https://www.ompharma.com/home
www.organon.com
http://orion.fi/en/
https://www.otsuka.com/en/
http://www.otsukakj.jp/en/
www.pari.com/eFlow-partnering
partex.io
http://www.peptidream.com/en/
www.pharmacosmos.com
www.pharmaessentia.com
www.pharmaessentia.com
www.pharmamar.com/en
https://pharmanovia.com/
http://pharmaresearch.co.kr/
https://www.pharmathen.com/
200 www.pharming.com
www.pierre-fabre.com
https://www.linkedin.com/company/pint-pharma/
www.polpharmabiologics.com
http://poseida.com/
http://www.protalix.com
www.ptcbio.com
http://www.purduepharma.com/
www.radiuspharm.com
 http://www.rafa.co.il/en
733 https://rakuten-med.com
http://www.recordati.com/en/
900 www.recursionpharma.com
www.Regeneron.com
www.regenxbio.com
www.relaytx.com
http://www.remegen.com
www.revvity.com
https://ribocure.com/
http://www.rocketpharma.com/
http://www.roivant.com/
www.rosemontpharma.com
http://www.ryvu.com
www.salus.eu
www.svt.com
www.samil-pharm.com
https://www.samjinpharm.co.kr/front/en/main/index.asp
https://www.samsungbioepis.com/en/index.do
https://www.samyangbiopharm.com/en/index
http://sana.com/
www.sangamo.com
https://www.sanofi.com
https://www.sanofi.com
www.sanofi.com/en/your-health/vaccines
https://www.santen.com/en/
http://www.skk-net.com/en/
https://www.sarepta.com/
https://www.sauravchemicals.com/
http://www.schrodinger.com
www.sciclone.com
http://www.seacrosspharma.com/
http://www.sebelapharma.com/
http://www.senju.co.jp/english/
https://serb.eu/
serestherapeutics.com
http://www.servier.com/
https://www.huaota.com/en/about.html
http://www.jmkx.com/en/
https://shcell.com/40/index.html
http://www.shinpoong.co.kr/en/main/main.php
http://www.shionogi.co.jp/en/
http://www.sinergiumbiotech.com/en/
https://www.sinobiopharm.com/en/
www.sinomab.com
 http://www.skbp.com
https://www.skbioscience.co.kr/en/main
https://www.skchemicals.com/en/ls/main.aspx
www.skplasma.com/en
www.sparktx.com
https://www.sri.com/
www.srslife.com
https://www.stada.com/
http://www.stallergenes.fr
https://www.sumitomo-pharma.com/
www.sunpharma.com
https://www.sunsho.co.jp/en/
www.sutrobio.com
www.sobi.com
http://www.tabukpharmaceuticals.com/
https://www.taihooncology.com/us/
https://www.taiho.co.jp/en/
http://www.taisho.co.jp/en/
www.takeda.com
www.tamergroup.com
www.taro.com
tarsusrx.com
https://en.tasly.com/tslyy.jhtml
https://www.teijin.com/products/health-care/
http://www.teikoku.co.jp/english/index_eng.html
www.telixpharma.com
http://www.tenrypharm.com/en
600 https://www.tesseratherapeutics.com/
www.teuto.com.br
www.tevapharm.com
www.theramex.com
www.tillotts.com
http://www.toray.com/
http://www.transcenta.com/
www.travere.com
290 https://www.trinomab.com/en-us
www.trispharma.com
https://www.tsumura-usa.com/
http://www.tty.com.tw/en-us/
https://www.ube.co.jp/ube/en/index.html
www.ucb.com
www.ultragenyx.com
http://www.unither.com/index.html
www.valneva.com
http://www.vervetx.com
 http://vetoquinol.com
www.viatris.com
https://viivhealthcare.com/en-gb/
www.virbac.com
http://waterstonepharma.com/sy
http://www.wavelifesciences.com/
www.whanin.com
www.wiener-lab.com
www.xencor.com
www.xenon-pharma.com
www.xerispharma.com
800 https://www.xtalpi.com
800 https://www.xtalpi.com
http://www.xuanzhubio.com/
http://en.yifanyy.com/
http://www.yypharm.co.kr
http://eng.yuhan.co.kr/Main/
www.zailaboratory.com
https://www.zambon.com
www.zealandpharma.com
https://www.zelgen.com/en/
https://www.zentiva.com/
http://www.zeria.co.jp/english/index.html
http://www.zymeworks.com
 Main email Main phone Country

huangluping@3sbio.com +86 21 58552737 China

huangluping@3sbio.com +86 21 58552737 China
hua.jiang@abbisko.com (+86)18621082209 China
United States
partnerships@abbvie.com United States
604.559.9005 Canada
Info@abogenbio.com China
DHarvey@acadia-pharm.com +1 (858) 558-2871 United States
United Kingdom
joao.vissoci@ache.com.br 551126088773 Brazil
gabrielle.maria@ache.com.br 551126088773 Brazil
business.development@acino.swiss Switzerland
partnership@adaptimmune.com 441235430000 United Kingdom
rahul@advancedenzymes.com +91 (022) 41703200 India
businessdevelopment@advanzpharma.com United Kingdom
zack.armen@agenusbio.com 781.674.4459 United States
partnering@agios.com United States
United States
chk@ajupharm.co.kr +82-2-2630-0702 South Korea
info@akebia.com +1 617-871-2098 United States
christian.carlson@alantra.com United States
United States
Italy
e.baldyga@aetpharma.com
busdev@alkermes.com +353 1 772 8000 Ireland
allife@allifetech.com (86) 1056386278 China
BD@almatica.com 844-889-8686 opt. 1 United States
maria.manez@almirall.com +34 93 2913745 Spain
businessdevelopment@alnylam.com 617-551-8200 United States
info@alvogen.com United Kingdom
Parasuram.Ramanathan@alvotech.com Iceland
gpotash@americanregent.com 914-419-4197
(805) 447-1000 United States
(805) 447-1000 United States
(805) 447-1000 United States
info@amicusrx.com +1 609-662-2000 United States
United States
bd@antengene.com United States
Austria
bd@apellis.com (617) 977-5700 United States
China
bd2@apotex.com 416-749-9300 Canada
Canada
luis.davoli@apsen.com.br +551156455046 Brazil
partnering@ardelyx.com 617.675.ARDX (2739) United States
info@argenx.com +32 9 310 34 00 Belgium
info@aristo-pharma.de Germany
info@arlok.com 4052711144 United States
+81-3-6699-3600 Japan
jeff.kmetz@ascentage.com United States
john.gargiulo@ascletis.com +86 571- 8538-9729 China
info@asieris.com +44 (0) 7939202 833 UK China
+81 3 5484 8361 Japan
Sweden
office@atarabio.com (650) 278-8930 United States
subir_d@aurigene.com +91 9611811733 India
ron.liu@austarpharma.com (732) 346-6655 United States
United Kingdom
tina.nuthulaganti@avantorsciences.com United States

sharilynne.cline@azurity.com (614) 477-0108 United States

info_basilea@basilea.com +41 61 606 11 11 Switzerland
andrea.fleminggowing@bauschhealth.com United States
United States
christina.swanson@beigene.com (857) 228-6923 United States
bd@benevolent.ai +44 203 7819 360 United Kingdom
vgazelos@besins-healthcare.com +33667386040 Monaco
914-215-1909 United States
han.guo@bettapharma.com 0571-86130357 China
info@bial.com 00351229866100 Portugal
6179458155 United States
France
chaoshe.guo@bbctg.com.cn United States
biofabri@biofabri.es +34 986 330400 Spain
laetitia.landru@biogaran.fr +33647266063 France
partnering@biogen.com +1 781 464 2000 United States
disilva@biolabfarma.com.br + 55 11 3573-6276 Brazil
disilva@biolabfarma.com.br + 55 11 3573-6276 Brazil
415-506-6700 United States
info@biontech.de +49-6131-9084-0 Germany
lfernandez@bioprofarma.com +541140166200 Argentina
BD@bioraypharm.com China
+86-20-3220-3220 China
China
herbert.silva@blanver.com.br +55 (11) 4138-8200 Brazil
bd@blau.com +551146159400 Brazil
United States
United States
 United States
info@bmikr.co.kr +82 70 8891 6627 South Korea
United States
Germany
salee5728@boryungbio.co.kr South Korea
globalboryung@boryung.co.kr South Korea
wx@bright-gene.com +1 9082030036 China
wx@bright-gene.com +1 9082030036 China
United States
tongling@buchangbio.com China
South Korea
BD@byondis.com +31 (0)24 679 5100 Netherlands
info@camurus.com +46462865730 Sweden
business@cansinotech.com China
gbaez@carnot.com +52 55 29649748 Mexico
bd@carsgen.com 86-21-54489928 China
+44 (0) 203 728 9500 United Kingdom
United States
South Korea
bd@celonpharma.com +48 22 751 59 33 Poland
info@centurion.com.tr +902122750708 Turkey
vincent.gleize@ceva.com +33 5 57 55 67 42 France
ey.yang@chamc.co.kr +82-31-881-7005 South Korea
yepeijun@baiyu.cn China
US_BD@cttq.com 86-518-86095128 / 86095133 China
transactions@chiesi.com Italy
zhangjiawen@chipscreen.com China
srjo@ckdpharm.com +821055823721 South Korea
partnering@chugai-pharm.co.jp Japan
mayur.parekh@cipla.com +1 5162979199 United States
United States
pharmaenquiries@clinigengroup.com :+44 (0) 1283 495 010 United Kingdom
khnam@chamc.co.kr South Korea
6507038558 United States
United States
Zkoenig@collegiumpharma.com 7812320793 United States
liuanjiang@createrna.com
Switzerland
julio.cordeiro@cristalia.com.br +55 11 98799-3286 Brazil
Corporate.Mail@csl.com.au +61 3 9389 1911 Australia
john.adamou@cspcus.com United States
luoying@cstonepharma.com United States
sharonse@cts.co.il +972547712360 Israel
licensing@curevac.com +49(0)7071 9883-0 Germany
lslicensing@cytiva.com United States
investor@cytokinetics.com (650) 624-3000 United States
South Korea
82-2-550-8800 South Korea
Japan
Partnering@debiopharm.com Switzerland
kelley.dealhoy@deciphera.com 781.209.6400 United States
contact@dnli.com United States
partnering@dendreon.com United States
United States
+ 90 212 692 92 92 Turkey
marc.landolf@dksh.com Switzerland
Italy
+82-2-920-8212 South Korea
sejin.kim@dong-wha.co.kr +82-10-4339-1891 South Korea
michael.seefeldt@drwolffgroup.com +49 521 8808 - 468 Germany
zentrale@drfalkpharma.de +49-761-15140 Germany
partnering_ea@eapharma.co.jp Japan
+86 21 3175 7888 China
info@editasmed.com 617-401-9000 United States
pesti.szabolcs@egis.hu Hungary
+81338175113 Japan
info@elevate.bio 617-433-2600 United States
United States
United States
United States
andre.garrido@ems.com.br Brazil
bernest@enableinjections.com 513.326.2800 United States
bd@er-kim.com Turkey
United States
Spain
caleb.park@eubiologics.com +82 70 4881 7118 South Korea
prakhar.verma@evercore.com United States
xiaojun.liu@evopointbio.com
bd@exagen.com 888-452-1522 United States
484-354-4274 United States
efernandez@exeltis.com United States
contact@exscientia.co.uk +44 (0) 1865 818941 United Kingdom
vatsa@extrovis.com +91-9618181612 Switzerland
aweber@faes.es 900-4650-153 Spain
+34 93 600 3700 Spain
+41 58 301 00 00 Switzerland
United States
617.868.1888 United States
ruina.zhang@fosunkitebio.com China
fengyulan@fosunpharma.com 13761072948
 United States
jimmyzhang@frontierbiotech.com ＋1 415-200-7879 United States
kushendra_chaudhary@fujipharma.jp +81-3-3556-3344 Japan
susumu.shimoyama@fujifilm.com +1-617-945-3763 Japan
+81 669691131 Japan
michael.bartenstein@gl-pharma.com +43 664 230 7667 Austria
vcarricarte@gador.com +541148589000 Argentina
giorgio.papitto@gaia-group.com United States
bd@glpg.com +32-15342900 Belgium
Zhi1.li@ganlee.com 801-450-9153 United States
82-31-260-9352 South Korea
gccell.GBD@gccorp.com +82-31-736-6700 South Korea
www.richter.hu/en-US/Pages/default.aspx (36) 1-431-4000 Hungary
United States
partner@generatebiomedicines.com United States
zhubin01@genscigroup.com 9739600651 United States
licensing@genmab.com Denmark
tigerhu@gensciences.cn +8613482171902 China
zhenyan.yan@genscript.com +1-732-902-1603 United States
United States
United States
Germany
China
partner@gritstone.com (510) 871-6100 United States
partnering@grunenthal.com +49 241 569-2985 Germany
United Kingdom
chen_sara@raynovent.com 8615013256779 China
LHR@gubra.dk Denmark
stephen@gilmartinir.com United States
Denmark
julie.pan@haihepharma.com 3023792238 United States
jiqian@haisco.com 008613322925975 China
Julie.Peng@Haisco-USA.com United States
yeonjung.lee@hanall.com +821095511621 United States
HyoJin.Lee@handok.com 82-2-527-5114 South Korea
China
jingsong.wang@harbourbiomed.com United States
info@helsinn.com Switzerland
ping_cao@henlius.com China
ssoutari@hikma.com United Kingdom
Japan
hana.park@inno-n.com South Korea
dyjeong@hlbpharma.co.kr +821041951856 South Korea
yuxi@eastchinapharm.com +86 186 0210 3595 China
bd@hutch-med.com +86-21-20673000 China
bd@hypera.com.br + 55 11 3627-4000 Brazil
bd@hypera.com.br + 55 11 3627-4000 Brazil
BD@hdpharm.co.kr South Korea
min.zhang@iasobio.com China
United States
United States
hyojeong.park@ildong.com 82-2-526-3325 South Korea
partnering@immatics.com Germany
+44 (0)1235 438600 United Kingdom
1-855-4-INCYTE United States
bd@innocarepharma.com China
maria.dahl@Innoventbio.com + 44 793 2661 726 United Kingdom
ino@inovio.com 267.440.4200 United States
bd@insilicomedicine.com United States
BD@insmed.com (908) 977-9900 United States
gciccia@insud.com.ar +541148721200 Argentina
fgarcia@intaspharma.com +34637355489 Spain
+1-857-285-6200 United States
info@intracellulartherapies.com 212-923-3344 United States
France
jruberti@ironwoodpharma.com (617) 621-7722 United States
+390264433319 Italy
rgrover@jamppharma.com Canada
ootaki-momoko@jbpo.or.jp +81-3-6435-6513 Japan
corporateaffairsmediainfo@jazzpharma.com +353.1.634.7800 Ireland
kern-b@us.jcrpharm.com Japan
han_sangh@jeilpharm.co.kr +82-2-549-7451 South Korea
wangjy@ctfh.com.cn China
bd@hengrui.com United States
United States
Japan
agunan.krishnan@jubilanttx.com +12678884319 United States
BD@jumpcan.com China
licensing@jw-pharma.co.kr +82 2 840 6777 South Korea
+81-3-5977-5001 Japan
+972 8 9406472 Israel
617-658-0600 United States
Paras.vasanani@kashivbio.com +91 9924967259 United States
zhangyimeng@kelun.com +86 18620959357 China
BD@keymedbio.com China
China
public_relations@kissei.co.jp +81-(0)263-25-9081 Japan
global-strategy@kmbiologics.com +81-96-344-2755 Japan
info@gud-knight.com +1-514-484-4483 Canada
yeri_choi@kolon.com +82-2-3677-4182 South Korea
eunseon_cho@kolon.com +82221208522 South Korea
bdl@kowa.co.jp Japan
mjkim3@kuhnil.com South Korea
+82-2-6006-7777 South Korea
+81-3-6374-9700 Japan
y_nakamura@kyoritsuseiyaku.com +81-3-3263-2991 Japan
+81-3-3282-0917 Japan
dfafasuli@bago.com.ar +5491156018457 Argentina
bd@biopasgroup.com + 507 3882615 Panama
bd@rovi.es +34 91 375 62 30 Spain
svalentinotti@liomont.com.mx +525558141200 Mexico
kncamacho@pisa.com.mx 800 6277 799 Mexico
lab@saval.cl (+56) 227073000 Chile
poteiza@silanes.com.mx +525554883751 Mexico
etienne.montagut@lantheus.com 9784308444 United States
sarah.johnson@legendbiotech.com +1 (732)2213170 United States
United States
bd@lepubiopharma.com China
South Korea
info@lifearc.org United Kingdom
o.antonova@lnc-pharm.com +97144054187 United Arab Emirates
epr@lubrizol.com +1(440)336-2703 United States
United States
xiaowei.cen@mabwell.com China
3012515172 United States
United States
rameshm@mankindpharma.com +919820022965 India
bd@mannkindcorp.com 8186615051 United States
Brazil
+81663718876 Japan
maruishi_bd_licensing@maruishi-pharm.co.jp Japan
marjeta.udovic@medis.com +385 993 100 399 Slovenia
Japan
partnering@meiragtx.com United States
Italy
mrlbdlm@merck.com 732-594-4000 United States
United States
Germany
United States
United States
Japan
Japan
Ran.L@neopharmisrael.com 97239373737 Israel
bussinessdev@neogen.it Italy
+34 93 475 96 00 Spain
 1-858-617-7600 United States
zhengbin.li@neurophth.com
bd@nbpharma.com +971 4 429 8700 United Arab Emirates
erubin@biohealthinnovation.org 4105914736 United States
bd@chemiphar.co.jp +81-3-3863-1204 Japan
+81-3-6731-5200 Japan
+81-3-4463-8370 Japan
akinobu.soma@nitto.com +81-50-3815-8522 Japan
info@nobelpharma.co.jp +81-3-6670-3821 Japan
aditi.kalra@nomura.com 3478494649 United States
simon.barras@nordicpharma.com +31 621683089 Netherlands
hello@noucor.com +34 93 737 66 90 Spain
Switzerland
novartis.cdmo@novartis.com Switzerland
(240) 268-2000 United States
9738608374 United States
Denmark
investorinfo@novocure.com United Kingdom
info@nurixtx.com 415-660-5320 United States
BusDev@nxera.life Japan
BusDev@nxera.life +44 (0)1223 949 100 United Kingdom
mailbox@ompharma.com +41227831111 Switzerland
partnering@organon.com United States
Finland
+81 (0)3-6717-1410 Japan
Yoshihara.Tadao@otsuka.jp +81-88-685-1151 Japan
+49 89 74 28 46 831 Germany
nidhi@partex.io Germany
info@peptidream.com ＋81442701322 Japan
Denmark
muriel_huang@pharmaessentia.com Taiwan
muriel_huang@pharmaessentia.com Taiwan
bdl@pharmamar.com +34 91 846 6000 Spain
BD@pharmanovia.com +44 (0)1268 943700 United Kingdom
sangjin.choi@pharmaresearch.co.kr +1-812-287-3986 United States
ContactBD@pharmathen.com Greece
BD@pharming.com +31 71 524 7400 Netherlands
France
Austria
office@polpharmabiologics.com +48 58 770 95 59 Poland
info@poseida.com United States
IR@protalix.com +972-4-902-8100 United States
info@ptcbio.com +1-908-222-7000 United States
david.rosen@pharma.com 203‑588‑8000 United States
617-551-4000 United States
 02-5893980 Israel
partnerships@rakuten-med.com United States
licensing@recordati.com +39 02 487871 Italy
matt.kinn@recursionpharma.com (385) 269-0203 United States
United States
United States
United States
dan.ross@remegenbio.com United States
ir@revvity.com United States
john.taylor@ribocure.com 0732759604 Sweden
info@rocketpharma.com 646-440-9100 United States
ir@roivant.com 212-847-6204 United States
marketing@rosemontpharma.com +44 (0)7834752893 United Kingdom
ryvu@ryvu.com Poland
info@salus.eu 00386 51 325 335 Slovenia
bd@svt.com 13059264318 United States
South Korea
South Korea
+82-32-455-6114 South Korea
South Korea
206-550-5053 United States
busdev@sangamo.com United States
+32468145709 France
Australia
France
+81-6-6321-7000 Japan
info-skk-2@ml.skk-net.com Japan
United States
udayan@sauravchemicals.com +9198100412229 India
info@schrodinger.com +1 503 299 1150 United States
bd@sciclone.com +86 (0) 21 2319 3800 China
BD_NA@seacrosspharma.com 617-444-8774 United States
844-SEBELA1 United States
takeshi-horie@senju.co.jp +81-6-6201-9698 Japan
a.pignot@serb.eu +33 6 35 10 11 03 France
(617) 2033555 United States
France
jixiong.jiang@huaota.com China
China
China
sptrade@shinpoong.co.kr +82-2-2189-3497 South Korea
+81-6-6202-2161 Japan
info@sinergiumbiotech.com +54 (0) 11 32207300 Argentina

message@sinomab.com (852) 34269833 Hong Kong

yongmin.cho@sk.com South Korea
paulen.kim@sk.com +82-2-20082543 South Korea
South Korea
South Korea
888-772-7560 United States
melissa.wagner@sri.com 650-656-5482 United States
rajan.dubey@srslife.com +91-8871000001 Singapore
Germany
01 55 59 20 60 France
Japan
manoj.thombare@sunpharma.com +919930128320 India
uniorv@sunsho.co.jp 819065011584 Japan
general@sutrobio.com 650.392.8412 United States
info@sobi.com Sweden
wisam.alkhatib@tabukpharmaceuticals.com Saudi Arabia
taihooncology@gcihealth.com 609-750-5300 United States
satoshi-fukaya@taiho.co.jp +81-3-3294-4524 Japan
Japan
marissa.thomas@takeda.com +1 617-444-4424 United States
karim.sherif@tamergroup.com +966541840080 Saudi Arabia
ron.schlinger@taro.com +972-4-847-5358 Israel
corpcomms@tarsusrx.com United States
China
Japan
+81-879-25-2221 Japan

China
United States
peter.lay@teuto.com.br 5562981390631 Brazil
United States
info@theramex.com United Kingdom
tillotts@tillotts.com +41 799472175 Switzerland
+81-3-3245-5111 Japan
kevin.lin@transcenta.com 2132453115 United States
info@travere.com (760) 260-8600 United States
liz.zeng@trinomab.com +8613581878098 China
anelson@trispharma.com United States
United States
info@tty.com.tw +886-2-26525999 Taiwan
noriaki.iwase@ube.com 81-80-8230-2912 Japan
Belgium
info@ultragenyx.com 415-483-8800 United States
877-864-8437 United States
investors@valneva.com +33228073710 France
(617) 603-0070 United States
lalit.gaur@vetoquinol.com +1 (817)470-6374 United States
+1 724.514.1800 United States
+44 (0)20 8380 6200 United Kingdom
contact@virbac.com +33 4 92 08 71 00 France
China
info@wavelifesci.com (617) 949-2900 United States
bd@whanin.com +82-2-405-3050 South Korea
marketing@wiener-lab.com +5493414344700 Argentina
myasin@xencor.com 626-305-5900 United States
info@xenon-pharma.com 604-484-3300 (Main) Canada
ktsukerman@xerispharma.com 844.445.5704 United States
bd@xtalpi.com United States
bd@xtalpi.com United States
China
jianmin.chen@yifanyy.com United States
jinbo@yypharm.co.kr +82262027095 South Korea
South Korea
BD@zailaboratory.com +86 21 6163 2588 China
Switzerland
info@zealandpharma.com +45 88 77 36 00 Denmark
BD@zelgen.com China
lachezar.popov@zentiva.com (+420) 702231602 Czech Republic
03-3663-2351 Japan
info@zymeworks.com (604) 678-1388 Canada
 State City

Shanghai
Shanghai
Shanghai Shanghai Pudong New Area
Illinois Abbott Park
IL North Chicago
BC Vancouver
Suzhou
CA San Diego
London
São Paulo Guarulhos
São Paulo Guarulhos

Oxfordshire Abingdon
MAHARASHTRA Thane
London
Massachusetts Lexington
Massachusetts Cambridge
New York
Seoul
MA Cambridge

MA Boston
Bologna
Maryland Gaithersburg
Dublin 4
Beijing Beijing
NJ Morristown
Barcelona Barcelona
MA Cambridge
London
Reykjavik
New Jersey
CA Thousand Oaks
CA Thousand Oaks
CA Thousand Oaks
PA Philadelphia
NJ
Pennsylvania
Vienna
MA Waltham
Guangzhou
Ontario Toronto
São Paulo São Paulo
MA Waltham
Zwijnaarde-Gent

Oklahoma Oklahoma City

Tokyo
CA Livermore
Zhejiang Hangzhou
Shanghai Shanghai
Tokyo

CA South San Francisco

Karnataka Bangalore
New Jersey Edison
London
Radnor

GA Atlanta
Allschwil
New Jersey Bridgewater

MA Cambridge
London
Monaco
MA Boston
Zhejiang Hangzhou
Porto Porto
Massachusetts Cambridge
Gentilly
Massachusetts Waltham
Pontevedra-Galicia O Porriño

MA Cambridge
SP Sao Paulo
SP Sao Paulo
CA San Rafael
Mainz
Capital Federal

Guangdong Province Guangzhou

Zhuhai
São Paulo Taboão da Serra
São Paulo Cotia
MA Somerville
Massachussetts Cambridge
MA Cambridge
Jeju
Georgia Duluth

Seoul
Seoul
Jiangsu Suzhou
Jiangsu
NY NY
Beijing Beijing
Seoul Seoul
Gelderland Nijmegen
Lund

Mexico City Ciudad de México

Shanghai
London
New York
Incheon
Kiełpin
Istanbul Istanbul
Libourne Libourne
Gyeonggi-do Seongnam-si

Jiangsu Province Nanjing

Parma
Shenzhen
Seoul Seodaemun-gu
Tokyo Chuo-ku, Tokyo
New Jersey Warren
New York New York
Staffordshire Burton on Trent
Gyeonggi-do
CA Redwood City
California Redwood Shores
MA Stoughton

Basel
São Paulo Campinas, SP
Victoria Parkville (Melbourne)
New Jersey Princeton
NJ
Hod Hasharon
Baden-Württemberg Tuebingen
Massachusetts Marlborough
CA South San Francisco
Seoul
Seoul Seoul
Tokyo Tokyo
Vaud Lausanne
MA Waltham
California South San Francisco
California Seal Beach
NY New York
İstanbul

Milan
Dongdaemun-Gu Seoul
Seoul
Bielefeld
BW Freiburg im Breisgau
Tokyo Tokyo
Shanghai
MA Cambridge
Budapest
Tokyo
Massachusetts waltham
Indiana Indianapolis
MA Billerica
Maryland Gaithersburg
São Paulo Hortolândia
Ohio Cincinnati

MICHIGAN Ann Arbor

Barcelona
Seoul
New York New York
Massachusetts Lexington
CA Vista
Pennsylvania Philadelphia
NJ FLORHAM PARK
Oxford
Baar
Madrid Madrid
Province of Barcelona Barcelona
Saint Prex Saint-Prex
CA San Francisco
MA Cambridge
Shanghai
Shanghai Shanghai
NJ Princeton
California San Francisco
Tokyo Tokyo
Tokyo Minato-ku
Osaka
Styria
Buenos Aires
Massachusetts Cambridge
Mechelen
New Jersey BridgewaterTownship
Gyeonggi-do Yongin
Gyeonggi-do Yongin-si
Budapest
CA South San Francisco
MA Boston
Massachusetts Cambridge
Valby Copenhagen V
Shanghai Shanghai
New Jersey Piscataway
New Jersey Piscataway
CA Foster City
Bavaria Groebenzell

CA Emeryville
NRW Aachen
Middlesex
Guangdong Guangzhou
Hørsholm Hørsholm
California San Diego
Copenhagen - Valby
Pennsylvania Schwenksville
Shanghai SHANGHAI
New Jersey
MD Rockville
Seoul

Massachusetts Natick
Cantone Ticino Pazzallo Lugano
Shanghai
United Kingdom London
Tokyo Tokyo
Seoul
Gyeonggi-do Hwaseong-si
Zhejiang Hangzhou
Shanghai Shanghai
SÃO PAULO SÃO PAULO
SÃO PAULO SÃO PAULO
Seoul
Shanghai
New York New York
CA Mountain View
Seoul
Tuebingen
Oxfordshire Abingdon
DE Wilmington
Beijing
LONDON
PA Plymouth Meeting
New York New York
NJ BRIDGEWATER
Buenos Aires
Barcelona
MA Cambridge
New York New York
Île-de-France Boulogne-Billancourt
MA Boston
Cinisello Balsamo (Milano)
Québec Boucherville
Tokyo
Dublin
Ashiya, Hyogo
Seoul
Jiangsu
New Jersey Princeton
New Brunswick
Tokyo Tokyo
New Jersey Bedminster
Shanghai Shanghai
Gyeonggi-do Gwacheon-si
Tokyo
Rehovot
MA Newton
New Jersey Piscataway, New Jersey
Sichuan Chengdu

Suzhou
Nagano Prefecture Matsumoto City
Kumamoto pref. Kumamoto
Québec Montreal
Gangseo-gu Seoul
Gyeonggi Gwacheon
Tokyo
Seoul
Seoul
Tokyo Tokyo
Tokyo
Tokyo
Buenos Aires Ciudad Autónoma de Buenos Aires
Ciudad de Panama
Madrid
Mexico City México City
Jalisco Guadalajara
Renca - Santiago de Chile
México DF México

New Jersey Piscataway

NJ
Shanghai
Seoul
London

Ohio Wickliffe
NJ Somerset
Shanghai Shanghai
MD Rockville
PA Conshohocken
Maharashtra Navi Mumbai
CT Danbury
São Paulo São Paulo
Osaka
Osaka
EU Ljubljana
Tokyo Tokyo
New York New York

NJ Rahway
NJ Madison
Frankfurt
CA Emeryville
California Foster City

Tokyo
Petach-Tikva
Lombardy Milan
Barcelona
CA San Diego

Dubai Dubai
Maryland Bethesda
Tokyo Chiyoda-ku
Tokyo Chiyoda-ku
Tokyo
Osaka Ibaraki
Tokyo Tokyo
New York New York
Hoofddorp

Basel
Basel
MD Gaithersburg
Florida Miami
Copenhagen
St. Helier, Jersey Isle
California San Francisco
Tokyo Tokyo
Cambridge
Meyrin (Geneva)
New Jersey Jersey City
Espoo
Tokyo
Tokushima Naruto
Bavaria Gräfelfing

Kanagawa Kawasaki
Holbaek
Taipei
Taipei
Madrid
Essex Basildon
California Costa Mesa
Athens
ZH Leiden
Boulogne-Billancourt
Vienna
Gdańsk
California San Diego
NJ Hackensack
New Jersey South Plainfield
CT Stamford
Massachusetts Boston
 Jerusalem
California San Diego
Lombardy Milano
Utah Salt Lake City
NY Tarrytown
MD Rockville
MA Cambridge
California San Francisco
MA Waltham

NY New York
NY New York
Leeds
Krakow
EU Ljubljana
Florida Miami
Seoul
Seoul
Incheon

WA Seattle
CA Brisbane
Paris

France Lyon
Osaka
Aichi Nagoya
Massachusetts Cambridge
New Delhi New Delhi
NY New York
Shanghai Shanghai
MA Cambridge
GA Roswell
Osaka Osaka
Paris
MA - Massachusetts Cambridge
France SURESNES
Shanghai
Shanghai SHANGHAI

- Seoul
Osaka Osaka
Buenos Aires Garin

Hong Kong
 Seongnam-si
Gyeonggi-do Seongnam-si
SeongNam-si
Gyeonggi-do Sungnam-si
Pennsylvania Philadelphia
CA Menlo Park
Singapore Singapore
Hessen Bad Vilbel
Antony
Tokyo Tokyo
Maharashtra Mumbai
Tokyo
CA South San Francisco
Stockholm
Riyadh
NJ Princeton
Tokyo
Tokyo
Massachusetts Cambridge
Jeddah
Haifa
CA Irvine
Tianjin Tianjin
Tokyo
Kagawa Higashikagawa

Shanghai shanghai
MA Somerville

London
Rheinfelden
Kanagawa Kamakura
NJ Princeton
San Diego San Diego
Guangdong Zhuhai
NJ Monmouth Junction

Taipei City
Yamaguchi

California Novato
MD and NC Silver Spring, MD and Research Triangle Park, NC
SAINT HERBLAIN
Massachusetts Boston
TX Fort Worth
Pennsylvania Canonsburg
Brentford, Middlesex
Carros Cedex
Wuhan
MA Cambridge
SEOUL Seoul
Santa Fe Rosario
California Pasadena
British Columbia Burnaby
Illinois Chicago
MA Cambridge
MA Cambridge
Beijing

Seoul
Seoul
Shanghai Shanghai

Soeborg
Jiangsu Kunshan
Prague
Tokyo
BC Vancouver
 Street address Postal code

No. 399 Libing Road 201203

No. 399 Libing Road 201203
Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park 201203
100 Abbott Park Road 60064
1 North Waukegan Rd 60064
2215 Yukon Street V5Y 0A1

12830 El Camino Real, Suite 400 92130

319 Sage House, Pinner Road, North Harrow,UK HA1 4HF
Rodovia Presidente Dutra, Km 222 07034904
Rodovia Presidente Dutra, Km 222 07034904

60 Jubilee Ave, Milton Park OX14 4RX

5th Floor, Sun Magnetica, Louiswadi, LIC Service Road, 400604
Thane - West
Dashwood House, 69 Old Broad Street, 2nd Floor EC2M 1QS
3 Forbes Road 02421-7305
88 Sidney Street 02139-4169
142 W 57TH ST 10018
600 Gyeongin-ro, Guro-gu, Aju Building 6F 08213
245 First Street, Suite 1400 02142

121 Seaport Blvd 02210

Connaught House, 1 Burlington Road D04 C5Y6

Building No. 13, VPark, Yizhuang Economic And 100176
Technological Development Zone
44 Whippany Road 07960
General MItre, 151 08022
300 Third St 02142
3rd Floor, Kings House, 174 Hammersmith Rd,
Hammersmith,
Saemundargata London
15-19 W6 7JP, United Kingdom 101

1 Amgen Center Dr. 91320

1 Amgen Center Dr. 91320
1 Amgen Center Dr. 91320
3675 Market Street 19104

3805 Old Easton Rd #2200

Leopold-Ungar-Platz 2 1190
100 Fifth Avenue, 3rd Floor 02451
17F, Yunrun Building, No 27 Huanyu Road, Huangpu 510320
District
400 Fifth Avenue, Suite 210 02451
Industriepark 7 9052
Wallenroderstr. 8-10
840 Research Parkway, Ste. 546 73104
1-1-2 Yurakucho, Chiyoda-ku 100-0006

12F, Building D, 198 Qidi Road, HIPARK, Xiaoshan 311200

District,
BuildingHangzhou, Zhejiang
56 1000 Jinhai Road,Province, PRC
City of the Elite, Pudong 201206
2-5-1, Shibaura, Minato-ku 1088532

611 Gateway Blvd, Suite 900 94080

39-40, KIADB Industrial Area, Phase II, Electronic City 560100
Hosur Road, Ave,Edison, NJ 08837
18 Mayfield 08837

100 Matsonford Road 19087

6 Concourse Pkwy 30328

Hegenheimermattweg 167b 4123

55 Cambridge Parkway, Suite 700W 02142

4-8 Maple Street W1T 5HD
Le Concorde, 11 rue du Gabian 98000
2 Seaport Lane, Suite 9A 02210
No. 355 Xingzhong Road Linping Economic and 311100
Technological Development
À Av. da Siderurgia NacionalArea 4745-457 Coronado (S. Romão e S. Mamede)
35 Cambridge Park Dr 02140
22, rue des Aqueducs 94250
300 Third Ave 02451
A Relva s/n 36400

225 Binney Street 02142

Av Faria Lima 4509 14º floor 04538133
Av Faria Lima 4509 14º floor 04538133
770 Lindaro Street 94901
An der Goldgrube 12 65131
Terrada 1270 1416

Building A6-5fl, 11 Kai-Yuan Blvd, Science City 510530

Rua Joaquim Faustino de Camargo, 201 06767-385

Rodovia Raposo Tavares Km 30,5 Nr 2833, Barro Branco, 06705030
Cotia,
455 Grand Union Blvd 02145
45 Sidney Street 02139
238 Main Street 02142
11 Cheomdan-7-Gil, Jeju-do
3239 Satellite Blvd 30096

136, Changgyeonggung-ro, Jongro-gu 03127

Boryung Bldg., 136, Changgyeonggung-ro, Jongno-gu 03127
215123 Building C25-C28, No. 218, Xinghu Road

345 Park Ave 10154

Room8406,Yongchang No.8, Hongda Industrial Park Ho
7, Sangdo-ro, Dongjak-gu 06955
Microweg 22 6545 CM
Ideon Science Park SE-22370

Nicolás San Juan 1046, Colonia del Valle 03100

388 Yindu Road, Building B, Xuhui District 200231
12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond SE1 9RT
430 East 29th Street 10016
20, Academy-ro 51, Yeonsu-gu 22014
Ogrodowa 2A St. 05-092
Maslak Mah. Eski, Büyükdere Cad. No:1 İç Kapı No:16 34485
Maslak, Sarıyer
ZI La Ballastiere 33500
335 Pangyo-ro, Bundang-gu 13488

1099 Fuying Rd, Jiangning District, 211100

8, Chungjeong-ro 03742
1-1 Nihonbashi- Muromachi 2-Chome 103-8324

150 Greenwich Street 10007

Picairn House, Crown Square, First Avenue DE14 2WW
CHA Bio Complex, 335 Pangyo-ro, Bundang-gu 13488
200 Penobscot Dr 94063
333 Twin Dolphin Dr #600 94065
100 Technology Center Drive 02072

45 Poplar Road 3052

302 Carnegie Center Blvd 08540

Haharash 4 4524075
Friedrich-Miescher-Str. 15 72076
100 Results Way 01752
350 Oyster Point Boulevard 94080

12, Bongeunsa-ro 114-gil, Gangnam-gu 06170

3-5-1 Nihonbashi Honcho, Chuo-ku 103-8426
Forum "Après-demain", Chemin Messidor 5-7 1006
200 Smith Street 02451
161 Oyster Point Blvd 94080
1700 Saturn Way
1 Columbus Circle 10019
Halkalı Merkez Mah. Basın Ekspres Cad. No:1 34303
Kucukcekmece
Via Santa Lucia, 6 20122
64, Cheonho-Daero 02587
24, Namdaemun-ro 9-gil, Jung-gu, Seoul, Republic of Korea 04522
Sudbrackstrasse 56 33611
Leineweberstr. 5 79108
2-1-1, Irifune, chuo-ku 104-0042
Unit 122-129, Building A3, No. 700 Wan Rong Road 200072
11 Hurley St. 02141
30-38 Keresztúri út 1106
4-6-10 Koishikawa, Bunkyo-ku 1128088
200 smith street 02451
Lilly Corporate Center 46285
45 A Middlesex Turnpike 01821
300 Professional Drive 20879
Rod Jornalista Francisco A. Proença, Km 08 13186-901
2863 E Sharon Rd 45241
34340
3891 Ranchero Drive 48108
Passeig de la Zona Franca 109 08038
8F Seongdo Building, 207 Dosan-daero, Sinsa-dong,
Gangnam-gu
55 East 52nd Street 10055

1261 Liberty Way 92081

07932
The Schrödinger Building, Oxford Science Park OX4 4GE
Bahnhof-Park 4 6340
Parque Empresarial Cristalia Edif 2 - 2º Izquierda. C/ Vía de 28033
los Poblados
Avda. Diagonal, 549 08029
Chemin de la Vergognausaz 50 1162
409 Illinois Street 94158
55 Cambridge Parkway, Suite 800E 02142

Yishan Road 1289

104 Carnegie Center Drive 08540
1700 Owens St, Suite 515 94158
5-7 Sanbancho, Chiyoda-ku 102-0075
7-3, Akasaka 9-chome 107-0052
2-3-11, Morinomiya, Joto-ku, Osaka 536-8523
Schlossplatz 1
Darwin 429 C1414CUI
1 Broadway, Kendall Square 02141
Generaal De Wittelaan L11 A3 2800
Gan & Lee Pharmaceuticals, USA Corp 520 US Highway 22 08807
East, Suite 302 Bridgewater,
107, Ihyeon-ro, 30 beon-gil, Giheung-gu 16924
93, Ihyeon-ro 30beon-gil, Giheunggu 16924
Gyömrői út 19-21. H-1103

245 First Street Suite 1800 02142

Carl Jacobsens Vej 30 2500
200000
860 Centennial Ave 08854
860 Centennial Avenue 08854
333 Lakeside Drive 94404
Industriestr . 31 82194

5858 Horton Street, Suite 210 94608

Zieglerstr. 6 52078
980 Great West Road, Brentford TW8 9GS
Room 501, Building D, No. 288 Shenzhou Road, Huangpu
District
Hørsholm Kongevej 11B 2970
12770 High Bluff Drive, Suite 150 92130
Ottiliavej 9 DK 2500
1258 Winter lane
No 838 ZHANGYANG RD 200135

1 Church Street Suite 103 20850

132 Teheran-ro, Gangnam-gu 06235

22 Strathmore Rd, Suite 355, Natick, MA 01760, USA 01760

Via Pian Scairolo 9
Xuhui District, Yizhou Road, #188 200233
1 New Burlington Place W1S 2HR
Marunouchi 2-4-1, Chiyoda-ku 100-6330
100 Eulji-ro, Jung-gu 04551
808, 51-9, Dongtancheomdansaneop 1-ro 18469
No.866 Moganshan Road, Hangzhou 310011
917 Halei Road, Zhangjiang Hi-Tech Park 201203
Av. Magalhães de Castro, 4800 - Continental Tower - 24th 05676-120
floor
Av. Magalhães de Castro, 4800 - Continental Tower - 24th 05676-120
floor
135 Bongeunsa-ro, Gangnam-gu 06121

2 Baumoe-ro 27-gil Seocho-gu 06752

Paul-Ehrlich-Strasse 15
92 Park Drive, Milton Park OX14 4RY
1801 Augustine Cut-Off 19803

Registered Address 1 Vine Street W1J 0AH

660 West Germantown Pike, Suite 110 19462

700 US 206 08807-3365

Paraguay 1535 C1061ABC

40 Erie St, Suite 130 02139

430 East 29th Street, New York, NY 10016
65 Quai Georges Gorse 92100
100 Summer Street (Suite 2300) 02110
Via dei Lavoratori, 54 20092
1310 rue Nobel J4B 5H3
15F Tamachi Station TowerN, 3-1-1 Shibaura, Minato-ku 108-0023
Waterloo Exchange, Waterloo Road, 4
3-19 Kasuga-cho 659-0021
343, Sapyeong-daero, Seocho-gu 06543
No. 6 Wenrui Rd., Qixia District, Nanjing
400 Alexander Park Rd 08540

3-4-1, Nihonbashi-honcho, Chuo-ku 103-0023

1430 US Highway 206, Suite 110 07921

38, Gwacheon-daero 7-gil, 13840

2-28-8, Honkomagome, Bunkyo-ku 113-8650
Holzman St, Science Park, P.O Box 4081 7670402
85 Wells Ave, 2nd Floor 02459
20 New England Ave. 08854
No.36 West Baihua Road, Qingyang District 610000
Building D2, No.18 Bio-Town Middle Road, Chengdu
Tianfu
SongbeiInternational
Road No. 20,Bio-Town, ShuangliuPark
Suzhou Industrial District, Chengdu,
Sichuan, PRC
19-48, Yoshino 399-8710
1-6-1 Okubo, Kita-ku, 860-8568
3400 De Maisonneuve West, Suite 1055 H3Z3B8
Kolon One&Only Tower, 110 Magokdong-ro 07793
11 Kolon-ro 13837
4-14, Nihonbashi-honcho 3-chome, Chuo-ku 103-8433
14, jungdong-gil, Joong-Gu, Seoul, Korea 04516
85, Seochojungang-ro, Seocbo-gu 06650
1-3-7, Otemachi, Chiyoda-ku 100-0004
1-6-5 Kudanminami, Chiyoda-ku 102-0074
Otemachi Financial City, Grand Cube, 1-9-2 Otemachi, 1000004
Chiyoda-ku
Bdo. de Irigoyen 248 1072
Torre BICSA - Piso 62
Julian Camarillo 35 28037
Adolfo López Mateos 68 05000
Avenida España #1840, Colonia Moderna 44190
Avda. Presidente Eduardo Frei Montalva 4600 8640002
Paseo de las Palmas 3er piso, Lomas de Chapultepec V 11000
seccion
10 Knightsbridge Road 08854

LG Science Park, 70, Magokjungang 10-ro, Gangseo-gu 07795

7-12 Tavistock Square 7th Floor WC1H 9LT
LB16105, Jebel Ali Free Zone, Dubai, UAE
29400 Lakeland Blvd 44092
400 Campus Drive 08873
No. 576 Libing Road, Pudong District 201210
9704 Medical Center Drive 20850

Mumbai 400706
1 Casper Street 06810

1-5-21 Nakatsu, Kita-ku 5310071

2-4-2 Imazu-Naka, Tsurumi-ku 538-0042
Brnčičeva 1 1000
2-4-16, Kyobashi, Chuo-ku 104-8002
430 E. 29th Street, 14th Floor 10016

126 East Lincoln Avenue 07065

2 Giralda Farms 07940

5959 Horton St, 7th Floor 94608

950 Tower Lane, Suite 1050 94404

7, Yotsuya 1-chome, Shinjuku-ku 160-8515

6 Hashiloach St. 49170
Via S. G. Cottolengo 15 20143
Avinguda de Barcelona 69, Sant Joan Despi 08970
12780 El Camino Real 92130

Dubai Science Park

6701 Rockledge Dr. 20852
2-2-3, Iwamoto-cho 101-0032
1-1, Marunouchi 2-chome 100-0005
5-1, Nihonbashi 2-chome, Chuo-ku 103-6119
1-1-2 Shimohozumi 567-8680
1-17-24 Shinkawa Chuo-ku 103-0033
309 West 49th Street, 16th floor 10019
Siriusdreef 41 2132 WT

21 Firstfield Road 20878

11960 SW 144th Street 33186
Novo Allé DK 2880
Le Masurier House, La Rue Le Masurier St. Helier JE2 4YE JE2 4YE
1700 Owens Street, Suite 205 94158

Steinmetz Building, Granta Park Great Abington CB2 6GP

Rue du Bois-du-Lan 22 1217
30 Hudson St 07302
P.O. Box 65 02101
2-16-4 Konan, Minato-ku 108-8242
115 Kuguhara, Tateiwa, Muya-cho 772-8601
Lochhamer Schlag 21 82166

3-25-23 Tonomachi, Kawasaki ku 210-0821

Roervangsvej 30 4300
13F, No. 3, Park St, Nangang District , Taipei 115, Taiwan 115
13F, No. 3, Park St, Nangang District , Taipei 115, Taiwan 115
Avda de los Reyes, 1, Colmenar Viejo 28770
Sovereign House, Miles Gray Road SS14 3FR
555 Anton Blvd Suite 213 92626

Darwinweg 24 2333CR
33 avenue Emile Zola 92100

Trzy Lipy 3 80-172

9390 Towne Centre Drive, Suite 200 92121
2 University Plaza Dr. Suit 100 07601
100 Corporate Court 07080
201 Tresser Blvd. 06901
22 Boston Wharf Rd
Shlomo Halevi 5 9777019
11080 Roselle St 92121
1, Via Civitali 20148
41 S. Rio Grande St. 84101

9804 Medical Center Drive 20850

02142
650 Gateway Dr, #100 94080
940 Winter Street 02451

Empire State Building, 350 Fifth Avenue, Suite 7530 10118

151 W 42nd Street, 15th floor 10018
Rosemont House, Yorkdale Industrial Park, Braithwaite LS11 9XE
Street
Sternbacha 2 30394
Litostrojska 46 A 1000
201 South Biscayne Blvd - Suite 2810 - 28th floor 33132
155 Hyoryeong-ro, Seocho-gu 06666
90, Magokjungang 10-ro, Gangseo-gu 07794
107,Cheomdan-daero,Yeonsu-gu

188 E. Blaine St 98102

501 Canal Blvd 94005

2, Avenue Pont Pasteur F-69367 Lyon cedex 07

4-20, Ofukacho, Kita-ku 530-8552
35 HIGASHISOTOBORI-CHO, HIGASHI-KU, NAGOYA, 461-8631
AICHI
Saurav Chemicals Ltd. DSM 445, DLF Towers, Shivaji 110015
Marg, New Delhi24th
1540 Broadway - 110015
Floor 10036
22/F, Central Plaza, 381 Middle Huaihai Road, 200000
245 First Street 02142
645 Hembree Parkway, Suite I 30076
3-1-9, Kawara-machi, Chuo-ku 541-0048
40 avenue George V 75008
200 Sidney Street 02139
50 rue Carnot 92150
538 Cailun Road, Zhangjiang High Tech Park, Pudong New 201203
District

161 Yeoksam-ro, Gangnam-gu 06246

1-8, Doshomachi 3-chome, Chuo-ku 541-0045
Ruta Panamericana 38.7Km 1619

Unit 305-307, 15W, Hong Kong Science & Technology

Park, Shatin
221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do 13494
ECO Hub 332, Pangyo-ro, Bundang-gu 13493
310, Pangyo-ro, Bundang-gu 13494
310 Pangyo-ro, Bundang-gu 13494
3737 Market St., Suite 1300 19104
333 Ravenswood Ave. 94025
71, Robinson Road 068895
Stadastraße 2-18 61118
6 rue Alexis de Tocqueville 92160
13-1, Kyobashi 1-Chome, Chuo-ku 104-8356
Sun House, Plot No 201/B-2, Wester Express Highway, 400063
Goregaon East, Mumbai
111 Oyster Point Blvd 94080

101 Carnegie Center, Suite 101 08540

1-27, kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444 Japan
3-24-1, Takada, Toshima-ku 170-8633
40 Landsdowne St. 02139

14 Hakitor street 26110

15440 Laguna Canyon Road, Ste 160 92618

Kasumigaseki Common Gate West Tower, 2-1, 100-8585

Kasumigaseki 3-chome, Chiyoda-ku
567 Sanbonmatsu 769-2695

6th Floor, Building B, Honghui International Plaza, 1602

Zhongshan West Road, Xuhui District, Shanghai
101 South Street 02143

50 Broadway, 5th Floor, London SW1H 0BL

Baslerstrasse 15 4310
Kamakura Tebiro 6-10-1 248-8555
100 Overlook Center, #2-2166 08540
3611 Valley Centre Drive, Suite 300 92130
2F, Building 6C, Zhizao Street, Hongqi Town, Jinwan 519000
District,
2033, UsZhuhai, Guangdong
Hwy 130, 08852

3F., No.3-1, Park St., Nangang Dist. 11503

1978-5, Kogushi, Ube 755-8633

60 Leveroni Court 94949

6 rue Alain Bombard 44800

201 Brookline Ave. 02215
4250 N. Sylvania Ave 76137
1000 Mylan Blvd. 15317
980 Great West Road TW8 9GS
13E RUE LID - BP27 06511
Building B3-4, Optics Valley Biological City, Wuhan East
Lake NationalAve
733 Concord High-tech Zone 02138
8~11F, Whanin Bldg., 11, Beobwon-ro 6-gil, Songpa-gu, 05855
Seoul, Korea
Riobamba 2944 2000
465 N. Halstead St. Ste. 200 91107
3650 Gilmore Way V5G 4W8
1375 W Fulton St, Suite 1300 60607
245 Main St, 2nd Floor 02142
245 Main St, 2nd Floor 02142

93, Hyoryoung ro, Seocho gu 137-843

74, Noryangjin-ro, Daebang-dong, Dongjak-gu 06927
4560 Jinke Rd, Bldg. 1, 4/F, Pudong 201210

Sydmarken 2860

U Kabelovny 130 102 37 Prague 10

10-11, Nihonbashi Kobuna-cho, Chuo-ku 103-8351
114 East 4th Avenue, Suite 800 V5T1G4
 Created date/time Last updated date/time

04/26/2024 6:45 PM 05/06/2024 7:44 AM

05/14/2024 8:21 PM 05/14/2024 8:21 PM
03/06/2024 6:12 PM 03/28/2024 11:59 AM
03/20/2024 6:59 PM 05/01/2024 7:59 PM
02/21/2024 11:12 PM 05/11/2024 10:05 AM
03/12/2024 12:42 AM 03/29/2024 12:18 AM
03/04/2024 8:36 PM 05/18/2024 1:54 PM
02/21/2024 11:26 PM 05/08/2024 3:06 AM
02/21/2024 11:28 PM 05/08/2024 12:11 PM
05/03/2024 9:32 PM 05/09/2024 8:09 PM
03/22/2024 6:19 PM 05/23/2024 2:11 AM
05/09/2024 9:59 PM 05/22/2024 2:36 AM
03/05/2024 6:49 PM 03/05/2024 6:49 PM
04/13/2024 3:01 AM 05/30/2024 3:35 PM
02/23/2024 1:08 AM 04/26/2024 7:13 PM
05/20/2024 11:45 PM 05/23/2024 11:14 PM
02/27/2024 11:16 PM 03/29/2024 10:08 PM
03/07/2024 2:34 AM 03/07/2024 2:34 AM
02/27/2024 11:18 PM 05/30/2024 11:52 AM
04/25/2024 10:21 PM 05/01/2024 7:21 PM
05/23/2024 4:39 PM 05/23/2024 7:59 PM
04/02/2024 1:08 AM 05/03/2024 10:11 PM
03/25/2024 11:51 PM 05/30/2024 6:46 PM
02/29/2024 8:59 PM 04/08/2024 10:09 PM
02/29/2024 8:31 PM 04/16/2024 7:38 PM
04/24/2024 6:58 PM 05/06/2024 10:40 PM
03/02/2024 1:00 AM 03/02/2024 1:00 AM
03/06/2024 6:13 PM 04/30/2024 12:01 AM
03/06/2024 2:24 AM 03/06/2024 2:24 AM
05/09/2024 4:55 PM 05/09/2024 4:55 PM
03/07/2024 7:14 PM 03/07/2024 7:14 PM
03/12/2024 1:29 AM 04/24/2024 7:42 PM
03/20/2024 7:11 PM 03/20/2024 7:11 PM
03/19/2024 7:07 PM 03/19/2024 7:07 PM
03/19/2024 7:06 PM 05/29/2024 8:29 PM
02/29/2024 8:36 PM 02/29/2024 8:36 PM
03/08/2024 1:11 AM 05/16/2024 10:34 PM
02/27/2024 6:55 PM 04/29/2024 2:09 PM
05/08/2024 9:36 PM 05/08/2024 9:36 PM
04/05/2024 11:03 PM 04/05/2024 11:03 PM
04/25/2024 6:21 PM 05/15/2024 11:20 AM
02/27/2024 6:56 PM 02/27/2024 6:56 PM
03/25/2024 9:26 PM 05/08/2024 9:33 PM
03/08/2024 2:01 AM 05/01/2024 1:27 AM
05/15/2024 2:12 AM 05/20/2024 8:23 PM
02/23/2024 1:19 AM 03/26/2024 1:59 AM
02/29/2024 9:10 PM 04/17/2024 6:48 PM
05/31/2024 7:30 PM 05/31/2024 7:30 PM
02/23/2024 1:20 AM 05/13/2024 6:54 PM
05/13/2024 11:53 PM 05/15/2024 2:18 AM
02/27/2024 6:59 PM 04/30/2024 10:58 PM
04/05/2024 11:04 PM 04/10/2024 11:08 PM
02/29/2024 9:15 PM 05/21/2024 2:22 PM
02/27/2024 7:01 PM 04/28/2024 1:22 AM
02/27/2024 7:01 PM 02/27/2024 7:01 PM
02/29/2024 9:22 PM 04/10/2024 3:22 PM
03/11/2024 11:39 PM 04/17/2024 9:06 AM
02/27/2024 7:02 PM 04/26/2024 4:24 PM
05/29/2024 2:30 AM 05/29/2024 2:32 AM
03/25/2024 8:12 PM 03/28/2024 2:36 AM
03/02/2024 12:22 AM 04/01/2024 8:23 PM
03/04/2024 6:15 PM 03/04/2024 6:15 PM
02/23/2024 2:58 AM 05/17/2024 11:19 PM
05/03/2024 8:01 PM 05/10/2024 2:55 AM
03/02/2024 12:23 AM 03/02/2024 12:23 AM
04/25/2024 11:29 PM 05/30/2024 11:59 PM
03/08/2024 2:09 AM 04/12/2024 1:42 PM
05/02/2024 9:38 PM 05/17/2024 2:06 AM
04/24/2024 7:00 PM 04/25/2024 2:11 PM
02/23/2024 3:06 AM 04/10/2024 7:35 PM
03/04/2024 7:28 PM 04/12/2024 6:25 PM
03/06/2024 6:41 PM 04/30/2024 2:27 PM
03/02/2024 1:25 AM 05/03/2024 6:32 PM
05/09/2024 10:30 PM 05/14/2024 1:42 PM
03/04/2024 6:14 PM 03/04/2024 6:14 PM
02/23/2024 1:59 AM 02/23/2024 1:59 AM
04/12/2024 7:04 PM 04/18/2024 10:28 PM
03/07/2024 8:03 PM 05/27/2024 6:32 PM
05/04/2024 2:31 AM 05/08/2024 12:07 AM
02/23/2024 1:26 AM 05/29/2024 9:27 PM
05/09/2024 11:03 PM 05/09/2024 11:03 PM
03/02/2024 1:32 AM 04/15/2024 12:26 PM
04/24/2024 11:08 PM 05/22/2024 1:38 AM
03/02/2024 1:41 AM 05/24/2024 10:50 AM
04/24/2024 7:20 PM 05/09/2024 1:34 PM
05/21/2024 7:33 PM 05/21/2024 7:33 PM
02/23/2024 3:14 AM 02/23/2024 3:14 AM
05/01/2024 9:30 PM 05/01/2024 9:30 PM
04/04/2024 8:25 PM 05/21/2024 6:16 PM
04/11/2024 10:34 PM 04/19/2024 12:11 PM
03/11/2024 9:28 PM 03/11/2024 9:28 PM
03/11/2024 9:28 PM 05/16/2024 7:58 PM
03/04/2024 7:13 PM 04/02/2024 6:25 AM
04/18/2024 1:50 AM 05/24/2024 8:03 AM
04/26/2024 6:14 PM 05/14/2024 9:09 AM
05/22/2024 7:14 PM 05/23/2024 7:46 AM
03/13/2024 11:28 PM 03/13/2024 11:28 PM
05/07/2024 3:45 PM 05/09/2024 8:51 AM
03/07/2024 7:41 PM 05/14/2024 1:55 PM
04/16/2024 9:52 PM 05/07/2024 7:05 PM
02/23/2024 3:28 AM 05/28/2024 4:08 PM
04/02/2024 8:40 PM 04/19/2024 9:19 AM
02/27/2024 7:03 PM 02/27/2024 7:03 PM
03/06/2024 2:18 AM 05/10/2024 8:22 AM
03/01/2024 1:17 AM 05/13/2024 6:17 PM
03/01/2024 1:18 AM 04/03/2024 2:58 PM
04/01/2024 11:08 PM 05/02/2024 11:04 AM
04/12/2024 7:29 PM 04/30/2024 6:14 AM
03/01/2024 10:08 PM 03/29/2024 7:20 PM
03/01/2024 10:12 PM 03/01/2024 10:12 PM
04/15/2024 8:22 PM 04/22/2024 1:05 PM
05/04/2024 2:17 AM 05/04/2024 2:17 AM
03/06/2024 3:34 AM 04/29/2024 6:40 PM
03/01/2024 10:26 PM 05/03/2024 8:32 AM
03/08/2024 6:32 PM 05/07/2024 9:01 AM
05/03/2024 8:06 PM 05/14/2024 11:57 AM
03/01/2024 12:50 AM 04/23/2024 9:27 AM
03/01/2024 12:49 AM 05/23/2024 3:54 AM
05/18/2024 2:02 AM 05/18/2024 2:33 AM
04/15/2024 8:43 PM 05/15/2024 1:00 PM
03/07/2024 7:56 PM 05/02/2024 11:01 AM
03/26/2024 5:48 AM 05/22/2024 8:47 PM
04/05/2024 7:00 PM 04/25/2024 1:28 AM
03/22/2024 11:10 PM 04/02/2024 11:49 PM
03/20/2024 11:41 PM 04/18/2024 10:26 PM
04/06/2024 2:38 AM 04/06/2024 2:38 AM
04/25/2024 12:20 AM 05/07/2024 12:38 AM
03/01/2024 12:49 AM 05/13/2024 6:24 AM
03/25/2024 8:14 PM 05/10/2024 7:12 PM
03/06/2024 6:48 PM 04/26/2024 8:22 PM
03/06/2024 8:02 PM 04/21/2024 4:18 PM
03/01/2024 11:20 PM 05/13/2024 5:35 PM
03/18/2024 5:33 PM 03/18/2024 5:33 PM
03/07/2024 8:24 PM 05/15/2024 4:57 AM
03/01/2024 11:41 PM 05/01/2024 6:19 PM
02/23/2024 12:56 AM 04/15/2024 8:09 AM
03/30/2024 1:55 AM 06/02/2024 10:26 AM
03/01/2024 9:04 PM 04/23/2024 6:55 PM
03/27/2024 10:38 PM 04/12/2024 8:19 PM
05/06/2024 11:03 PM 05/06/2024 11:03 PM
03/25/2024 8:44 PM 05/09/2024 8:10 PM
03/01/2024 9:16 PM 05/01/2024 8:24 PM
04/26/2024 7:49 PM 05/02/2024 7:11 PM
04/22/2024 11:39 PM 04/23/2024 1:53 PM
04/10/2024 9:20 PM 04/22/2024 6:06 PM
02/23/2024 12:57 AM 05/02/2024 11:51 AM
04/11/2024 10:10 PM 05/02/2024 10:43 AM
03/06/2024 7:36 PM 04/05/2024 5:59 PM
02/23/2024 1:03 AM 05/02/2024 2:02 PM
03/01/2024 7:17 PM 03/27/2024 3:50 PM
04/15/2024 8:47 PM 05/20/2024 2:49 PM
04/10/2024 1:00 AM 04/10/2024 1:00 AM
03/01/2024 7:18 PM 04/29/2024 9:11 PM
03/01/2024 7:20 PM 03/26/2024 2:50 AM
05/01/2024 7:08 PM 05/01/2024 7:08 PM
03/23/2024 1:17 AM 05/07/2024 9:58 PM
03/05/2024 10:58 PM 05/08/2024 11:03 PM
05/31/2024 8:20 PM 05/31/2024 8:54 PM
05/02/2024 8:06 PM 05/02/2024 8:06 PM
05/02/2024 11:24 PM 05/11/2024 1:28 AM
05/11/2024 1:07 AM 05/11/2024 1:07 AM
03/28/2024 10:04 PM 05/02/2024 2:37 AM
03/07/2024 8:30 PM 03/07/2024 8:30 PM
05/02/2024 11:05 PM 05/23/2024 10:51 AM
03/01/2024 8:08 PM 03/01/2024 8:08 PM
03/06/2024 2:12 AM 05/28/2024 6:38 AM
05/04/2024 2:32 AM 05/14/2024 3:59 AM
04/08/2024 8:06 PM 04/26/2024 10:51 PM
03/25/2024 7:22 PM 03/25/2024 7:22 PM
03/01/2024 8:15 PM 05/11/2024 4:26 AM
05/09/2024 7:34 PM 05/16/2024 12:37 PM
03/07/2024 9:04 PM 03/07/2024 9:04 PM
03/06/2024 10:20 PM 05/10/2024 7:00 PM
03/01/2024 12:59 AM 03/01/2024 12:59 AM
04/16/2024 1:47 AM 05/16/2024 11:13 PM
03/07/2024 3:06 AM 04/27/2024 8:37 AM
04/08/2024 8:07 PM 05/09/2024 11:40 AM
05/02/2024 6:58 PM 05/12/2024 12:17 PM
03/05/2024 11:55 PM 04/11/2024 9:38 PM
03/04/2024 6:39 PM 03/04/2024 6:39 PM
05/05/2024 1:44 AM 05/20/2024 7:33 AM
04/29/2024 9:26 PM 05/14/2024 2:46 AM
03/01/2024 8:30 PM 03/27/2024 1:28 PM
04/29/2024 8:42 PM 05/02/2024 2:21 PM
05/13/2024 7:34 PM 05/15/2024 5:32 PM
03/01/2024 11:43 PM 06/02/2024 4:22 AM
04/22/2024 10:11 PM 04/30/2024 6:49 PM
04/25/2024 1:04 AM 05/10/2024 2:16 PM
03/01/2024 11:45 PM 05/22/2024 6:51 AM
03/15/2024 8:25 PM 05/09/2024 6:34 PM
03/01/2024 11:21 PM 03/01/2024 11:21 PM
04/11/2024 12:20 AM 04/22/2024 11:04 PM
04/12/2024 9:40 PM 04/22/2024 11:24 PM
03/01/2024 10:15 PM 05/21/2024 1:32 AM
03/01/2024 11:29 PM 04/15/2024 7:06 PM
03/05/2024 6:35 PM 04/06/2024 12:05 PM
03/07/2024 9:12 PM 03/07/2024 9:12 PM
04/11/2024 10:11 PM 04/11/2024 10:11 PM
04/10/2024 11:51 PM 04/11/2024 3:33 AM
03/05/2024 10:59 PM 04/30/2024 7:35 PM
05/13/2024 1:39 PM 05/14/2024 1:36 PM
05/01/2024 11:24 PM 05/01/2024 11:24 PM
03/02/2024 12:18 AM 03/02/2024 12:18 AM
03/02/2024 12:05 AM 04/08/2024 7:31 PM
03/04/2024 7:32 PM 04/01/2024 8:22 AM
03/26/2024 12:42 AM 05/13/2024 1:14 AM
04/08/2024 8:19 PM 05/21/2024 12:57 PM
03/01/2024 9:26 PM 03/01/2024 9:26 PM
03/03/2024 12:04 AM 03/03/2024 12:04 AM
03/06/2024 8:04 PM 05/16/2024 2:30 PM
03/01/2024 9:27 PM 05/01/2024 11:53 PM
03/07/2024 9:16 PM 05/10/2024 8:21 PM
03/06/2024 6:56 PM 05/16/2024 2:41 PM
02/21/2024 2:41 AM 04/26/2024 3:38 AM
05/22/2024 2:06 PM 05/30/2024 4:43 PM
02/21/2024 2:51 AM 04/18/2024 6:14 PM
04/04/2024 12:44 AM 05/01/2024 9:52 PM
03/01/2024 9:43 PM 05/16/2024 3:28 PM
03/15/2024 1:45 AM 04/30/2024 3:28 PM
05/03/2024 12:17 AM 05/03/2024 12:17 AM
03/26/2024 8:42 PM 05/02/2024 10:58 AM
03/06/2024 8:04 PM 03/06/2024 8:04 PM
03/01/2024 9:52 PM 05/21/2024 3:36 PM
04/16/2024 1:51 AM 05/28/2024 4:45 PM
05/03/2024 9:14 PM 05/10/2024 7:35 PM
03/04/2024 7:33 PM 05/16/2024 11:10 AM
03/05/2024 7:04 PM 05/08/2024 3:15 PM
05/08/2024 5:43 PM 05/14/2024 1:27 AM
04/08/2024 8:21 PM 04/08/2024 8:21 PM
03/07/2024 6:58 PM 04/08/2024 6:25 AM
03/06/2024 8:10 PM 04/17/2024 10:32 AM
04/08/2024 8:21 PM 04/19/2024 9:07 PM
04/23/2024 11:29 PM 04/23/2024 11:29 PM
03/01/2024 1:59 AM 05/30/2024 10:55 PM
04/25/2024 6:52 PM 04/25/2024 6:52 PM
03/01/2024 2:04 AM 05/23/2024 6:31 AM
03/05/2024 11:15 PM 05/08/2024 7:32 AM
03/25/2024 9:21 PM 05/02/2024 9:10 PM
05/14/2024 1:36 AM 05/16/2024 1:46 AM
03/01/2024 8:34 PM 03/01/2024 8:34 PM
03/01/2024 8:36 PM 04/02/2024 7:38 PM
05/04/2024 12:47 AM 05/06/2024 11:07 PM
03/01/2024 8:48 PM 03/01/2024 8:48 PM
04/04/2024 11:20 PM 04/10/2024 12:58 AM
03/01/2024 8:52 PM 03/29/2024 12:02 AM
05/10/2024 11:55 PM 05/15/2024 9:10 PM
04/01/2024 3:44 PM 04/10/2024 6:22 AM
03/02/2024 12:17 AM 03/02/2024 12:17 AM
03/02/2024 12:11 AM 03/02/2024 12:11 AM
03/04/2024 8:05 PM 04/24/2024 10:47 AM
05/06/2024 6:19 PM 05/11/2024 12:40 PM
04/08/2024 10:44 PM 05/30/2024 9:58 AM
03/29/2024 11:56 PM 05/22/2024 2:12 AM
02/23/2024 1:08 AM 05/13/2024 8:00 PM
03/01/2024 10:06 PM 05/01/2024 8:22 PM
05/10/2024 4:23 PM 05/13/2024 8:24 AM
03/05/2024 9:26 PM 05/20/2024 10:19 AM
03/03/2024 7:42 PM 05/17/2024 12:55 PM
05/21/2024 9:22 PM 05/25/2024 3:28 AM
05/17/2024 6:31 AM 05/17/2024 6:41 AM
05/20/2024 8:05 PM 05/23/2024 6:19 PM
03/26/2024 7:32 PM 04/09/2024 8:32 AM
04/09/2024 7:43 PM 04/09/2024 7:43 PM
04/25/2024 6:56 PM 04/25/2024 6:56 PM
03/02/2024 1:28 AM 03/26/2024 7:37 PM
03/05/2024 6:32 PM 03/05/2024 6:32 PM
05/13/2024 7:42 PM 05/14/2024 12:55 AM
05/05/2024 4:12 PM 05/05/2024 4:12 PM
03/07/2024 8:53 PM 03/07/2024 8:53 PM
03/02/2024 1:06 AM 04/18/2024 7:48 PM
03/04/2024 8:17 PM 03/04/2024 8:17 PM
03/08/2024 7:48 PM 03/08/2024 7:48 PM
03/02/2024 1:08 AM 05/14/2024 1:42 PM
05/20/2024 8:08 PM 05/20/2024 8:08 PM
02/27/2024 11:36 PM 04/18/2024 10:18 AM
02/29/2024 9:48 PM 02/29/2024 9:48 PM
03/08/2024 1:32 AM 03/08/2024 1:32 AM
03/28/2024 1:13 AM 05/17/2024 4:24 PM
05/15/2024 10:53 PM 05/16/2024 8:01 PM
05/25/2024 12:33 AM 06/01/2024 12:34 AM
04/24/2024 9:19 PM 04/24/2024 9:19 PM
03/08/2024 3:41 AM 04/05/2024 2:25 AM
02/27/2024 11:33 PM 02/27/2024 11:33 PM
02/27/2024 11:31 PM 05/23/2024 10:44 PM
03/01/2024 8:54 PM 05/10/2024 7:58 PM
03/08/2024 7:57 PM 04/09/2024 4:55 AM
03/06/2024 7:26 PM 04/17/2024 5:13 AM
05/08/2024 9:30 PM 06/02/2024 11:44 PM
02/29/2024 10:17 PM 02/29/2024 10:17 PM
04/17/2024 2:17 AM 05/30/2024 7:49 PM
02/29/2024 10:23 PM 04/29/2024 9:41 PM
03/01/2024 9:27 PM 05/16/2024 1:53 PM
03/18/2024 9:22 PM 05/13/2024 10:14 PM
04/24/2024 8:31 PM 04/24/2024 9:11 PM
03/10/2024 1:52 AM 03/10/2024 1:52 AM
02/27/2024 6:31 PM 02/27/2024 6:31 PM
04/05/2024 12:41 AM 05/15/2024 10:53 PM
02/27/2024 6:30 PM 03/28/2024 8:00 AM
02/27/2024 6:30 PM 04/25/2024 7:09 AM
03/01/2024 10:32 PM 05/09/2024 6:21 PM
03/01/2024 10:34 PM 05/15/2024 10:02 AM
05/02/2024 4:35 AM 05/02/2024 4:35 AM
03/01/2024 10:35 PM 05/03/2024 4:00 PM
03/19/2024 9:34 PM 05/21/2024 7:32 PM
03/19/2024 9:33 PM 05/16/2024 2:24 AM
03/08/2024 12:54 AM 05/07/2024 1:43 AM
03/10/2024 1:50 AM 05/30/2024 11:35 AM
03/08/2024 8:01 PM 04/26/2024 2:11 AM
04/08/2024 11:39 PM 05/24/2024 9:29 AM
05/01/2024 6:51 PM 05/13/2024 12:25 PM
03/05/2024 8:23 PM 03/05/2024 8:23 PM
05/03/2024 7:06 PM 05/31/2024 1:13 PM
03/04/2024 8:27 PM 05/13/2024 7:35 PM
03/01/2024 5:39 PM 03/01/2024 5:39 PM
03/14/2024 11:40 PM 04/28/2024 12:05 PM
05/05/2024 4:15 PM 05/06/2024 10:10 AM
04/23/2024 7:14 PM 04/23/2024 7:14 PM
03/01/2024 5:40 PM 05/30/2024 2:11 PM
03/01/2024 5:40 PM 05/10/2024 11:47 AM
03/06/2024 6:53 PM 04/30/2024 2:15 PM
04/23/2024 7:18 PM 05/21/2024 1:49 PM
03/03/2024 7:43 PM 04/20/2024 7:01 PM
03/02/2024 1:15 AM 03/02/2024 1:15 AM
03/06/2024 6:53 PM 05/08/2024 8:00 PM
03/08/2024 3:41 AM 04/15/2024 10:27 AM
04/18/2024 1:23 AM 05/16/2024 8:24 AM
04/19/2024 1:18 AM 05/08/2024 4:56 PM
05/21/2024 5:50 AM 05/29/2024 11:10 PM
05/15/2024 9:10 PM 05/15/2024 9:17 PM
03/18/2024 5:31 PM 05/03/2024 3:41 AM
05/08/2024 12:00 AM 05/08/2024 12:00 AM
02/27/2024 6:17 PM 04/13/2024 4:26 AM
04/04/2024 8:17 PM 04/12/2024 3:41 PM
03/01/2024 9:37 PM 04/16/2024 3:45 PM
02/27/2024 6:14 PM 05/02/2024 8:44 PM
03/20/2024 11:37 PM 05/16/2024 11:47 PM
03/05/2024 6:29 PM 04/18/2024 1:39 PM
03/15/2024 8:25 PM 05/24/2024 10:24 AM
03/27/2024 9:04 PM 03/27/2024 9:04 PM
02/23/2024 3:47 AM 02/23/2024 3:47 AM
04/05/2024 10:53 PM 05/17/2024 4:58 PM
02/23/2024 3:46 AM 05/01/2024 12:00 PM
02/26/2024 7:24 PM 04/19/2024 12:53 PM
04/29/2024 8:14 PM 04/29/2024 8:14 PM
04/22/2024 7:34 PM 04/22/2024 7:34 PM
04/29/2024 8:13 PM 04/30/2024 3:00 PM
02/23/2024 3:05 AM 05/01/2024 6:42 PM
03/01/2024 9:18 PM 04/23/2024 10:52 AM
05/08/2024 1:37 AM 05/08/2024 8:46 PM
02/27/2024 6:09 PM 05/27/2024 3:56 PM
03/01/2024 8:58 PM 05/21/2024 6:48 PM
02/27/2024 6:09 PM 04/30/2024 2:18 PM
03/25/2024 8:07 PM 05/27/2024 7:03 PM
02/26/2024 7:23 PM 04/27/2024 12:44 AM
02/23/2024 3:36 AM 02/23/2024 3:36 AM
03/06/2024 10:23 PM 04/04/2024 7:52 PM
04/05/2024 10:50 PM 05/31/2024 6:59 PM
03/01/2024 8:53 PM 04/01/2024 11:31 PM
05/08/2024 12:15 AM 05/09/2024 6:52 PM
03/12/2024 1:31 AM 03/12/2024 1:31 AM
02/29/2024 1:17 AM 03/27/2024 10:55 PM
03/01/2024 5:35 PM 03/01/2024 5:35 PM
04/26/2024 2:49 AM 05/22/2024 6:02 PM
05/21/2024 2:21 AM 05/22/2024 11:22 PM
05/04/2024 12:00 AM 05/09/2024 1:04 AM
03/06/2024 6:38 PM 03/06/2024 6:38 PM
04/11/2024 8:05 PM 04/19/2024 2:15 AM
04/05/2024 9:16 PM 05/02/2024 5:54 PM
04/09/2024 8:20 PM 04/10/2024 12:06 AM
02/23/2024 1:23 AM 04/25/2024 12:10 AM
02/26/2024 7:21 PM 05/28/2024 5:03 PM
04/02/2024 10:17 PM 05/08/2024 3:23 PM
04/19/2024 7:26 PM 04/22/2024 2:37 PM
05/15/2024 12:59 AM 05/15/2024 2:00 AM
03/05/2024 6:23 PM 04/01/2024 11:05 AM
03/06/2024 6:06 PM 04/22/2024 6:34 AM
05/14/2024 7:45 PM 05/14/2024 7:45 PM
02/23/2024 3:27 AM 02/23/2024 3:27 AM
02/23/2024 3:43 AM 05/09/2024 10:10 PM
04/18/2024 11:29 PM 05/15/2024 9:55 PM
03/11/2024 9:45 PM 06/01/2024 12:22 AM
05/06/2024 6:53 PM 06/03/2024 7:42 PM
03/11/2024 9:46 PM 03/11/2024 9:46 PM
02/28/2024 2:28 AM 02/28/2024 2:28 AM
02/23/2024 3:26 AM 05/10/2024 12:30 PM
04/23/2024 6:45 PM 04/23/2024 6:45 PM
05/08/2024 7:44 PM 05/21/2024 11:40 AM
02/23/2024 3:18 AM 05/05/2024 8:25 PM
04/12/2024 7:07 PM 04/19/2024 8:52 AM
02/23/2024 3:16 AM 06/02/2024 11:45 PM
03/28/2024 4:00 AM 03/28/2024 8:01 PM
02/23/2024 3:15 AM 04/05/2024 3:25 AM
03/04/2024 8:30 PM 03/04/2024 8:30 PM
04/24/2024 10:25 PM 04/24/2024 10:25 PM
03/25/2024 6:44 PM 04/12/2024 5:25 PM
03/06/2024 8:07 PM 05/16/2024 7:27 AM
03/01/2024 8:51 PM 05/17/2024 7:34 AM
04/29/2024 8:05 PM 04/29/2024 8:05 PM
02/23/2024 3:43 AM 04/22/2024 2:29 PM
02/23/2024 3:14 AM 05/28/2024 4:06 PM
05/16/2024 1:58 AM 05/20/2024 11:25 PM
03/28/2024 8:07 PM 04/12/2024 4:29 PM
05/10/2024 4:21 PM 05/24/2024 6:10 AM
03/01/2024 8:50 PM 05/27/2024 10:36 AM
03/07/2024 8:50 PM 04/29/2024 7:25 PM
02/27/2024 6:06 PM 05/29/2024 12:18 PM
04/19/2024 7:22 PM 05/28/2024 6:30 AM
04/04/2024 8:24 PM 04/04/2024 8:24 PM
02/23/2024 3:10 AM 05/07/2024 1:04 AM
05/06/2024 8:23 PM 05/09/2024 1:54 PM
04/15/2024 11:00 PM 05/10/2024 2:22 AM
04/16/2024 9:44 PM 04/16/2024 9:44 PM
04/23/2024 6:46 PM 04/24/2024 1:09 PM
03/04/2024 8:14 PM 03/04/2024 8:14 PM
03/07/2024 8:15 PM 05/22/2024 9:37 PM
02/23/2024 3:20 AM 02/23/2024 3:20 AM
02/26/2024 7:20 PM 04/17/2024 9:32 PM
04/30/2024 7:51 PM 04/30/2024 7:51 PM
03/26/2024 11:36 PM 04/11/2024 12:54 AM
02/28/2024 12:23 AM 04/04/2024 1:45 PM
02/23/2024 3:20 AM 05/23/2024 4:52 AM
03/12/2024 10:20 PM 05/06/2024 8:28 PM
06/01/2024 2:42 AM 06/01/2024 9:27 PM
04/08/2024 8:54 PM 04/10/2024 3:25 PM
03/08/2024 6:29 PM 05/20/2024 1:55 AM
03/05/2024 6:11 PM 05/08/2024 10:06 AM
04/16/2024 8:01 PM 04/25/2024 2:18 PM
02/28/2024 9:05 PM 02/28/2024 9:05 PM
03/27/2024 8:26 PM 05/29/2024 10:28 AM
05/06/2024 7:43 PM 06/03/2024 6:58 AM
05/17/2024 2:53 PM 05/17/2024 7:05 PM
03/07/2024 9:22 PM 05/07/2024 4:28 AM
03/05/2024 6:10 PM 04/10/2024 10:27 PM
05/07/2024 9:23 PM 05/09/2024 7:19 PM
03/26/2024 1:53 AM 03/26/2024 1:53 AM
02/28/2024 2:24 AM 02/28/2024 2:24 AM
03/07/2024 7:32 PM 05/15/2024 3:21 PM
04/03/2024 11:16 PM 04/17/2024 4:28 AM
02/27/2024 6:03 PM 05/22/2024 9:17 PM
03/07/2024 2:37 AM 05/15/2024 11:06 PM
03/21/2024 7:23 PM 05/09/2024 2:05 PM
02/23/2024 1:07 AM 02/23/2024 1:07 AM
03/04/2024 8:12 PM 03/04/2024 8:12 PM
02/27/2024 10:08 PM 03/26/2024 11:59 AM
04/16/2024 2:20 AM 04/16/2024 2:20 AM
03/20/2024 1:14 AM 03/20/2024 1:14 AM
02/23/2024 1:07 AM 05/13/2024 3:57 PM
05/08/2024 11:36 PM 05/09/2024 12:52 AM
02/23/2024 3:01 AM 02/23/2024 3:01 AM
02/23/2024 3:01 AM 03/29/2024 10:44 PM
04/16/2024 9:09 PM 04/16/2024 9:09 PM
02/23/2024 12:26 AM 02/23/2024 12:26 AM
04/15/2024 9:07 PM 04/19/2024 4:04 AM
02/22/2024 7:55 PM 03/27/2024 12:53 AM
02/22/2024 7:20 PM 04/01/2024 7:18 AM
05/14/2024 7:24 PM 05/22/2024 1:24 AM
04/04/2024 1:57 AM 04/04/2024 4:10 AM
03/06/2024 3:04 AM 04/04/2024 1:44 AM
04/22/2024 11:56 PM 04/22/2024 11:56 PM
03/25/2024 10:03 PM 03/25/2024 10:03 PM
04/13/2024 3:27 AM 04/24/2024 12:18 AM
03/04/2024 8:09 PM 05/14/2024 9:28 PM
05/07/2024 11:27 PM 06/03/2024 10:41 PM
03/05/2024 6:05 PM 04/16/2024 6:10 AM
03/01/2024 8:15 PM 03/01/2024 8:15 PM
02/21/2024 2:55 AM 02/21/2024 2:55 AM
04/30/2024 8:29 PM 05/08/2024 3:04 PM
05/15/2024 4:25 AM 05/17/2024 9:32 PM
03/07/2024 9:21 PM 04/07/2024 1:33 PM
02/21/2024 2:54 AM 04/15/2024 6:23 PM
03/04/2024 8:07 PM 05/09/2024 12:50 PM
03/25/2024 9:57 PM 04/19/2024 12:34 AM
Company name Meeting status Company status Investor type Brief description
Description Objectives Investment stage preference Preferred company type(s)
Preferred asset type(s) Prefered therapeutic area(s)
Preferred asset development phase(s) Website Main email Main phone Country State
City Street address Postal code Created date/time Last updated date/time